OA17357A - Novel 4-(substituted-amino)-7H-pyrrolo[2,3d]pyrimidines as LRRK2 inhibitors. - Google Patents
Novel 4-(substituted-amino)-7H-pyrrolo[2,3d]pyrimidines as LRRK2 inhibitors. Download PDFInfo
- Publication number
- OA17357A OA17357A OA1201400555 OA17357A OA 17357 A OA17357 A OA 17357A OA 1201400555 OA1201400555 OA 1201400555 OA 17357 A OA17357 A OA 17357A
- Authority
- OA
- OAPI
- Prior art keywords
- pyrrolo
- pyrimidin
- morpholin
- benzonitrile
- pyrimidine
- Prior art date
Links
- 102000009784 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Human genes 0.000 title abstract description 3
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 title abstract description 3
- 230000002401 inhibitory effect Effects 0.000 title description 37
- 239000003112 inhibitor Substances 0.000 title description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 223
- -1 4,5disubstituted-7H-pyrrolo[2,3-d]pyrimidine Chemical class 0.000 claims abstract description 120
- 206010061536 Parkinson's disease Diseases 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 427
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 323
- 150000003230 pyrimidines Chemical class 0.000 claims description 164
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 56
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 53
- 125000005842 heteroatoms Chemical group 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 229910052717 sulfur Inorganic materials 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 19
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 229910003827 NRaRb Inorganic materials 0.000 claims description 10
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7H-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- LAWUZBKFMNSOGG-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=[C]S1 LAWUZBKFMNSOGG-UHFFFAOYSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 5
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical compound C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 claims description 4
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- QDXQAOGNBCOEQX-UHFFFAOYSA-N 1-methylcyclohexa-1,4-diene Chemical compound CC1=CCC=CC1 QDXQAOGNBCOEQX-UHFFFAOYSA-N 0.000 claims description 3
- 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 claims description 3
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims description 3
- VMWJCFLUSKZZDX-UHFFFAOYSA-N N,N-dimethylmethanamine Chemical group [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 3
- HAASCECTXNYFCI-UHFFFAOYSA-N morpholine-2-carbonitrile Chemical compound N#CC1CNCCO1 HAASCECTXNYFCI-UHFFFAOYSA-N 0.000 claims description 3
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims description 3
- ZGNXATVKGIJQGC-UHFFFAOYSA-N piperidine-3-carbonitrile Chemical compound N#CC1CCCNC1 ZGNXATVKGIJQGC-UHFFFAOYSA-N 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- PQXAADSTABWHNC-UHFFFAOYSA-N 1-[5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol Chemical compound CC1=CN=CC(C=2C3=C(N4CC(O)CCC4)N=CN=C3NC=2)=C1 PQXAADSTABWHNC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- XTIGQBGLUHGYQF-UHFFFAOYSA-N 3-(2-methyl-4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound C=12C(C=3C=C(C=CC=3)C#N)=CNC2=NC(C)=NC=1N1CCOCC1 XTIGQBGLUHGYQF-UHFFFAOYSA-N 0.000 claims description 2
- GCHHHYMKNXQPDG-UHFFFAOYSA-N 3-[4-(3-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1C(N)CCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 GCHHHYMKNXQPDG-UHFFFAOYSA-N 0.000 claims description 2
- QSSCZIVWHWTPLQ-UHFFFAOYSA-N 3-[4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1CC(F)(F)CCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 QSSCZIVWHWTPLQ-UHFFFAOYSA-N 0.000 claims description 2
- BDJRDQDPISRMLT-ZDUSSCGKSA-N 3-[4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1[C@@H](F)CCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 BDJRDQDPISRMLT-ZDUSSCGKSA-N 0.000 claims description 2
- WAKBGPGJEVOMFS-LBPRGKRZSA-N 3-[4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzoic acid Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C(O)=O)=CN2 WAKBGPGJEVOMFS-LBPRGKRZSA-N 0.000 claims description 2
- GAMPREVSPQKZEE-UHFFFAOYSA-N 3-methoxy-5-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound COC1=CC(C#N)=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 GAMPREVSPQKZEE-UHFFFAOYSA-N 0.000 claims description 2
- PXYVAWXCGMFHEJ-UHFFFAOYSA-N 4-[5-(2,5-difluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C(F)C(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 PXYVAWXCGMFHEJ-UHFFFAOYSA-N 0.000 claims description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 claims 4
- AXVWXYOCYXZGCZ-UHFFFAOYSA-N 4-[5-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 AXVWXYOCYXZGCZ-UHFFFAOYSA-N 0.000 claims 2
- SWBMTULEVBPEDZ-UHFFFAOYSA-N 1-(5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-3-carboxamide Chemical compound C1C(C(=O)N)CCCN1C1=NC=NC2=C1C(C=1C=CC=CC=1)=CN2 SWBMTULEVBPEDZ-UHFFFAOYSA-N 0.000 claims 1
- XTVZGNYXKQQSKT-UHFFFAOYSA-N 1-[5-(1-methylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol Chemical compound C1=NN(C)C=C1C1=CNC2=NC=NC(N3CC(O)CCC3)=C12 XTVZGNYXKQQSKT-UHFFFAOYSA-N 0.000 claims 1
- AFVZXTFKZIXUDK-UHFFFAOYSA-N 2-fluoro-3-(2-methyl-4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound C=12C(C=3C(=C(C#N)C=CC=3)F)=CNC2=NC(C)=NC=1N1CCOCC1 AFVZXTFKZIXUDK-UHFFFAOYSA-N 0.000 claims 1
- YIDVVQGSCVWPGO-UHFFFAOYSA-N 2-fluoro-3-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound FC1=C(C#N)C=CC=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 YIDVVQGSCVWPGO-UHFFFAOYSA-N 0.000 claims 1
- JZYGFRYCZUEFLK-UHFFFAOYSA-N 3-(4-piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound N#CC1=CC=CC(C=2C3=C(N4CCCCC4)N=CN=C3NC=2)=C1 JZYGFRYCZUEFLK-UHFFFAOYSA-N 0.000 claims 1
- ZIIYDYQRAOEXTB-UHFFFAOYSA-N 3-[4-(3,3-dimethylpiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1C(C)(C)CCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 ZIIYDYQRAOEXTB-UHFFFAOYSA-N 0.000 claims 1
- RRUCJMTTXOEWQO-UHFFFAOYSA-N 3-[4-(3-oxo-2,7-diazaspiro[4.5]decan-7-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1NC(=O)CC21CN(C=1C=3C(C=4C=C(C=CC=4)C#N)=CNC=3N=CN=1)CCC2 RRUCJMTTXOEWQO-UHFFFAOYSA-N 0.000 claims 1
- QYMXFRIVGZZMAD-UHFFFAOYSA-N 3-[4-[2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound O1C(C)=NC(CC2OCCN(C2)C=2C=3C(C=4C=C(C=CC=4)C#N)=CNC=3N=CN=2)=N1 QYMXFRIVGZZMAD-UHFFFAOYSA-N 0.000 claims 1
- QGBBQZOBGGTKLP-UHFFFAOYSA-N 3-chloro-5-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound ClC1=CC(C#N)=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 QGBBQZOBGGTKLP-UHFFFAOYSA-N 0.000 claims 1
- ZONYIIVYWCZHAS-UHFFFAOYSA-N 4-(5-pyrazolo[1,5-a]pyrimidin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine Chemical compound C1COCCN1C1=NC=NC2=C1C(C1=C3N=CC=CN3N=C1)=CN2 ZONYIIVYWCZHAS-UHFFFAOYSA-N 0.000 claims 1
- UZSUNCZXHIZLKQ-UHFFFAOYSA-N 4-(5-pyridin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine Chemical compound C1COCCN1C1=NC=NC2=C1C(C=1C=NC=CC=1)=CN2 UZSUNCZXHIZLKQ-UHFFFAOYSA-N 0.000 claims 1
- OJIYMEIFXMQAHK-NSHDSACASA-N 4-[(3S)-3-methylpiperidin-1-yl]-5-(1-methylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C1=CN(C)N=C1)=CN2 OJIYMEIFXMQAHK-NSHDSACASA-N 0.000 claims 1
- IGWCOHZVLMWAFD-UHFFFAOYSA-N 4-[5-(2,3-difluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1F IGWCOHZVLMWAFD-UHFFFAOYSA-N 0.000 claims 1
- VAMWIRPKQLTAMA-UHFFFAOYSA-N 4-[5-(2-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound ClC1=CC=CC=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 VAMWIRPKQLTAMA-UHFFFAOYSA-N 0.000 claims 1
- JWNOQCCPFZXUTN-UHFFFAOYSA-N 4-[5-(5-chloro-2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=C(Cl)C=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 JWNOQCCPFZXUTN-UHFFFAOYSA-N 0.000 claims 1
- KUQRUOBHXPBUPN-UHFFFAOYSA-N 4-[5-(6-methoxypyrazin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CN=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=N1 KUQRUOBHXPBUPN-UHFFFAOYSA-N 0.000 claims 1
- KMYQVQCPFIBPJU-UHFFFAOYSA-N 4-methoxy-3-[4-(3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound COC1=CC=C(C#N)C=C1C1=CNC2=NC=NC(N3CC(C)CCC3)=C12 KMYQVQCPFIBPJU-UHFFFAOYSA-N 0.000 claims 1
- MMXALXCYCNOIET-UHFFFAOYSA-N 5-(2-methoxyphenyl)-4-pyrrolidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=CC=C1C1=CNC2=NC=NC(N3CCCC3)=C12 MMXALXCYCNOIET-UHFFFAOYSA-N 0.000 claims 1
- CZDNODODMNYBAC-UHFFFAOYSA-N CN1C=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=N1 Chemical compound CN1C=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=N1 CZDNODODMNYBAC-UHFFFAOYSA-N 0.000 claims 1
- 125000004802 cyanophenyl group Chemical group 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 abstract description 45
- 201000010099 disease Diseases 0.000 abstract description 29
- 150000003839 salts Chemical class 0.000 abstract description 25
- 206010001897 Alzheimer's disease Diseases 0.000 abstract description 16
- 206010053643 Neurodegenerative disease Diseases 0.000 abstract description 8
- 206010011401 Crohn's disease Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 5
- 206010024229 Leprosy Diseases 0.000 abstract description 4
- 229940083082 Pyrimidine derivatives acting on arteriolar smooth muscle Drugs 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 126
- 239000000243 solution Substances 0.000 description 95
- 239000000047 product Substances 0.000 description 82
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 70
- 239000000203 mixture Substances 0.000 description 66
- 230000015572 biosynthetic process Effects 0.000 description 65
- 238000003786 synthesis reaction Methods 0.000 description 65
- 230000002194 synthesizing Effects 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 62
- 239000011541 reaction mixture Substances 0.000 description 61
- 239000007787 solid Substances 0.000 description 53
- 102100003216 LRRK2 Human genes 0.000 description 52
- 101700041831 LRRK2 Proteins 0.000 description 52
- 239000002904 solvent Substances 0.000 description 42
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 41
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 38
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 37
- 238000006243 chemical reaction Methods 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 34
- 238000000746 purification Methods 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 24
- 239000003208 petroleum Substances 0.000 description 23
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 23
- 229910052796 boron Inorganic materials 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 125000004432 carbon atoms Chemical group C* 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 125000004429 atoms Chemical group 0.000 description 19
- 239000003480 eluent Substances 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- 125000001424 substituent group Chemical group 0.000 description 19
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- 238000006069 Suzuki reaction reaction Methods 0.000 description 16
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 238000007792 addition Methods 0.000 description 14
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- 235000019253 formic acid Nutrition 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000001184 potassium carbonate Substances 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000000908 ammonium hydroxide Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrugs Drugs 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102000001253 Protein Kinases Human genes 0.000 description 8
- JMOMEVFJRJVJNY-ZDUSSCGKSA-N [3-[4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]methanol Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=C(CO)C=CC=1)=CN2 JMOMEVFJRJVJNY-ZDUSSCGKSA-N 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 108091000081 Phosphotransferases Proteins 0.000 description 7
- 230000001808 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- IOKHVMNITOWKOY-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1.OC1CCCNC1 IOKHVMNITOWKOY-UHFFFAOYSA-N 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- ZAYWYRLGHFAOON-UHFFFAOYSA-N 3-(6-methyl-4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound C=12C(C=3C=C(C=CC=3)C#N)=C(C)NC2=NC=NC=1N1CCOCC1 ZAYWYRLGHFAOON-UHFFFAOYSA-N 0.000 description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- 102200092160 LRRK2 G2019S Human genes 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N Lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 208000009025 Nervous System Disease Diseases 0.000 description 6
- 206010029305 Neurological disorder Diseases 0.000 description 6
- 229940076279 Serotonin Drugs 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K Tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- KVXNKFYSHAUJIA-UHFFFAOYSA-M ethoxyethane;acetate Chemical compound CC([O-])=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-M 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 229940113083 morpholine Drugs 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 238000004808 supercritical fluid chromatography Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- YNHIGQDRGKUECZ-UHFFFAOYSA-L Bis(triphenylphosphine)palladium(II) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- 102000006378 EC 2.1.1.6 Human genes 0.000 description 5
- 108020002739 EC 2.1.1.6 Proteins 0.000 description 5
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000000018 receptor agonist Substances 0.000 description 5
- 239000002464 receptor antagonist Substances 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000011593 sulfur Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 230000000699 topical Effects 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N 3-hydroxy-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- 206010057668 Cognitive disease Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- CURUTKGFNZGFSE-UHFFFAOYSA-N Dicycloverine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 102000010909 EC 1.4.3.4 Human genes 0.000 description 4
- 108010062431 EC 1.4.3.4 Proteins 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 4
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Tolvon Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940079593 drugs Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 4
- 229960003946 selegiline Drugs 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000001187 sodium carbonate Substances 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 3
- OYPPVKRFBIWMSX-SXGWCWSVSA-N (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- GIJXKZJWITVLHI-PMOLBWCYSA-N Benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 3
- 210000004556 Brain Anatomy 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 3
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 3
- 206010015037 Epilepsy Diseases 0.000 description 3
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 3
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 3
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N Homotaurine Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 108090000028 MMP12 Proteins 0.000 description 3
- 102100013322 MTOR Human genes 0.000 description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 3
- 206010061920 Psychotic disease Diseases 0.000 description 3
- 102100012085 RPS6KA1 Human genes 0.000 description 3
- 101710010021 RPS6KA1 Proteins 0.000 description 3
- 102100012084 RPS6KA3 Human genes 0.000 description 3
- 101710009860 RPS6KA3 Proteins 0.000 description 3
- MIQPIUSUKVNLNT-UHFFFAOYSA-N Tasmar Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 3
- MXUNKHLAEDCYJL-UHFFFAOYSA-N Toloxatone Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N Trifluoromethanesulfonic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 3
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 229960001081 benzatropine Drugs 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 201000006180 eating disease Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 229960003907 linezolid Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004640 memantine Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 229960005434 oxybutynin Drugs 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003419 tautomerization reaction Methods 0.000 description 3
- 229960004603 tolcapone Drugs 0.000 description 3
- 229960002431 trimipramine Drugs 0.000 description 3
- 235000019798 tripotassium phosphate Nutrition 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- AELCINSCMGFISI-DTWKUNHWSA-N (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@@H]1C[C@H]1C1=CC=CC=C1 AELCINSCMGFISI-DTWKUNHWSA-N 0.000 description 2
- XEAOPVUAMONVLA-QGZVFWFLSA-N (2R)-2-[(4-chlorophenyl)sulfonyl-[[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide Chemical compound C=1C=C(Cl)C=CC=1S(=O)(=O)N([C@H](CCC(F)(F)F)C(=O)N)CC(C(=C1)F)=CC=C1C=1N=CON=1 XEAOPVUAMONVLA-QGZVFWFLSA-N 0.000 description 2
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 2
- PLQIAEXRNLFVCU-UHFFFAOYSA-N 1-[5-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol Chemical compound COC1=CC=CC=C1C1=CNC2=NC=NC(N3CC(O)CCC3)=C12 PLQIAEXRNLFVCU-UHFFFAOYSA-N 0.000 description 2
- IEPMBXMCDYITET-UHFFFAOYSA-N 2-(3-methyl-1,2-oxazol-5-yl)morpholine Chemical compound O1N=C(C)C=C1C1OCCNC1 IEPMBXMCDYITET-UHFFFAOYSA-N 0.000 description 2
- IMCDTSZTCIFXNN-UHFFFAOYSA-N 2-(4-benzylmorpholin-2-yl)acetonitrile Chemical compound C1COC(CC#N)CN1CC1=CC=CC=C1 IMCDTSZTCIFXNN-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- PFFIEMXZEROLOA-LBPRGKRZSA-N 3-[4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1CO[C@@H](C)CN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 PFFIEMXZEROLOA-LBPRGKRZSA-N 0.000 description 2
- CZQDUHIXGSFBGB-UHFFFAOYSA-N 3-[4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound OC1=CC=CC(C2OCCN(C2)C=2C=3C(C=4C=C(C=CC=4)C#N)=CNC=3N=CN=2)=C1 CZQDUHIXGSFBGB-UHFFFAOYSA-N 0.000 description 2
- MMCZXHZCSBHBOJ-UHFFFAOYSA-N 4-[5-[3-(1,2,4-oxadiazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound C1COCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C1=NOC=N1)=CN2 MMCZXHZCSBHBOJ-UHFFFAOYSA-N 0.000 description 2
- ATIUQIBTYSVBQP-UHFFFAOYSA-N 4-benzyl-2-(3-methyl-1,2-oxazol-5-yl)morpholin-2-ol Chemical compound O1N=C(C)C=C1C1(O)OCCN(CC=2C=CC=CC=2)C1 ATIUQIBTYSVBQP-UHFFFAOYSA-N 0.000 description 2
- LLTRAEBZNNXPBC-UHFFFAOYSA-N 4-benzyl-2-(3-methyl-1,2-oxazol-5-yl)morpholine Chemical compound O1N=C(C)C=C1C1OCCN(CC=2C=CC=CC=2)C1 LLTRAEBZNNXPBC-UHFFFAOYSA-N 0.000 description 2
- NAWYNSSXFPEQKE-UHFFFAOYSA-N 4-benzylmorpholine-2-carbonitrile Chemical compound C1COC(C#N)CN1CC1=CC=CC=C1 NAWYNSSXFPEQKE-UHFFFAOYSA-N 0.000 description 2
- YABCYQHQVZEFNM-UHFFFAOYSA-N 5-(3-fluorophenyl)-4-pyrrolidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine Chemical compound FC1=CC=CC(C=2C3=C(N4CCCC4)N=CN=C3NC=2)=C1 YABCYQHQVZEFNM-UHFFFAOYSA-N 0.000 description 2
- 101700006583 AKT2 Proteins 0.000 description 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229960003805 Amantadine Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 2
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 206010002855 Anxiety Diseases 0.000 description 2
- 206010057666 Anxiety disease Diseases 0.000 description 2
- BFNCJMURTMZBTE-UHFFFAOYSA-N Aptiganel Chemical compound CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 BFNCJMURTMZBTE-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 2
- PXXJHWLDUBFPOL-UHFFFAOYSA-N Benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 208000001183 Brain Injury Diseases 0.000 description 2
- 210000000481 Breast Anatomy 0.000 description 2
- 229960004205 CARBIDOPA Drugs 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229960001231 Choline Drugs 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- KYYIDSXMWOZKMP-UHFFFAOYSA-N Desvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 2
- 206010013663 Drug dependence Diseases 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N EXELON Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- JRURYQJSLYLRLN-BJMVGYQFSA-N Entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 2
- 229940088598 Enzyme Drugs 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000010111 Ezrin/radixin/moesin Human genes 0.000 description 2
- 108050001788 Ezrin/radixin/moesin Proteins 0.000 description 2
- 206010016072 Factitious disease Diseases 0.000 description 2
- 229960001582 Fenfluramine Drugs 0.000 description 2
- 229960002464 Fluoxetine Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N GABA Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960002449 Glycine Drugs 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmin Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
- 208000004559 Hearing Loss Diseases 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- 102100009274 IDE Human genes 0.000 description 2
- 101710002884 IKBKE Proteins 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 206010061215 Impulse-control disease Diseases 0.000 description 2
- 229960000905 Indomethacin Drugs 0.000 description 2
- 108090000828 Insulysin Proteins 0.000 description 2
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 2
- 102100019517 JAK1 Human genes 0.000 description 2
- 101700034277 JAK1 Proteins 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 102200092223 LRRK2 R1441G Human genes 0.000 description 2
- IWMCPJZTADUIFX-UHFFFAOYSA-N LRRK2-IN-1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N(CC1)CCC1N1CCN(C)CC1 IWMCPJZTADUIFX-UHFFFAOYSA-N 0.000 description 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 description 2
- 108091007472 MAP kinase family Proteins 0.000 description 2
- 102000038027 MAP kinase family Human genes 0.000 description 2
- 102000001291 MAP kinase kinase kinase family Human genes 0.000 description 2
- 108060006687 MAP kinase kinase kinase family Proteins 0.000 description 2
- 102100006473 MAP2K1 Human genes 0.000 description 2
- 101700067592 MST1 Proteins 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 229960003194 Meglumine Drugs 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 2
- 206010027599 Migraine Diseases 0.000 description 2
- 208000008085 Migraine Disorders Diseases 0.000 description 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
- 108090000823 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- 102100019070 NEK7 Human genes 0.000 description 2
- 101700078591 NEK7 Proteins 0.000 description 2
- 229960003057 Nialamide Drugs 0.000 description 2
- NOIIUHRQUVNIDD-UHFFFAOYSA-N Nialamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 2
- 229960002748 Norepinephrine Drugs 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N Obedrex Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- 102100013270 PIP4K2C Human genes 0.000 description 2
- 101710038361 PIP4K2C Proteins 0.000 description 2
- 229960001779 Pargyline Drugs 0.000 description 2
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N Physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 241000243142 Porifera Species 0.000 description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 description 2
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000002027 Psychomotor Disorders Diseases 0.000 description 2
- 102100011601 RPS6KB1 Human genes 0.000 description 2
- 101710009878 RPS6KB1 Proteins 0.000 description 2
- 102100011600 RPS6KB2 Human genes 0.000 description 2
- 101710009879 RPS6KB2 Proteins 0.000 description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N Rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 2
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 2
- 102100002801 STK3 Human genes 0.000 description 2
- 101700025207 STK3 Proteins 0.000 description 2
- 102100019671 STK4 Human genes 0.000 description 2
- 101700023684 STK4 Proteins 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- CDAISMWEOUEBRE-CDRYSYESSA-N Scyllo-Inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010040984 Sleep disease Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229960000894 Sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 229940118176 Surmontil Drugs 0.000 description 2
- 101710019450 TARS2 Proteins 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 229960001685 Tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N Tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- SYTBZMRGLBWNTM-SNVBAGLBSA-N Tarenflurbil Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- JICJBGPOMZQUBB-UHFFFAOYSA-N Tianeptine Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229960001032 Trihexyphenidyl Drugs 0.000 description 2
- 229940035504 Tromethamine Drugs 0.000 description 2
- MMAYTCMMKJYIAM-PHKAQXKASA-N Voacangine Natural products C([C@@H]1C[C@@H]([C@H]2[C@]3(C1)C(=O)OC)CC)N2CCC1=C3NC2=CC=C(OC)C=C12 MMAYTCMMKJYIAM-PHKAQXKASA-N 0.000 description 2
- 101700011053 WNK2 Proteins 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N XPhos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- HGTDLKXUWVKLQX-UHFFFAOYSA-N [3-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=CC(B(O)O)=C1 HGTDLKXUWVKLQX-UHFFFAOYSA-N 0.000 description 2
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 2
- 229960004047 acamprosate Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 229960003692 aminobutyric acid Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000001078 anti-cholinergic Effects 0.000 description 2
- 108090001123 antibodies Proteins 0.000 description 2
- 102000004965 antibodies Human genes 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- PCCNIENXBRUYFK-UHFFFAOYSA-O azanium;cerium(4+);pentanitrate Chemical compound [NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O PCCNIENXBRUYFK-UHFFFAOYSA-O 0.000 description 2
- 125000004602 benzodiazinyl group Chemical group N1=NC(=CC2=C1C=CC=C2)* 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- HDYQLGLEPPGPEV-UHFFFAOYSA-N benzyl 2,2,2-trifluoroacetate Chemical compound FC(F)(F)C(=O)OCC1=CC=CC=C1 HDYQLGLEPPGPEV-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 2
- 210000004027 cells Anatomy 0.000 description 2
- 201000001084 cerebrovascular disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 229960001623 desvenlafaxine Drugs 0.000 description 2
- PBWZKZYHONABLN-UHFFFAOYSA-N difluoroacetic acid Chemical compound OC(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 229960003337 entacapone Drugs 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N ethoxyethane;trifluoroborane Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 229940013945 gamma-Aminobutyric Acid Drugs 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 229960003049 iproniazid Drugs 0.000 description 2
- 229960002672 isocarboxazid Drugs 0.000 description 2
- 125000005438 isoindazolyl group Chemical group 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 210000004901 leucine-rich repeat Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960004644 moclobemide Drugs 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 201000008895 mood disease Diseases 0.000 description 2
- 230000001095 motoneuron Effects 0.000 description 2
- 101710031797 mst101(1) Proteins 0.000 description 2
- 101700084897 mst2 Proteins 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 101710031992 pRL90232 Proteins 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 101710035540 plaa2 Proteins 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 229960000697 propantheline Drugs 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 229960000245 rasagiline Drugs 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229960004181 riluzole Drugs 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 230000001932 seasonal Effects 0.000 description 2
- IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical compound [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 2
- BLFQGGGGFNSJKA-XHXSRVRCSA-N sertraline hydrochloride Chemical compound Cl.C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 BLFQGGGGFNSJKA-XHXSRVRCSA-N 0.000 description 2
- QHJLLDJTVQAFAN-UHFFFAOYSA-M sodium meclofenamate monohydrate Chemical compound O.[Na+].CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl QHJLLDJTVQAFAN-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 229960005138 tianeptine Drugs 0.000 description 2
- 229960002309 toloxatone Drugs 0.000 description 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 229960003741 tranylcypromine Drugs 0.000 description 2
- 229960000281 trometamol Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- BWUUEUAYXWWRBY-LURJTMIESA-N (2S)-2-(difluoromethylamino)-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound FC(F)N[C@H](C(=O)O)CC1=CC=C(O)C(O)=C1 BWUUEUAYXWWRBY-LURJTMIESA-N 0.000 description 1
- LQMMFVPUIVBYII-YFKPBYRVSA-N (2S)-2-methylmorpholine Chemical compound C[C@H]1CNCCO1 LQMMFVPUIVBYII-YFKPBYRVSA-N 0.000 description 1
- GEQODLSAFKKFCC-ZETCQYMHSA-N (2S)-3-(3,4-dihydroxyphenyl)-2-(fluoromethylamino)propanoic acid Chemical compound FCN[C@H](C(=O)O)CC1=CC=C(O)C(O)=C1 GEQODLSAFKKFCC-ZETCQYMHSA-N 0.000 description 1
- WZOCVLIZBXKCIZ-NSHDSACASA-N (2S)-4-[5-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-2-methylmorpholine Chemical compound C1CO[C@@H](C)CN1C1=NC=NC2=C1C(C=1C=C(F)C=CC=1)=CN2 WZOCVLIZBXKCIZ-NSHDSACASA-N 0.000 description 1
- DWLTUUXCVGVRAV-XWRHUKJGSA-N (2S)-5-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopen Chemical compound N([C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O DWLTUUXCVGVRAV-XWRHUKJGSA-N 0.000 description 1
- ORJNLCKHRRUOMU-OGPPPPIKSA-N (3R,4S)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenylpiperidine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 ORJNLCKHRRUOMU-OGPPPPIKSA-N 0.000 description 1
- JEGMWWXJUXDNJN-LURJTMIESA-N (3S)-3-methylpiperidine Chemical compound C[C@H]1CCCNC1 JEGMWWXJUXDNJN-LURJTMIESA-N 0.000 description 1
- LBJYPLZODCWHKE-GOSISDBHSA-N (4R)-4-cyclopropyl-8-fluoro-5-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-1,4-dihydropyrazolo[4,3-c]quinoline Chemical compound C1([C@H]2N(C3=CC=C(C=C3C=3NN=CC=32)F)S(=O)(=O)C=2C=NC(=CC=2)C(F)(F)F)CC1 LBJYPLZODCWHKE-GOSISDBHSA-N 0.000 description 1
- VHNYOQKVZQVBLC-RTCGXNAVSA-N (4R,7E,9aS)-7-[[3-methoxy-4-(4-methylimidazol-1-yl)phenyl]methylidene]-4-(3,4,5-trifluorophenyl)-1,3,4,8,9,9a-hexahydropyrido[2,1-c][1,4]oxazin-6-one Chemical compound C1([C@@H]2COC[C@@H]3CC\C(C(N32)=O)=C/C=2C=C(C(=CC=2)N2C=C(C)N=C2)OC)=CC(F)=C(F)C(F)=C1 VHNYOQKVZQVBLC-RTCGXNAVSA-N 0.000 description 1
- DQNMZSIJHFEYTM-LEWJYISDSA-N (4S,5R)-3-[3-(azepan-1-yl)propyl]-4-(2-methylpropyl)-5-phenyl-1,3-oxazolidin-2-one Chemical compound O([C@@H]([C@@H]1CC(C)C)C=2C=CC=CC=2)C(=O)N1CCCN1CCCCCC1 DQNMZSIJHFEYTM-LEWJYISDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- LQGZMKDJRWNKAR-BTJKTKAUSA-N (Z)-but-2-enedioic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine Chemical compound OC(=O)\C=C/C(O)=O.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 LQGZMKDJRWNKAR-BTJKTKAUSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-Heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-Tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- NCWDBNBNYVVARF-UHFFFAOYSA-N 1,3,2-dioxaborolane Chemical compound B1OCCO1 NCWDBNBNYVVARF-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-Triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- HYFNBIVNYJGFJD-UHFFFAOYSA-N 1-(4-benzylmorpholin-2-yl)ethanone Chemical compound C1COC(C(=O)C)CN1CC1=CC=CC=C1 HYFNBIVNYJGFJD-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-Chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- QEMSVZNTSXPFJA-HNAYVOBHSA-N 1-[(1S,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]-4-phenylpiperidin-4-ol Chemical compound C1([C@H](O)[C@H](C)N2CCC(O)(CC2)C=2C=CC=CC=2)=CC=C(O)C=C1 QEMSVZNTSXPFJA-HNAYVOBHSA-N 0.000 description 1
- FFFVFLJBIVJUEA-UHFFFAOYSA-N 1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-3-carboxamide Chemical compound C1C(C(=O)N)CCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 FFFVFLJBIVJUEA-UHFFFAOYSA-N 0.000 description 1
- BEHWSSWEKOLCEQ-UHFFFAOYSA-N 1-[5-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol Chemical compound C1C(O)CCCN1C1=NC=NC2=C1C(C=1C=C(F)C=CC=1)=CN2 BEHWSSWEKOLCEQ-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- OZNNCYFDQWZWPW-UHFFFAOYSA-N 1-methyl-4-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)imidazole-2-carbonitrile Chemical compound N1=C(C#N)N(C)C=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 OZNNCYFDQWZWPW-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NEMLPWNINZELKP-UHFFFAOYSA-N 2-(2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetyl)oxyethyl-diethyl-methylazanium Chemical compound C=1C=CSC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCC1 NEMLPWNINZELKP-UHFFFAOYSA-N 0.000 description 1
- FAEMYGLKMXUYSG-UHFFFAOYSA-N 2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)morpholine Chemical compound C1CC1C1=NC(C2OCCNC2)=NO1 FAEMYGLKMXUYSG-UHFFFAOYSA-N 0.000 description 1
- BODOVUIEOQOQKC-UHFFFAOYSA-N 2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholine Chemical compound O1C(C)=NC(C2OCCNC2)=N1 BODOVUIEOQOQKC-UHFFFAOYSA-N 0.000 description 1
- XNIOWJUQPMKCIJ-UHFFFAOYSA-N 2-(benzylamino)ethanol Chemical compound OCCNCC1=CC=CC=C1 XNIOWJUQPMKCIJ-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-Phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- RATZLMXRALDSJW-CYBMUJFWSA-N 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole Chemical compound C1([C@@]2(OC3=CC=CC=C3C2)CC)=NCCN1 RATZLMXRALDSJW-CYBMUJFWSA-N 0.000 description 1
- QWGGHPHJMPOSRL-UHFFFAOYSA-N 2-[(4-chloro-5-iodo-2-methylpyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound CC1=NC(Cl)=C2C(I)=CN(COCC[Si](C)(C)C)C2=N1 QWGGHPHJMPOSRL-UHFFFAOYSA-N 0.000 description 1
- HWKSQZFJUUYAMP-UHFFFAOYSA-N 2-[(4-chloro-5-iodo-6-methylpyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C(C)=C(I)C2=C1Cl HWKSQZFJUUYAMP-UHFFFAOYSA-N 0.000 description 1
- XXGYVFAKVLKYMQ-UHFFFAOYSA-N 2-[(4-chloro-5-iodopyrrolo[2,3-d]pyrimidin-7-yl)methoxy]ethyl-trimethylsilane Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=C(I)C2=C1Cl XXGYVFAKVLKYMQ-UHFFFAOYSA-N 0.000 description 1
- DCZPZZUDXLLUEI-UHFFFAOYSA-N 2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]morpholine Chemical compound O1C(C)=NC(CC2OCCNC2)=N1 DCZPZZUDXLLUEI-UHFFFAOYSA-N 0.000 description 1
- JZLHMVWIPPKTKN-UHFFFAOYSA-N 2-[(6-methylpyridin-3-yl)oxymethyl]morpholine Chemical compound C1=NC(C)=CC=C1OCC1OCCNC1 JZLHMVWIPPKTKN-UHFFFAOYSA-N 0.000 description 1
- CUOZKSZYVNPFKE-UHFFFAOYSA-N 2-[[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]methyl]morpholine Chemical compound O1C(C(F)F)=NC(CC2OCCNC2)=N1 CUOZKSZYVNPFKE-UHFFFAOYSA-N 0.000 description 1
- DUGMCDWNXXFHDE-VZYDHVRKSA-N 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C([C@@H](NC(=O)C(C)(N)C)C(=O)N1CCC2(C3=CC=CC=C3N(C2)S(C)(=O)=O)CC1)OCC1=CC=CC=C1 DUGMCDWNXXFHDE-VZYDHVRKSA-N 0.000 description 1
- HRRCOIFSSWCOEA-UHFFFAOYSA-N 2-bromo-1-(3-methyl-1,2-oxazol-5-yl)ethanone Chemical compound CC=1C=C(C(=O)CBr)ON=1 HRRCOIFSSWCOEA-UHFFFAOYSA-N 0.000 description 1
- CALRWNBFESDNSC-UHFFFAOYSA-N 2-chloro-1-fluoro-3-iodo-4-methoxybenzene Chemical compound COC1=CC=C(F)C(Cl)=C1I CALRWNBFESDNSC-UHFFFAOYSA-N 0.000 description 1
- RWKKEILFRAYSDQ-UHFFFAOYSA-N 2-chloro-1-fluoro-4-methoxybenzene Chemical compound COC1=CC=C(F)C(Cl)=C1 RWKKEILFRAYSDQ-UHFFFAOYSA-N 0.000 description 1
- XWSSFRJLOZQOCX-UHFFFAOYSA-N 2-chloro-6-methoxypyrazine Chemical compound COC1=CN=CC(Cl)=N1 XWSSFRJLOZQOCX-UHFFFAOYSA-N 0.000 description 1
- WXQULZKGDNSDIT-UHFFFAOYSA-N 2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1C(O)CCCN1C1=NC=NC2=C1C(C=1C(=C(C#N)C=CC=1)F)=CN2 WXQULZKGDNSDIT-UHFFFAOYSA-N 0.000 description 1
- AHNKWHJBFLDDJQ-UHFFFAOYSA-N 2-fluoro-3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1CC(F)CCN1C1=NC=NC2=C1C(C=1C(=C(C#N)C=CC=1)F)=CN2 AHNKWHJBFLDDJQ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- YRKZBSVDJPNZCS-UHFFFAOYSA-N 2-morpholin-2-ylacetonitrile Chemical compound N#CCC1CNCCO1 YRKZBSVDJPNZCS-UHFFFAOYSA-N 0.000 description 1
- SUFZSYPRKXTQKW-UHFFFAOYSA-N 2-pyrimidin-4-ylmorpholine Chemical compound C1NCCOC1C1=CC=NC=N1 SUFZSYPRKXTQKW-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 description 1
- DGEILIRHSDUTDK-XTEPFMGCSA-N 3-(1,1-dioxothiazinan-2-yl)-5-(ethylamino)-2-fluoro-N-[(2S,3R)-3-hydroxy-1-phenyl-4-[[3-(trifluoromethyl)phenyl]methylamino]butan-2-yl]benzamide Chemical compound FC=1C(C(=O)N[C@@H](CC=2C=CC=CC=2)[C@H](O)CNCC=2C=C(C=CC=2)C(F)(F)F)=CC(NCC)=CC=1N1CCCCS1(=O)=O DGEILIRHSDUTDK-XTEPFMGCSA-N 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N 3-(2-piperidin-4-ylethyl)-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- WRCUUITXMHZHGJ-UHFFFAOYSA-N 3-(4-pyrrolidin-1-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound N#CC1=CC=CC(C=2C3=C(N4CCCC4)N=CN=C3NC=2)=C1 WRCUUITXMHZHGJ-UHFFFAOYSA-N 0.000 description 1
- OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 description 1
- OCVWQSSLXDPQBU-UHFFFAOYSA-N 3-[2-methyl-4-morpholin-4-yl-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C=12C(C=3C=C(C=CC=3)C#N)=CN(COCC[Si](C)(C)C)C2=NC(C)=NC=1N1CCOCC1 OCVWQSSLXDPQBU-UHFFFAOYSA-N 0.000 description 1
- RZRWSNMIDNLNTM-UHFFFAOYSA-N 3-[4-(2-oxa-9-azaspiro[4.5]decan-9-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2C3=C(N4CC5(COCC5)CCC4)N=CN=C3NC=2)=C1 RZRWSNMIDNLNTM-UHFFFAOYSA-N 0.000 description 1
- RNFUZCRIGVXDNJ-UHFFFAOYSA-N 3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile Chemical compound C1=2C(N(C)C)=NC=NC=2NC=C1C1=CC(C#N)=CC=C1F RNFUZCRIGVXDNJ-UHFFFAOYSA-N 0.000 description 1
- CTQLDDHACGXLAE-AWEZNQCLSA-N 3-[4-[(3S)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1[C@@H](O)CCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 CTQLDDHACGXLAE-AWEZNQCLSA-N 0.000 description 1
- XHHPXPWBWLLEJU-LBPRGKRZSA-N 3-[4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzamide Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C(N)=O)=CN2 XHHPXPWBWLLEJU-LBPRGKRZSA-N 0.000 description 1
- NERVYHZAYISIMC-UHFFFAOYSA-N 3-[4-[2-(1,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2C3=C(N4CC(OCC4)C=4ON=CC=4)N=CN=C3NC=2)=C1 NERVYHZAYISIMC-UHFFFAOYSA-N 0.000 description 1
- PPIDYHAZFFBKOT-UHFFFAOYSA-N 3-[4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C1COC(COC)CN1C1=NC=NC2=C1C(C=1C=C(C=CC=1)C#N)=CN2 PPIDYHAZFFBKOT-UHFFFAOYSA-N 0.000 description 1
- KJNNWYBAOPXVJY-UHFFFAOYSA-N 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine Chemical compound CCCCC1=NC(C=2C=CC(OCCCN(CC)CC)=CC=2)=CN1C(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 KJNNWYBAOPXVJY-UHFFFAOYSA-N 0.000 description 1
- PJPNUCDUTMFJAC-UHFFFAOYSA-N 3-[4-[3-(1H-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound N#CC1=CC=CC(C=2C3=C(N4CC(CCC4)C=4NC=CN=4)N=CN=C3NC=2)=C1 PJPNUCDUTMFJAC-UHFFFAOYSA-N 0.000 description 1
- ORFVTYVOAVAUBV-UHFFFAOYSA-N 3-[4-chloro-6-methyl-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C12=C(Cl)N=CN=C2N(COCC[Si](C)(C)C)C(C)=C1C1=CC=CC(C#N)=C1 ORFVTYVOAVAUBV-UHFFFAOYSA-N 0.000 description 1
- NYBATJQRPVYHQE-UHFFFAOYSA-N 3-[4-morpholin-4-yl-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C12=C(N3CCOCC3)N=CN=C2N(COCC[Si](C)(C)C)C=C1C1=CC=CC(C#N)=C1 NYBATJQRPVYHQE-UHFFFAOYSA-N 0.000 description 1
- RDHBVAXWJKDFSK-UHFFFAOYSA-N 3-[6-(difluoromethyl)-4-morpholin-4-yl-7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C12=C(N3CCOCC3)N=CN=C2N(COCC[Si](C)(C)C)C(C(F)F)=C1C1=CC=CC(C#N)=C1 RDHBVAXWJKDFSK-UHFFFAOYSA-N 0.000 description 1
- ONPUDLCOMXVDQL-UHFFFAOYSA-N 3-[6-(difluoromethyl)-4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C=12C(C=3C=C(C=CC=3)C#N)=C(C(F)F)NC2=NC=NC=1N1CCOCC1 ONPUDLCOMXVDQL-UHFFFAOYSA-N 0.000 description 1
- ZYKWKRXHROCPTA-UHFFFAOYSA-N 3-[7-(hydroxymethyl)-6-methyl-4-morpholin-4-ylpyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile Chemical compound C12=C(N3CCOCC3)N=CN=C2N(CO)C(C)=C1C1=CC=CC(C#N)=C1 ZYKWKRXHROCPTA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-M 3-cyclopentylpropanoate Chemical compound [O-]C(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-M 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- ILZPYTXOIXLWFM-UHFFFAOYSA-N 4-(4-fluoropiperidin-1-yl)-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=CC=C1C1=CNC2=NC=NC(N3CCC(F)CC3)=C12 ILZPYTXOIXLWFM-UHFFFAOYSA-N 0.000 description 1
- MUOUHNBOXJIELS-UHFFFAOYSA-N 4-(5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)morpholine Chemical compound C1COCCN1C1=NC=NC2=C1C(C=1C=CC=CC=1)=CN2 MUOUHNBOXJIELS-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- LYJFMIVHZQICEH-LBPRGKRZSA-N 4-[(3S)-3-methylpiperidin-1-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=C(C)C=NC=1)=CN2 LYJFMIVHZQICEH-LBPRGKRZSA-N 0.000 description 1
- AMGLEELZBJNIIZ-ZDUSSCGKSA-N 4-[(3S)-3-methylpiperidin-1-yl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=CC=CC=1)=CN2 AMGLEELZBJNIIZ-ZDUSSCGKSA-N 0.000 description 1
- OLOPFQBPHVBUAY-LBPRGKRZSA-N 4-[(3S)-3-methylpiperidin-1-yl]-5-pyridin-3-yl-7H-pyrrolo[2,3-d]pyrimidine Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=NC=CC=1)=CN2 OLOPFQBPHVBUAY-LBPRGKRZSA-N 0.000 description 1
- MOSVQOBFLZHZNS-LBPRGKRZSA-N 4-[4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=CC(O)=CC=1)=CN2 MOSVQOBFLZHZNS-LBPRGKRZSA-N 0.000 description 1
- PVMURCNOAKOEIY-UHFFFAOYSA-N 4-[5-(1-methylpyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]thiomorpholine Chemical compound C1=NN(C)C=C1C1=CNC2=NC=NC(N3CCSCC3)=C12 PVMURCNOAKOEIY-UHFFFAOYSA-N 0.000 description 1
- ZQFMADILMOIBBC-UHFFFAOYSA-N 4-[5-(2,6-difluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound FC1=CC=CC(F)=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 ZQFMADILMOIBBC-UHFFFAOYSA-N 0.000 description 1
- WOWULVZMWDEPKC-UHFFFAOYSA-N 4-[5-(2-chloro-3-fluoro-6-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CC=C(F)C(Cl)=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 WOWULVZMWDEPKC-UHFFFAOYSA-N 0.000 description 1
- YSHZFIKJKZMGKM-UHFFFAOYSA-N 4-[5-(3-methylsulfanylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound CSC1=CC=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 YSHZFIKJKZMGKM-UHFFFAOYSA-N 0.000 description 1
- BDANSBILGUASKD-UHFFFAOYSA-N 4-[5-(5-fluoro-2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound COC1=CC=C(F)C=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 BDANSBILGUASKD-UHFFFAOYSA-N 0.000 description 1
- BGKRVFNWCIAJLP-UHFFFAOYSA-N 4-[5-(5-fluoro-2-methylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine Chemical compound CC1=CC=C(F)C=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 BGKRVFNWCIAJLP-UHFFFAOYSA-N 0.000 description 1
- IOTSLMMLLXTNNH-UHFFFAOYSA-N 4-bromo-1-methylimidazole Chemical compound CN1C=NC(Br)=C1 IOTSLMMLLXTNNH-UHFFFAOYSA-N 0.000 description 1
- QTPVVNCZZLQQTE-UHFFFAOYSA-N 4-bromo-1-methylimidazole-2-carbonitrile Chemical compound CN1C=C(Br)N=C1C#N QTPVVNCZZLQQTE-UHFFFAOYSA-N 0.000 description 1
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 1
- NRPQELCNMADTOZ-OAQYLSRUSA-N 4-cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazin-1-yl]propyl]-N-pyridin-2-ylbenzamide Chemical compound C([C@@H](C)N1CCN(CC1)C=1C=2OCCOC=2C=CC=1)N(C=1N=CC=CC=1)C(=O)C1=CC=C(C#N)C=C1 NRPQELCNMADTOZ-OAQYLSRUSA-N 0.000 description 1
- UNUXAPUQXDNFJP-UHFFFAOYSA-N 4-fluoro-3-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile Chemical compound FC1=CC=C(C#N)C=C1C1=CNC2=NC=NC(N3CCOCC3)=C12 UNUXAPUQXDNFJP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- BVJKIJWYMMWEGO-LBPRGKRZSA-N 5-(1H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=3C=NNC=3C=CC=1)=CN2 BVJKIJWYMMWEGO-LBPRGKRZSA-N 0.000 description 1
- PYYFMDJYNIMQLA-UHFFFAOYSA-N 5-(3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC(F)=CC(C=2C3=C(N4CCC(F)CC4)N=CN=C3NC=2)=C1 PYYFMDJYNIMQLA-UHFFFAOYSA-N 0.000 description 1
- CNKMORSUWBKGDA-UHFFFAOYSA-N 5-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Chemical compound COC1=CC=C(F)C=C1C1=CNC2=NC=NC(N3CCC(F)CC3)=C12 CNKMORSUWBKGDA-UHFFFAOYSA-N 0.000 description 1
- QNWOSJAGFSUDFE-UHFFFAOYSA-N 5-(aminooxymethyl)-2-bromophenol Chemical compound NOCC1=CC=C(Br)C(O)=C1 QNWOSJAGFSUDFE-UHFFFAOYSA-N 0.000 description 1
- OWUIYQRIRLOCAQ-UHFFFAOYSA-N 5-bromo-2-methylpyrazole-3-carbonitrile Chemical compound CN1N=C(Br)C=C1C#N OWUIYQRIRLOCAQ-UHFFFAOYSA-N 0.000 description 1
- GUMIYPXTEYKCBT-UHFFFAOYSA-N 5-bromoimidazo[2,1-b][1,3]thiazole Chemical compound S1C=CN2C(Br)=CN=C21 GUMIYPXTEYKCBT-UHFFFAOYSA-N 0.000 description 1
- QQWUGDVOUVUTOY-UHFFFAOYSA-N 5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)C(C)C QQWUGDVOUVUTOY-UHFFFAOYSA-N 0.000 description 1
- HNEBPTAKURBYRM-UHFFFAOYSA-N 6-bromopyridine-2-carbonitrile Chemical compound BrC1=CC=CC(C#N)=N1 HNEBPTAKURBYRM-UHFFFAOYSA-N 0.000 description 1
- DHLUJPLHLZJUBW-UHFFFAOYSA-N 6-methylpyridin-3-ol Chemical compound CC1=CC=C(O)C=N1 DHLUJPLHLZJUBW-UHFFFAOYSA-N 0.000 description 1
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102100001248 AKT1 Human genes 0.000 description 1
- 101700006234 AKT1 Proteins 0.000 description 1
- 102100001250 AKT2 Human genes 0.000 description 1
- 102100006725 AKT3 Human genes 0.000 description 1
- 101700004058 AKT3 Proteins 0.000 description 1
- 229940005529 ANTIPSYCHOTICS Drugs 0.000 description 1
- 229940013181 Advil Drugs 0.000 description 1
- 241001251200 Agelas Species 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- FZSPJBYOKQPKCD-UHFFFAOYSA-N Alaproclate Chemical compound CC(N)C(=O)OC(C)(C)CC1=CC=C(Cl)C=C1 FZSPJBYOKQPKCD-UHFFFAOYSA-N 0.000 description 1
- 229960003225 Alaproclate Drugs 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940060515 Aleve Drugs 0.000 description 1
- 229960000836 Amitriptyline Drugs 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010001954 Amnestic disease Diseases 0.000 description 1
- 208000006141 Amyloid angiopathy Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 229940025141 Anafranil Drugs 0.000 description 1
- 229940072359 Anaprox Drugs 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 229940089918 Ansaid Drugs 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N Anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 229950001180 Aptiganel Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940039856 Aricept Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- 229940022802 Atropen Drugs 0.000 description 1
- 229960000396 Atropine Drugs 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 108009000409 Autophagy Proteins 0.000 description 1
- 229950008567 Avagacestat Drugs 0.000 description 1
- 229940031774 Azilect Drugs 0.000 description 1
- 101700044176 BACE Proteins 0.000 description 1
- 101700051112 BACE1 Proteins 0.000 description 1
- 102100015650 BACE1 Human genes 0.000 description 1
- WDJDFFUFZOPSJA-MRVPVSSYSA-N BAY 73-6691 Chemical compound N1C=C2C(=O)N=C(C[C@@H](C)C(F)(F)F)N=C2N1C1=CC=CC=C1Cl WDJDFFUFZOPSJA-MRVPVSSYSA-N 0.000 description 1
- 102100004328 BRAF Human genes 0.000 description 1
- 101700004551 BRAF Proteins 0.000 description 1
- 229950001863 Bapineuzumab Drugs 0.000 description 1
- 229950000017 Befloxatone Drugs 0.000 description 1
- IALVDLPLCLFBCF-CHWSQXEVSA-N Befloxatone Chemical compound O=C1O[C@@H](COC)CN1C1=CC=C(OCC[C@@H](O)C(F)(F)F)C=C1 IALVDLPLCLFBCF-CHWSQXEVSA-N 0.000 description 1
- 229940088007 Benadryl Drugs 0.000 description 1
- 229960000911 Benserazide Drugs 0.000 description 1
- 229940090012 Bentyl Drugs 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N Benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940050390 Benzoate Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940093239 Benztropine Drugs 0.000 description 1
- 229950010365 Bicifadine Drugs 0.000 description 1
- OFYVIGTWSQPCLF-NWDGAFQWSA-N Bicifadine Chemical compound C1=CC(C)=CC=C1[C@@]1(CNC2)[C@H]2C1 OFYVIGTWSQPCLF-NWDGAFQWSA-N 0.000 description 1
- QSQQPMHPCBLLGX-UHFFFAOYSA-N Bifemelane Chemical compound CNCCCCOC1=CC=CC=C1CC1=CC=CC=C1 QSQQPMHPCBLLGX-UHFFFAOYSA-N 0.000 description 1
- 208000004093 Binge-Eating Disorder Diseases 0.000 description 1
- 206010004939 Bipolar I disease Diseases 0.000 description 1
- 206010004940 Bipolar II disease Diseases 0.000 description 1
- 210000001218 Blood-Brain Barrier Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000006752 Brain Edema Diseases 0.000 description 1
- 208000009973 Brain Hypoxia-Ischemia Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 229950006941 Brasofensine Drugs 0.000 description 1
- NRLIFEGHTNUYFL-QJDHNRDASA-N Brasofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2/C=N/OC)=CC=C(Cl)C(Cl)=C1 NRLIFEGHTNUYFL-QJDHNRDASA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 229950000394 Brocresine Drugs 0.000 description 1
- 229950004068 Brofaromine Drugs 0.000 description 1
- WZXHSWVDAYOFPE-UHFFFAOYSA-N Brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- ALELTFCQZDXAMQ-UHFFFAOYSA-N Butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 description 1
- 229960004301 Butriptyline Drugs 0.000 description 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 description 1
- 229940010415 CALCIUM HYDRIDE Drugs 0.000 description 1
- 101700051654 CDK1 Proteins 0.000 description 1
- 102100003733 CDK11A Human genes 0.000 description 1
- 101710003874 CDK11A Proteins 0.000 description 1
- 102100003732 CDK11B Human genes 0.000 description 1
- 101710003872 CDK11B Proteins 0.000 description 1
- 102100008199 CDK17 Human genes 0.000 description 1
- 101700024597 CDK17 Proteins 0.000 description 1
- 102100008200 CDK18 Human genes 0.000 description 1
- 101700032726 CDK18 Proteins 0.000 description 1
- 101700024454 CDK19 Proteins 0.000 description 1
- 102100019396 CDK2 Human genes 0.000 description 1
- 101700048555 CDK2 Proteins 0.000 description 1
- 101710022231 CDK2AP1 Proteins 0.000 description 1
- 102100006129 CDK5 Human genes 0.000 description 1
- 101700001733 CDK5 Proteins 0.000 description 1
- 102100003970 CDK8 Human genes 0.000 description 1
- 102100019698 CHEK2 Human genes 0.000 description 1
- 108060006647 CHEK2 Proteins 0.000 description 1
- IWXUVYOOUMLUTQ-CZUORRHYSA-N CHEMBL2179105 Chemical compound C([C@H]([C@@H](C1)C=2NC(=O)C=3C=NN(C=3N=2)C2CCOCC2)C)N1CC1=NC=CC=N1 IWXUVYOOUMLUTQ-CZUORRHYSA-N 0.000 description 1
- 101710002883 CHUK Proteins 0.000 description 1
- 101710034369 CNKSR2 Proteins 0.000 description 1
- CLGWUCNXOBLWFM-UHFFFAOYSA-N CZC-25146 Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1NS(C)(=O)=O CLGWUCNXOBLWFM-UHFFFAOYSA-N 0.000 description 1
- UUGAXJGDKREHIO-UHFFFAOYSA-N Calcium hydride Chemical compound [H-].[H-].[Ca+2] UUGAXJGDKREHIO-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229940058898 Campral Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N Cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940047493 Celexa Drugs 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 229940097480 Cogentin Drugs 0.000 description 1
- 206010009887 Colitis Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025415 Cyclin-Dependent Kinase 8 Proteins 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N Cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940029644 Cymbalta Drugs 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 101700058684 DGKA Proteins 0.000 description 1
- 102100013597 DGKA Human genes 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 229950008614 Davunetide Drugs 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- MUGNLPWYHGOJEG-UHFFFAOYSA-N Delucemine Chemical compound C=1C=CC(F)=CC=1C(CCNC)C1=CC=CC(F)=C1 MUGNLPWYHGOJEG-UHFFFAOYSA-N 0.000 description 1
- 229950006926 Delucemine Drugs 0.000 description 1
- 206010012256 Delusional disease Diseases 0.000 description 1
- WUFQLZTXIWKION-UHFFFAOYSA-N Deoxypeganine Chemical compound C1C2=CC=CC=C2N=C2N1CCC2 WUFQLZTXIWKION-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 229940076405 Detrol Drugs 0.000 description 1
- SSQJFGMEZBFMNV-PMACEKPBSA-N Dexanabinol Chemical compound C1C(CO)=CC[C@@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@H]21 SSQJFGMEZBFMNV-PMACEKPBSA-N 0.000 description 1
- 229950010249 Dexefaroxan Drugs 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N Dextromethorphan Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229960001985 Dextromethorphan Drugs 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N Dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 Dextrorphan Drugs 0.000 description 1
- 229960004515 Diclofenac Potassium Drugs 0.000 description 1
- 229960001193 Diclofenac Sodium Drugs 0.000 description 1
- 229960002777 Dicycloverine Drugs 0.000 description 1
- CSJLBAMHHLJAAS-UHFFFAOYSA-N Diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 1
- 229950010286 Diolamine Drugs 0.000 description 1
- 208000010309 Disruptive, Impulse Control, and Conduct Disorders Diseases 0.000 description 1
- 229940099170 Ditropan Drugs 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N Dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229950004794 Dizocilpine Drugs 0.000 description 1
- 229940072701 Dolobid Drugs 0.000 description 1
- 229940072340 Dolophine Drugs 0.000 description 1
- 229960003135 Donepezil hydrochloride Drugs 0.000 description 1
- 201000010374 Down syndrome Diseases 0.000 description 1
- 229960005426 Doxepin Drugs 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000010118 Dystonia Diseases 0.000 description 1
- 108030003004 EC 3.6.1.25 Proteins 0.000 description 1
- 102100016350 EIF2AK4 Human genes 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 102100015167 EZR Human genes 0.000 description 1
- 229940098766 Effexor Drugs 0.000 description 1
- 229940011681 Elavil Drugs 0.000 description 1
- 229940084238 Eldepryl Drugs 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 229940071670 Emsam Drugs 0.000 description 1
- 229950004685 Eprodisate Drugs 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N Ethyl iodide Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 229940108366 Exelon Drugs 0.000 description 1
- 229940012356 Eye Drops Drugs 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N Femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- CJOFXWAVKWHTFT-UHFFFAOYSA-N Fluvoxamine Chemical compound COCCCCC(=NOCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-UHFFFAOYSA-N 0.000 description 1
- 208000001914 Fragile X Syndrome Diseases 0.000 description 1
- 108009000484 Fragile X Syndrome Proteins 0.000 description 1
- 108060006676 GCN2 Proteins 0.000 description 1
- 102100008855 GRK6 Human genes 0.000 description 1
- 101700004419 GRK6 Proteins 0.000 description 1
- 102100002069 GSK3A Human genes 0.000 description 1
- 101700074239 GSK3A Proteins 0.000 description 1
- 102100007245 GSK3B Human genes 0.000 description 1
- QORVDGQLPPAFRS-XPSHAMGMSA-N Galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 1
- 229940009600 Gammagard Drugs 0.000 description 1
- 229950000264 Ganstigmine Drugs 0.000 description 1
- 229950002508 Gantenerumab Drugs 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- WZBNEZWCNKUOSM-VOTSOKGWSA-N Gavestinel Chemical compound OC(=O)C=1NC2=CC(Cl)=CC(Cl)=C2C=1\C=C\C(=O)NC1=CC=CC=C1 WZBNEZWCNKUOSM-VOTSOKGWSA-N 0.000 description 1
- 229950005000 Gavestinel Drugs 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- 240000002883 Ginkgo biloba Species 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 229940049906 Glutamate Drugs 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- 229940015042 Glycopyrrolate Drugs 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N HF Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 206010011879 Hearing loss Diseases 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 201000001971 Huntington's disease Diseases 0.000 description 1
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N Hyoscyamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020765 Hypersomnia Diseases 0.000 description 1
- 101710002882 IKBKB Proteins 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102100016182 IRAK1 Human genes 0.000 description 1
- 101700063385 IRAK1 Proteins 0.000 description 1
- 102100016186 IRAK3 Human genes 0.000 description 1
- 101700048447 IRAK3 Proteins 0.000 description 1
- 102100016185 IRAK4 Human genes 0.000 description 1
- 101700044314 IRAK4 Proteins 0.000 description 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N Ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
- 229960002102 Imipramine Hydrochloride Drugs 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- 206010021425 Immune system disease Diseases 0.000 description 1
- 229940089536 Indocin Drugs 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 206010022568 Intermittent explosive disease Diseases 0.000 description 1
- 108010030046 Intravenous Immunoglobulins Proteins 0.000 description 1
- 229950010499 Ipenoxazone Drugs 0.000 description 1
- GGECDTUJZOXAAR-UHFFFAOYSA-N Iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
- 102100019516 JAK2 Human genes 0.000 description 1
- 101700016050 JAK2 Proteins 0.000 description 1
- 101700007593 JAK3 Proteins 0.000 description 1
- 102100019518 JAK3 Human genes 0.000 description 1
- 101700040760 KHS1 Proteins 0.000 description 1
- 102100019632 KSR1 Human genes 0.000 description 1
- 101700047952 KSR1 Proteins 0.000 description 1
- 102100019631 KSR2 Human genes 0.000 description 1
- 101700002529 KSR2 Proteins 0.000 description 1
- 229940039412 Ketalar Drugs 0.000 description 1
- 238000005577 Kumada cross-coupling reaction Methods 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- SFLSHLFXELFNJZ-MRVPVSSYSA-N L-Noradrenaline Natural products NC[C@@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-MRVPVSSYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100009083 LATS1 Human genes 0.000 description 1
- 101700016564 LATS1 Proteins 0.000 description 1
- 102100009086 LATS2 Human genes 0.000 description 1
- 101700040008 LATS2 Proteins 0.000 description 1
- 102200092155 LRRK2 I2020T Human genes 0.000 description 1
- 102200092303 LRRK2 M2397T Human genes 0.000 description 1
- 102200092222 LRRK2 R1441C Human genes 0.000 description 1
- 102200092216 LRRK2 R1441H Human genes 0.000 description 1
- 102200092172 LRRK2 R1628P Human genes 0.000 description 1
- 102200092167 LRRK2 Y1699C Human genes 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 229950008812 Ladostigil Drugs 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 229950007396 Lecozotan Drugs 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 229960003406 Levorphanol Drugs 0.000 description 1
- 210000004558 Lewy Bodies Anatomy 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 229940054157 Lexapro Drugs 0.000 description 1
- 229940002661 Lipitor Drugs 0.000 description 1
- 229940040692 Lithium Hydroxide Monohydrate Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N Lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229940009622 Luvox Drugs 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102100015877 MAP2K2 Human genes 0.000 description 1
- 102100015875 MAP2K3 Human genes 0.000 description 1
- 101710027475 MAP2K3 Proteins 0.000 description 1
- 102100015874 MAP2K4 Human genes 0.000 description 1
- 101710027749 MAP2K4 Proteins 0.000 description 1
- 102100012607 MAP2K6 Human genes 0.000 description 1
- 101710027753 MAP2K6 Proteins 0.000 description 1
- 102100016522 MAP3K1 Human genes 0.000 description 1
- 102100012881 MAP3K11 Human genes 0.000 description 1
- 101710007519 MAP3K11 Proteins 0.000 description 1
- 102100003434 MAP3K3 Human genes 0.000 description 1
- 101710039099 MAP3K3 Proteins 0.000 description 1
- 102100003435 MAP3K4 Human genes 0.000 description 1
- 101710039094 MAP3K4 Proteins 0.000 description 1
- 102100003436 MAP3K5 Human genes 0.000 description 1
- 101710039102 MAP3K5 Proteins 0.000 description 1
- 102100013144 MAP4K1 Human genes 0.000 description 1
- 101710038956 MAP4K1 Proteins 0.000 description 1
- 102100009762 MAP4K5 Human genes 0.000 description 1
- 101710038964 MAP4K5 Proteins 0.000 description 1
- 102100005527 MAPK10 Human genes 0.000 description 1
- 101710029927 MAPK10 Proteins 0.000 description 1
- 101710029923 MAPK7 Proteins 0.000 description 1
- 102100005531 MAPK8 Human genes 0.000 description 1
- 101710029924 MAPK8 Proteins 0.000 description 1
- 102100005528 MAPK9 Human genes 0.000 description 1
- 101710029922 MAPK9 Proteins 0.000 description 1
- 102100000541 MARK2 Human genes 0.000 description 1
- 101700064507 MARK2 Proteins 0.000 description 1
- 102100000543 MARK3 Human genes 0.000 description 1
- 101700085507 MARK3 Proteins 0.000 description 1
- 102100003061 MAST3 Human genes 0.000 description 1
- 101700023912 MAST3 Proteins 0.000 description 1
- 229950005726 MIBAMPATOR Drugs 0.000 description 1
- 101710026102 MIC-ACT-2 Proteins 0.000 description 1
- 101700082651 MLKL Proteins 0.000 description 1
- 102100014836 MLKL Human genes 0.000 description 1
- 101700082295 MST4 Proteins 0.000 description 1
- 102100018545 MYLK Human genes 0.000 description 1
- 101700047297 MYLK Proteins 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 229940110127 Marplan Drugs 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229940041334 Meclofenamate Sodium Drugs 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- 206010027175 Memory impairment Diseases 0.000 description 1
- 206010061284 Mental disease Diseases 0.000 description 1
- 206010027378 Mental retardation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000036650 Metabolic stability Effects 0.000 description 1
- 102000016193 Metabotropic Glutamate Receptors Human genes 0.000 description 1
- 108010010914 Metabotropic Glutamate Receptors Proteins 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N Methyldopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 229950006793 Metitepine Drugs 0.000 description 1
- 229960003955 Mianserin Drugs 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 210000000274 Microglia Anatomy 0.000 description 1
- 229960000600 Milnacipran Drugs 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 229940072709 Motrin Drugs 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- ULRDYYKSPCRXAJ-KRWDZBQOSA-N N-[(2R)-2-[4-[4-[2-(methanesulfonamido)ethyl]phenyl]phenyl]propyl]propane-2-sulfonamide Chemical compound C1=CC([C@@H](C)CNS(=O)(=O)C(C)C)=CC=C1C1=CC=C(CCNS(C)(=O)=O)C=C1 ULRDYYKSPCRXAJ-KRWDZBQOSA-N 0.000 description 1
- MCECSFFXUPEPDB-UHFFFAOYSA-N N-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1H-quinazolin-3-yl]methanesulfonamide Chemical compound CC(C)C1=CC=2NC(=O)N(NS(C)(=O)=O)C(=O)C=2C=C1C1=CC=NN1C MCECSFFXUPEPDB-UHFFFAOYSA-N 0.000 description 1
- 101700059746 NDR1 Proteins 0.000 description 1
- 101700049616 NDRG1 Proteins 0.000 description 1
- 102100018375 NEK1 Human genes 0.000 description 1
- 101700062786 NEK1 Proteins 0.000 description 1
- 101700013583 NEK5 Proteins 0.000 description 1
- 102100019071 NEK6 Human genes 0.000 description 1
- 101700076186 NEK6 Proteins 0.000 description 1
- 102100019068 NEK9 Human genes 0.000 description 1
- 101700083162 NEK9 Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 102100002496 NOS2 Human genes 0.000 description 1
- 101700049309 NOS2 Proteins 0.000 description 1
- 229940089466 Nalfon Drugs 0.000 description 1
- 229940033872 Namenda Drugs 0.000 description 1
- 229940090008 Naprosyn Drugs 0.000 description 1
- 229960003940 Naproxen sodium Drugs 0.000 description 1
- 229940087524 Nardil Drugs 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- OGZQTTHDGQBLBT-UHFFFAOYSA-N Neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 description 1
- 229950004543 Neramexane Drugs 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- 229950008980 Nitecapone Drugs 0.000 description 1
- UPMRZALMHVUCIN-UHFFFAOYSA-N Nitecapone Chemical compound CC(=O)C(C(C)=O)=CC1=CC(O)=C(O)C([N+]([O-])=O)=C1 UPMRZALMHVUCIN-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- MLBHFBKZUPLWBD-UHFFFAOYSA-N Norfenfluramine Chemical compound CC(N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-UHFFFAOYSA-N 0.000 description 1
- 229940079063 Norflex Drugs 0.000 description 1
- 229940087480 Norpramin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N OC(=O)C(N)CCCNC(N)=N Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229950004864 Olamine Drugs 0.000 description 1
- 229960005343 Ondansetron Drugs 0.000 description 1
- UEBBYLJZCHTLEG-UHFFFAOYSA-N Org 25935 Chemical compound OC(=O)CN(C)CC1CCC2=CC(OC)=CC=C2C1C1=CC=CC=C1 UEBBYLJZCHTLEG-UHFFFAOYSA-N 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N Orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229960003941 Orphenadrine Drugs 0.000 description 1
- 240000000645 Oxalis tuberosa Species 0.000 description 1
- 235000008469 Oxalis tuberosa Nutrition 0.000 description 1
- 229940097438 Oxytrol Drugs 0.000 description 1
- 102100003596 PAN3 Human genes 0.000 description 1
- 108060006669 PAN3 Proteins 0.000 description 1
- YZPOQCQXOSEMAZ-UHFFFAOYSA-N PBT2 Chemical compound ClC1=CC(Cl)=C(O)C2=NC(CN(C)C)=CC=C21 YZPOQCQXOSEMAZ-UHFFFAOYSA-N 0.000 description 1
- 101700084262 PDE1C Proteins 0.000 description 1
- 101710004245 PDPK2P Proteins 0.000 description 1
- 102100013273 PI4KB Human genes 0.000 description 1
- 101700081872 PI4KB Proteins 0.000 description 1
- 102100019473 PIK3C3 Human genes 0.000 description 1
- 101710027425 PIK3C3 Proteins 0.000 description 1
- 102100019474 PIK3CB Human genes 0.000 description 1
- 101710027441 PIK3CB Proteins 0.000 description 1
- 102100013248 PIK3CD Human genes 0.000 description 1
- 101710027435 PIK3CD Proteins 0.000 description 1
- 102100013249 PIK3CG Human genes 0.000 description 1
- 101710027438 PIK3CG Proteins 0.000 description 1
- 101710025242 PIKFYVE Proteins 0.000 description 1
- 102100012699 PIKFYVE Human genes 0.000 description 1
- 102100002775 PIP4K2A Human genes 0.000 description 1
- 101710038360 PIP4K2A Proteins 0.000 description 1
- 101710007088 PIP5K3 Proteins 0.000 description 1
- 102100012348 POLD1 Human genes 0.000 description 1
- 101710040092 POLD1 Proteins 0.000 description 1
- 102100012041 PRKAA2 Human genes 0.000 description 1
- 101710035826 PRKAA2 Proteins 0.000 description 1
- 102100016975 PRKD2 Human genes 0.000 description 1
- 101710025003 PRKD2 Proteins 0.000 description 1
- 102100003225 PRKDC Human genes 0.000 description 1
- 101700061400 PRKDC Proteins 0.000 description 1
- BSLXKMCHXRCBIH-UHFFFAOYSA-N PRX-07034 Chemical compound COC1=CC(Cl)=CC(C(C)NC=2C(=CC=C(C=2)N2CCNCC2)S(C)(=O)=O)=C1OC BSLXKMCHXRCBIH-UHFFFAOYSA-N 0.000 description 1
- 101710043635 PTK2B Proteins 0.000 description 1
- 102100017882 PTK2B Human genes 0.000 description 1
- 101710014227 PYK2 Proteins 0.000 description 1
- CXYRUNPLKGGUJF-OZVSTBQFSA-M Pamine Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-OZVSTBQFSA-M 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 206010033666 Panic disease Diseases 0.000 description 1
- 208000006199 Parasomnias Diseases 0.000 description 1
- 229940026768 Parcopa Drugs 0.000 description 1
- 208000003715 Parkinsonian Disorders Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229940087824 Parnate Drugs 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 229940001408 Paxil Drugs 0.000 description 1
- PRMWGUBFXWROHD-UHFFFAOYSA-N Perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 description 1
- 229960005198 Perampanel Drugs 0.000 description 1
- 229950006454 Perzinfotel Drugs 0.000 description 1
- BDABGOLMYNHHTR-UHFFFAOYSA-N Perzinfotel Chemical compound OP(O)(=O)CCN1CCCNC2=C1C(=O)C2=O BDABGOLMYNHHTR-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940066842 Petrolatum Drugs 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229960000964 Phenelzine Drugs 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229960001697 Physostigmine Drugs 0.000 description 1
- 229960001847 Physostigmine sulfate Drugs 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 201000011585 Pick's disease Diseases 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 229960005095 Pioglitazone Drugs 0.000 description 1
- 229950010765 Pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229950003486 Ponezumab Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940014148 Pristiq Drugs 0.000 description 1
- 229940099209 Probanthine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 229940035613 Prozac Drugs 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Quinoform Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- 101710016374 RABA4C Proteins 0.000 description 1
- 102100002826 RDX Human genes 0.000 description 1
- 102100014268 RIPK3 Human genes 0.000 description 1
- 101700064990 RIPK3 Proteins 0.000 description 1
- 102100012083 RPS6KA2 Human genes 0.000 description 1
- 101710010020 RPS6KA2 Proteins 0.000 description 1
- 102100012081 RPS6KA5 Human genes 0.000 description 1
- 101710009858 RPS6KA5 Proteins 0.000 description 1
- 101710009855 RPS6KC1 Proteins 0.000 description 1
- 102100011613 RPS6KC1 Human genes 0.000 description 1
- 229940051845 Razadyne Drugs 0.000 description 1
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 1
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038932 Retinopathy Diseases 0.000 description 1
- 229940072169 Rilutek Drugs 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N Ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 Ritanserin Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229940106905 Robinul Drugs 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102100018046 SGK3 Human genes 0.000 description 1
- 101700018107 SGK3 Proteins 0.000 description 1
- 102100004167 SMG1 Human genes 0.000 description 1
- 101700072540 SMG1 Proteins 0.000 description 1
- 101700065463 STK11 Proteins 0.000 description 1
- 102100019330 STK11 Human genes 0.000 description 1
- 102100000803 STK24 Human genes 0.000 description 1
- 101700058168 STK24 Proteins 0.000 description 1
- 102100000798 STK25 Human genes 0.000 description 1
- 101700050878 STK25 Proteins 0.000 description 1
- 102100000799 STK26 Human genes 0.000 description 1
- 101700049174 STK26 Proteins 0.000 description 1
- 102100002799 STK38 Human genes 0.000 description 1
- 101700074093 STK38 Proteins 0.000 description 1
- 102100000814 STK38L Human genes 0.000 description 1
- 101710022045 STK38L Proteins 0.000 description 1
- 229950002652 Safinamide Drugs 0.000 description 1
- NEMGRZFTLSKBAP-LBPRGKRZSA-N Safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 1
- 229950004454 Selurampanel Drugs 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229960002073 Sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229940001089 Sinemet Drugs 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 229950007874 Solanezumab Drugs 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N Spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 Spiperone Drugs 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N Staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000004490 Stress Disorders, Traumatic, Acute Diseases 0.000 description 1
- RINCXYDBBGOEEQ-UHFFFAOYSA-N Succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 1
- 102100005604 TBK1 Human genes 0.000 description 1
- 101700066570 TBK1 Proteins 0.000 description 1
- RBSRZNXPRRVYBU-UHFFFAOYSA-O TBK1 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)CO[P+](O)=O)C(OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OCC2C(CC(O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=O)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 RBSRZNXPRRVYBU-UHFFFAOYSA-O 0.000 description 1
- 102100009618 TLK1 Human genes 0.000 description 1
- 101700085639 TLK1 Proteins 0.000 description 1
- 102100009619 TLK2 Human genes 0.000 description 1
- 101700063512 TLK2 Proteins 0.000 description 1
- 102100011657 TNIK Human genes 0.000 description 1
- 101700072700 TNIK Proteins 0.000 description 1
- 102100009828 TP53RK Human genes 0.000 description 1
- 101710018044 TP53RK Proteins 0.000 description 1
- 206010043118 Tardive dyskinesia Diseases 0.000 description 1
- 229950005628 Tarenflurbil Drugs 0.000 description 1
- 229940000238 Tasmar Drugs 0.000 description 1
- 229950009970 Tesofensine Drugs 0.000 description 1
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N Tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 description 1
- 229960004523 Tiletamine Drugs 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940041597 Tofranil Drugs 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 229940035321 Transderm Scop Drugs 0.000 description 1
- 229950005135 Traxoprodil Drugs 0.000 description 1
- 229960003991 Trazodone Drugs 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N Triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N Trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- MDYOLVRUBBJPFM-UHFFFAOYSA-N Tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 description 1
- 102100014665 ULK3 Human genes 0.000 description 1
- 101700072461 ULK3 Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- NPTIPEQJIDTVKR-STQMWFEESA-N Vabicaserin Chemical compound C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 description 1
- 229950009968 Vabicaserin Drugs 0.000 description 1
- 229940063674 Voltaren Drugs 0.000 description 1
- 101700081474 WNK3 Proteins 0.000 description 1
- 101700056831 WNK4 Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 101700083482 ZAP70 Proteins 0.000 description 1
- 102100005283 ZAP70 Human genes 0.000 description 1
- 229940068543 Zelapar Drugs 0.000 description 1
- BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 description 1
- 229950009086 Zicronapine Drugs 0.000 description 1
- 229940072168 Zocor Drugs 0.000 description 1
- 229940072018 Zofran Drugs 0.000 description 1
- 229940020965 Zoloft Drugs 0.000 description 1
- 229940061740 Zyvox Drugs 0.000 description 1
- IHHXIUAEPKVVII-ZSCHJXSPSA-N [(1S)-5-amino-1-carboxypentyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCC[NH3+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 IHHXIUAEPKVVII-ZSCHJXSPSA-N 0.000 description 1
- LHXOCOHMBFOVJS-OAHLLOKOSA-N [(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate Chemical compound CCN(C)C(=O)OC1=CC=C2CC[C@@H](NCC#C)C2=C1 LHXOCOHMBFOVJS-OAHLLOKOSA-N 0.000 description 1
- JGAGHIIOCADQOV-CTNGQTDRSA-N [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-(2-methylphenyl)carbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1C JGAGHIIOCADQOV-CTNGQTDRSA-N 0.000 description 1
- PBHFNBQPZCRWQP-QUCCMNQESA-N [(3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] N-phenylcarbamate Chemical compound CN([C@@H]1[C@@](C2=C3)(C)CCN1C)C2=CC=C3OC(=O)NC1=CC=CC=C1 PBHFNBQPZCRWQP-QUCCMNQESA-N 0.000 description 1
- YYBNDIVPHIWTPK-KYJQVDHRSA-N [(3aS,8bS)-3,4,8b-trimethyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indol-3-ium-7-yl] N-methylcarbamate;sulfate Chemical compound [O-]S([O-])(=O)=O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CC[NH+]2C YYBNDIVPHIWTPK-KYJQVDHRSA-N 0.000 description 1
- ZOBDWFRKFSPCRB-UNMCSNQZSA-N [(4aS,9aS)-2,4a,9-trimethyl-4,9a-dihydro-3H-oxazino[6,5-b]indol-6-yl] N-(2-ethylphenyl)carbamate Chemical compound CCC1=CC=CC=C1NC(=O)OC1=CC=C(N(C)[C@@H]2[C@@]3(C)CCN(C)O2)C3=C1 ZOBDWFRKFSPCRB-UNMCSNQZSA-N 0.000 description 1
- CLTLWPSRLYCESA-UHFFFAOYSA-N [1-(5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanol Chemical compound C1CC(CO)CCN1C1=NC=NC2=C1C(C=1C=CC=CC=1)=CN2 CLTLWPSRLYCESA-UHFFFAOYSA-N 0.000 description 1
- BZLDSVLRJULHNF-UHFFFAOYSA-N [2-fluoro-5-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methanol Chemical compound C1=C(F)C(CO)=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 BZLDSVLRJULHNF-UHFFFAOYSA-N 0.000 description 1
- WSFKANMHWWIKSD-UHFFFAOYSA-N [3-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methanol Chemical compound OCC1=CC=CC(C=2C3=C(N4CCOCC4)N=CN=C3NC=2)=C1 WSFKANMHWWIKSD-UHFFFAOYSA-N 0.000 description 1
- FALGNGIGJAIJGO-UHFFFAOYSA-N [3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]methanol Chemical compound C1=2C(N(C)C)=NC=NC=2NC=C1C1=CC=CC(CO)=C1 FALGNGIGJAIJGO-UHFFFAOYSA-N 0.000 description 1
- NQQQLNQSORSJDK-IBGZPJMESA-N [3-[7-(4-methylphenyl)sulfonyl-4-[(3S)-3-methylpiperidin-1-yl]pyrrolo[2,3-d]pyrimidin-5-yl]phenyl]methanol Chemical compound C1[C@@H](C)CCCN1C1=NC=NC2=C1C(C=1C=C(CO)C=CC=1)=CN2S(=O)(=O)C1=CC=C(C)C=C1 NQQQLNQSORSJDK-IBGZPJMESA-N 0.000 description 1
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 201000005913 acute stress disease Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001773 anti-convulsant Effects 0.000 description 1
- 230000000561 anti-psychotic Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940111121 antirheumatic drugs Quinolines Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 201000002055 autistic disease Diseases 0.000 description 1
- 230000006877 autophagy Effects 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 108010047242 bapineuzumab Proteins 0.000 description 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
- IMNRJGSQCGFPHL-UHFFFAOYSA-N benzene;oxolane Chemical compound C1CCOC1.C1=CC=CC=C1 IMNRJGSQCGFPHL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 229940024774 benztropine mesylate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960004933 bifemelane Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 210000003008 brain-resident macrophage Anatomy 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-M camphorsulfonate anion Chemical compound C1CC2(CS([O-])(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 125000005586 carbonic acid group Chemical group 0.000 description 1
- 229960005123 cariprazine Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000008779 central nervous system disease Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960005228 clioquinol Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 108010002212 colostrinine Proteins 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 201000009929 conduct disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-M cyclohexylsulfamate Chemical compound [O-]S(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-M 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003436 cytoskeletal Effects 0.000 description 1
- 108010042566 davunetide Proteins 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- KXZOIWWTXOCYKR-UHFFFAOYSA-M diclofenac potassium Chemical compound [K+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KXZOIWWTXOCYKR-UHFFFAOYSA-M 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- DZBUCNOWPYGXJL-UHFFFAOYSA-L disodium;1,4-dioxane;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.C1COCCO1 DZBUCNOWPYGXJL-UHFFFAOYSA-L 0.000 description 1
- DKGJFKPIUSHDIT-UHFFFAOYSA-L disodium;propane-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCCS([O-])(=O)=O DKGJFKPIUSHDIT-UHFFFAOYSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-M dodecyl sulfate Chemical compound CCCCCCCCCCCCOS([O-])(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-M 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 108010055671 ezrin Proteins 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000011240 frontotemporal dementia Diseases 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 229960002024 galantamine hydrobromide Drugs 0.000 description 1
- 108010045722 gantenerumab Proteins 0.000 description 1
- 201000006529 generalized anxiety disease Diseases 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000003400 hallucinatory Effects 0.000 description 1
- 230000002140 halogenating Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229940076716 ibutamoren mesylate Drugs 0.000 description 1
- VSZJXVNWPNOCME-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical compound S1C=CN2[C]=CN=C21 VSZJXVNWPNOCME-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002589 iproclozide Drugs 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M isothiocyanate Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000002025 microglial Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000009457 movement disease Diseases 0.000 description 1
- 101700028563 msk1 Proteins 0.000 description 1
- 101710031795 mst101(3) Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 230000003533 narcotic Effects 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- DLWSRGHNJVLJAH-UHFFFAOYSA-N nitroflurbiprofen Chemical compound FC1=CC(C(C(=O)OCCCCO[N+]([O-])=O)C)=CC=C1C1=CC=CC=C1 DLWSRGHNJVLJAH-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- MMMNTDFSPSQXJP-UHFFFAOYSA-N orphenadrine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 MMMNTDFSPSQXJP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003585 oxepinyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 101710004309 p38a Proteins 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 108060002036 pde-2 Proteins 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229960003293 penthienate Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 description 1
- 229960002516 physostigmine salicylate Drugs 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 101700023985 pol3 Proteins 0.000 description 1
- 229920001888 polyacrylic acid Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 108010058215 ponezumab Proteins 0.000 description 1
- 201000008839 post-traumatic stress disease Diseases 0.000 description 1
- 230000001144 postural Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- JWRDEPYIIBDWDI-UHFFFAOYSA-M potassium;6-oxo-5-(3-piperidin-1-ylpropylcarbamoyl)-7-propan-2-ylthieno[2,3-b]pyridin-4-olate Chemical compound [K+].O=C1N(C(C)C)C=2SC=CC=2C([O-])=C1C(=O)NCCCN1CCCCC1 JWRDEPYIIBDWDI-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic Effects 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000005412 pyrazyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 108010048484 radixin Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 102220010566 rs74163686 Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000978 schizoaffective disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 201000000261 schizophreniform disease Diseases 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003678 selegiline hydrochloride Drugs 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 201000001880 sexual dysfunction Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 108010079667 solanezumab Proteins 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- LFWHFZJPXXOYNR-MFOYZWKCSA-N sulindac sulfide Chemical compound C1=CC(SC)=CC=C1\C=C\1C2=CC=C(F)C=C2C(CC(O)=O)=C/1C LFWHFZJPXXOYNR-MFOYZWKCSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FJYBLMJHXRWDAQ-UHFFFAOYSA-N tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC(CO)C1 FJYBLMJHXRWDAQ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003777 thiepinyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005161 thyroid carcinoma Diseases 0.000 description 1
- QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960003570 tramiprosate Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-M undecanoate Chemical compound CCCCCCCCCCC([O-])=O ZDPHROOEEOARMN-UHFFFAOYSA-M 0.000 description 1
- 201000004810 vascular dementia Diseases 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 229960003740 vilazodone Drugs 0.000 description 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N α-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
Abstract
The present invention provides novel 4,5disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R1, R2, R3, R4 and R5 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
Description
NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-cOPYRIMIDINES AS LRRK2 INHIBITORS
Field of the Invention
The présent invention relates to small molécule inhibitors of leucine-rich repeat kinase 2 (LRRK2). This invention also relates to methods of inhibiting, in mammals, including humans, LRRK2 by administration of the small molécule LRRK2 inhibitors. The présent invention also relates to the treatment of Parkinson's Disease (PD) and other neurodegenerative and/or neurological disorders in mammals, including humans with the LRRK2 inhibitors. More particularly, this invention relates to 4-(substitutedamino)-7H-pyrrolo[2,3-d]pyrimidine compounds useful for the treatment of neurodegenerative and/or neurological disorders, such as PD, Alzheimer’s Disease (AD) and other LRRK2 associated disorders.
Backqround of the Invention
LRRK2 is a 286 kDa active protein kinase in the ROCO protein family with a complex multidomain structure and which has structural homology to the MAP kinase kinase kinases (MAPKKK). LRRK2 has been shown to phosphorylate moeisin (at Thr558), ezrin and radixin in vitro. LRRK2 has been found in various régions of the brain as well as in the heart, lung, spleen and kidney. Independent domains that hâve been established for the LRRK2 protein include an ankyrin-like (ANK) domain, a leucine-rich repeat (LRR) domain, a Ras (renin-angiotensin system) of complex (ROC) domain, a Cterminal of ROC (COR) domain, a kinase (Kinase) domain and a C-terminal WD40 domain. The ROC domain binds guanosine triphosphate (GTP) and the COR domain may be a regulator of the ROC domain’s GTPase activity.
With multiple domains and both active kinase and guanosine triphosphatase (GTPase) activity, LRRK2 appears to play a complex rôle in multiple cellular processes. For example, LRRK2 has been associated with NFAT inhibition in the immune system and has been linked to vesicle trafficking, presynaptic homeostasis, mammalian target of rapamycin (mTOR) signaling, signaling through the receptor tyrosine kinase MET in papillary rénal and thyroid carcinomas, cytoskeletal dynamics, the mitogen-activated protein kinase (MAPK) pathway, the tumor necrosis factor-α (TNF-a) pathway, the Wnt pathway and autophagy. Recent genome-wide association (GWA) genetic studies hâve *
implicated LRRK2 in the pathogenesis of various human diseases such as PD, inflammatory bowel disease (Crohn’s disease), cancer and leprosy (Lewis, P.A. and Manzoni, C. Science Signaling 2012, 5(207), pe2).
Parkinson’s Disease is a relatively common age-related neurodegenerative disorder resulting from the progressive loss of dopamine-producing neurons and which affects up to 4% of the population over 80. PD is characterized by both motoric and non-motoric symptoms such as tremor at rest, rigidity, akinesia and postural instability as well as non-motor symptoms such as impairment of cognition, sleep and sense of smell. Genome-wide association studies hâve linked LRRK2 to PD and many patients with point mutations in LRRK2 présent symptoms that are indistinguishable from those with idiopathic PD. Over 20 LRRK2 mutations hâve been associated with autosomaldominant parkinsonism, and the R1441C, R1441G, R1441H, Y1699C, G2019S, I2020T and N1437H missense mutations are considered to be pathogenic. The LRRK2 R1441G mutation has been shown to increase the release of proinflammatory cytokines (higher Ievels of TNF-α, IL-1 β, IL-12 and lower Ievels of IL-10) in microglial cells from transgenic mice and thus may resuit in direct toxicity to neurons (Gillardon, F. et al. Neuroscience 2012, 208, 41-48). In a murine model of neuroinflammation, induction of LRRK2 in microglia was observed and inhibition of LRRK2 kinase activity with small molécule LRRK2 inhibitors (LRRK2-IN-1 or sunitinib) or LRRK2 knockout resulted in atténuation of TNF-α sécrétion and nitric oxide synthase (iNOS) induction (Moehle, M. et al. J. Neurosci. 2012, 32(5), 1602-1611). The most common of the LRRK2 mutations, G2019S, is présent in more than 85% of PD patients carrying LRRK2 mutations. This mutation, which is présent in the LRRK2 kinase domain, leads to an enhancement of LRRK2 kinase activity. In the human brain LRRK2 expression is highest in the same régions of the brain that are impacted by PD, and LRRK2 is found in Lewy Bodies, a hallmark of PD. Recent studies indicate that a potent, sélective, brain-penetrant kinase inhibitor for LRRK2 could be a therapeutic treatment for PD.
Dementia results from a wide variety of distinctive pathological processes. The most common pathological processes causing dementia are AD, cérébral amyloid angiopathy (CM) and prion-mediated diseases (see, e.g., Haan et al., Clin. Neurol. Neurosurg. 1990, 92(4):305-310; Glenner et al., J. Neurol. Sci. 1989, 94:1-28). AD is a progressive, neurodegenerative disorder characterized by memory impairment and cognitive dysfunction. AD affects nearly half of ail people past the âge of 85, the most
rapidly growing portion of the United States population. As such, the number of AD patients in the United States is expected to increase from about 4 million to about 14 million by 2050. LRRK2 mutations hâve been associated with AD-like pathology, which suggests that there may be a partial overlap between the neurodegenerative pathways 5 in both AD and PD (Zimprach, A. et al. Neuron 2004, 44, 601-607). In addition, the
LRRK2 R1628P variant (COR domain) has been associated with an increased incidence of AD in a certain population, perhaps resulting from increased apoptosis and cell death (Zhao, Y. et al.; Neurobiology of Aging 2011,32, 1990-1993.
An increased incidence of certain non-skin cancers such as rénal, breast, lung 10 and prostate cancers, as well as acute myelogenous leukemia (AML), has been reported in Parkinson’s disease patients with the LRRK2 G2019S mutation (SaundersPullman, R. et al.; Movement Disorders, 2010, 25(15), 2536-2541). Since the G2019S mutation is associated with increased LRRK2 kinase activity, inhibition of this activity may be useful in the treatment of cancer, such as kidney, breast, lung, prostate and 15 blood cancers.
Inflammatory bowel disease (IBD) or Crohn’s disease (CD) is a complex disease and is believed to resuit from an inappropriate immune response to microbiota in the intestinal tract. Genome-wide association studies hâve recently identified LRRK2 as a major susceptibility gene for Crohn’s disease, particularly the M2397T polymorphism in 20 the WD40 domain (Liu, Z. et al. Nat. Immunol. 2011, 12, 1063-1070). In a recent study LRRK2 déficient mice were found to be more susceptible to dextran sodium sulfate induced colitis than their wild-type counterparts, indicating that LRRK2 may play a rôle in the pathogenesis of IBD (Liu, Z. and Lenardo, M.; Cell Research 2012, 1-3).
Both non-selective and sélective small molécule compounds with LRRK2 25 inhibitory activity such as staurosporine, sunitinib, LRRK2-IN-1, CZC-25146, TAE684 and those in WO 2011/141756, WO 2012/028629 and WO 2012/058193 hâve been described. It is désirable to provide compounds which are potent and sélective inhibitors of LRRK2 with a favorable pharmacokinetic profile and the ability to to traverse the blood brain barrier. Accordingly, the présent invention is directed to novel 30 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidine compounds with LRRK2 inhibitory activity and the use of these compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases, including PD.
Summary of the Invention
A first embodiment of a first aspect of the présent invention is a compound of Formula I
or a pharmaceutically acceptable sait thereof wherein R1 and R2 are each independently hydrogen, CrCealkyl, C3-C7cycloalkyl, a four to seven membered heterocycloalkyl which contains one to three heteroatoms selected from N, O and S; or a five to six membered heteroaryl which contains one to four heteroatoms selected from N, O and S, wherein the CrCealkyl, C3-C7cycloalkyl, four to seven membered heterocycloalkyl, or five to six membered heteroaryl are optionally substîtuted with one to three R6; or R1 and R2 taken together with the nitrogen to which they are attached are a four to seven membered heterocycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S, and optionally contains one double bond; a six to eleven membered heterobicycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; or a six to twelve membered heterospirocycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; and wherein the four to seven membered heterocycloalkyl, six to eleven membered heterobicycloalkyl or six to twelve membered heterospirocycloalkyl is optionally substîtuted with one to three R7; R3 is phenyl or a five to ten membered heteroaryl which contains one to four heteroatoms selected from N, O and S; wherein the phenyl and five to ten membered heteroaryl are optionally substîtuted with one to three R9 and wherein the phenyl is optionally fused with a C5Cecycloalkyl or a five to six membered heterocycloalkyl which contains one to three heteroatoms selected from N, O and S and which is optionally substîtuted with oxo; R4 and R5 are each independently hydrogen or CrCealkyl; R6 at each occurrence is independently selected from CrCealkyl, CrCsalkoxy, hydroxy, halo, -NRaRb, C(O)NRaRb, or a four to seven membered heterocycloalkyl which contains one to three heteroatoms selected from N, O and S; R7 at each occurrence is independently
selected from halo, hydroxy, cyano, -NRaRb, -C(O)NRaRb, Ci-C6alkyl, Ci-C6alkoxy, phenyl, a five to six membered heteroaryl containing one to four heteroatoms selected from N, O and S, or two R7 when attached to the same carbon and taken together can be oxo; wherein the CrCealkyl, phenyl and five to six membered heteroaryl are optionally substituted with one to three R8; R8 at each occurrence is independently hydroxy, halo, cyano, Ci-C3alkoxy, NRaRb, CrC3alkyl optionally substituted with one to three halo, Ca-Czcycloalkyl, phenoxy optionally substituted with cyano, or a five to six membered heteroaryloxy containing one to four heteroatoms selected from N, O and S and which is optionally substituted with one or two halo or CrCealkyl; R9 at each occurrence is independently cyano, halo, hydroxy, CrC3alkyl-S-, -CO2H, -C(O)NH2, S(O)2NH2, CrCealkyl optionally substituted with one to three halo or hydroxy, or Cr Cealkoxy optionally substituted with one to three halo or hydroxy; and Ra and Rb at each occurrence are each independently hydrogen, CrCealkyl, C3-C7cycloalkyl or -C(0)Cr C6alkyl.
A second embodiment of a first aspect of the présent invention is the compound of the first embodiment of the first aspect wherein R4 and R5 are each hydrogen; or a pharmaceutically acceptable sait thereof.
A third embodiment of a first aspect of the présent invention is the compound of the second embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are azetidin-1 -yl, pyrrolidin-1 -yl, piperidin-1 -yl, morpholin-4-yl, thiomorpholin-4-yl, 6-oxa-3-aza-bicyclo[3.1.1]heptan-3-yl,
HN each of which is optionally substituted with one to three R7; or a pharmaceutically acceptable sait thereof.
A fourth embodiment of a first aspect of the présent invention is the compound of the third embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are piperidin-1-yl or morpholin-4-yl; each optionally
substituted with a hydroxy, methyl or 5-methyl-1,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable sait thereof.
A fifth embodiment of a first aspect of the présent invention is the compound of the fourth embodiment of the first aspect wherein R1 and R2 taken together with the 5 nitrogen to which they are attached are morpholin-4-yl optionally substituted with a methyl or 5-methyl-1,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable sait thereof.
A sixth embodiment of a first aspect of the présent invention is the compound of the second embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are methylamino, dimethylamino, diethylamino, N10 methylcyclopropylamino or pyrazolylamino; each of which is optionally substituted with one to three R6; or a pharmaceutically acceptable sait thereof.
An seventh embodiment of a first aspect of the présent invention is the compound of the third embodiment of the first aspect wherein R3 is phenyl substituted with one or two R9; and each R9 is independently selected from cyano, fluoro, chloro or 15 methoxy; or a pharmaceutically acceptable sait thereof.
An eighth embodiment of a first aspect the présent invention is the compound of the third embodiment of the first aspect wherein R3 is pyrazolyl, isothiazolyl, or pyridinyl, each optionally substituted with one R9; and R9 is cyano or methyl; or a pharmaceutically acceptable sait thereof.
A ninth embodiment of a first aspect of the présent invention is the compound of the first embodiment of the first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached is selected from the group consisting of:
OH
R3 is 1-methylpyrazol-4-yl, 1 /-/-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1,2-thiazol-5yl, 5-cyano-1-methylpyrrol-3-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3fluorophenyl, 2,3-difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 25 methoxy-5-fluorophenyl; and R4 and R5 are each independently hydrogen or methyl; or a pharmaceutically acceptable sait thereof.
A tenth embodiment of a first aspect of the présent invention is the compound of the ninth embodiment wherein R1 and R2 taken together with the nitrogen to which they are attached are a group selected from:
and R4 and R5 are each hydrogen; or a pharmaceutically acceptable sait thereof.
An eleventh embodiment of a first aspect of the présent invention is the compound of the tenth embodiment of the first aspect wherein R1 and R2 taken together 5 with the nitrogen to which they are attached is
or a pharmaceutically acceptable sait thereof.
A twelfth embodiment of a faspect of the présent invention is the compound of the eleventh embodiment of the first aspect wherein R3 is 3-cyanophenyl, 110 methylpyrazol-4-yl or 5-cyano-1-methylpyrrol-3-yl; or a pharmaceutically acceptable sait thereof.
A thirteenth embodiment of a first aspect of the présent invention is the compound of the first embodiment of a first aspect wherein R1 and R2 taken together with the nitrogen to which they are attached are piperidinyl or 3-hydroxypiperidinyl; R3 is 15 1-methylpyrazol-4-yl, 1/-/-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1,2-thiazol-5-yl, 3methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2-methoxy-5-fluorophenyl; and R4 and R5 are each independently hydrogen or methyl; or a pharmaceutically acceptable sait thereof.
A fourteenth embodiment of a first aspect of the invention is a compound of the first embodiment of the first aspect selected from the group consisting of:
5- (1-methyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
3-[6-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]pyridine-2-carbonitnle;
3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3-{4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimïdin-5-yl}benzonitrile;
(3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenyl)methanol;
4-(morpholin-4-yl)-5-(1/7-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
{3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]phenyl}methanol;
3-[4-(3,3-dimethylpiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(piperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
1-(5-phenyl-7/-/-pyrrolo[2,3-c/]pyrimidin-4-yl)piperidine-3-carboxamide;
3- {4-[(3S)-3-hydroxypiperidin-1-yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-methylpiperidin-1-yl]-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-methylpiperidin-1 -yl]-5-(1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5- phenyl-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
[1-(5-phenyl-7/-/-pyrrolo[2,3-c/|pyrimidin-4-yl)piperidin-4-yl]methanol;
1-{5-[3-(hydroxymethyl)phenyl]-7H-pyrrolo[2,3-d|pyrimidin-4-yl}piperidine-3-carbonitrile;
1-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-3-carbonitrile;
4-(3,5-c/s-dimethylpiperidin-1 -yl)-5-( 1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3ûflpyrimidine;
4- methoxy-3-[4-(3-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-^pyrimidin-5-yl]-4-methoxybenzonitrile;
5- (5-chloro-2-methoxyphenyl)-/V,A/-dimethyl-7H-pyrrolo[2,3-c/]pyrimidin-4-amine;
3-{4-[4-(1H-imidazol-2-yl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3-{4-[3-(methoxymethyl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile;
3-[4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5yl]benzonitrile;
3-[4-(3-methoxypiperidin-1-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile; /V3-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-d]pyrimidin-4-yl]-A/,/\/-dimethyl-beta-alaninamide;
3-[4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-a(]pyrimidin-5-yl]benzonitrile;
3-[4-(4-fluoropiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-{4-[4-(1H-pyrazol-3-yl)piperidin-1-yl]-7H-pyrrolo[2,3-cflpyrimidin-5-yl}benzonitrile;
3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3-G(]pyrimidin-5-yl}benzonitrile;
3-{4-[2-(1H-pyrazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl}benzonitrile;
3-{4-[3-(1 /-/-pyrazol-3-yl)piperidin-1 -yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile;
3-{4-[3-(1H-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-{4-[(1-methylpiperidin-3-yl)amino]-7H-pyrrolo[2,3-cy|pyrimidin-5-yl}benzonitrile;
3-[4-(3-oxo-2,7-diazaspiro[4.5]dec-7-yl)-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile;
3-[4-((3fî)-3-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-(4-{[2-(morpholin-4-yl)ethyl]amino}-7H-pyrrolo[2,3-c/|pyrimidin-5-yl)benzonitrile;
3- [4-(2-oxa-7-azaspiro[4.5]dec-7-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
/\/-{1-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-c/|pyrimidin-4-yl]piperidin-4-yl}acetamide;
5-(1/-/-indazol-5-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidine;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzenesulfonamide;
5-(2-fluorophenyl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidine;
5-(1H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidine;
5- (6-fluoro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3cflpyrimidine;
5-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl}-2,3-dihydro-1/-/isoindol-1-one;
4- [(3S)-3-methylpiperidin-1-yl]-5-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(7/-/-pyrrolo[2,3-b]pyridin-5-yl)-7/-/-pyrrolo[2,3- c/Jpyrimidine;
6- {4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl}-2,3-dihydro-1/-/isoindol-1-one;
4-[(3S)-3-methylpiperidin-1-yl]-5-(1/-/-pyrrolo[3,2-b]pyridin-6-yl)-7/-/-pyrrolo[2,3cdpyrimidine;
4-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}phenol;
4- {4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl}benzamide;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}phenol;
5- (2-chloro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3cflpyrimidine;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c(|pyrimidin-5-yl}benzamide;
3-[4-(3-fluoropiperidin-1-yl)-7/7-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-[4-(4-methylpiperidin-1-yl)-7H-pyrrolo[2,3-c(]pyrimidin-5-yl]benzonitrile;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoic acid;
3-[4-(methylamino)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(3,5-c/s-dimethylpiperidin-1 -yl)-7/-/-pyrrolo[2,3-dJpyrimidin-5-yl]-4- methoxybenzomtrile;
4-methoxy-3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-cdpyrimidin-5-yl}benzonitrile;
2- fluoro-3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
/V,/V-dimethyl-5-phenyl-7/-/-pyrrolo[2,3-dlpyrimidin-4-amine;
3- [4-(dimethylamino)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]-2-fluorobenzonitrile;
3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-((3fî)-3-methylpyrrolidin-1-yl)-7/-/-pyrrolo[2,3-cf]pyrimidin-5-yl]benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-4-fluorobenzonitrile;
3-[4-(diethylamino)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-{4-[(2fî)-2-(methoxymethyl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5yljbenzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pynmidin-5-yl]-5-fluorobenzonitrile;
3-{4-[2-(1H-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrirnidin-5-yl}benzonitrile;
3-[4-((3S)-3-methylpyrrolidin-1-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
2- fluoro-3-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3- {4-[(2F?)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
4- fluoro-3-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-cf|pyrimidin-5-yl]benzonitrile;
4- (4-fluoropiperidin-1 -y 1)-5-( 1 -methyl-1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
2-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidin-5-yl]benzonitrile;
5- (3-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidine;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidine;
5-(3-fluoro-5-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(2,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pynnnidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
{2-fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]phenyl}methanol;
5-(2,4-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-of|pyrimidine;
5-(3,5-difluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine;
4- (morpholin-4-yl)-5-phenyl-7/-/-pyrrolo[2,3-c(]pyrimidine;
5- (5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine;
5-(2-chlorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(5-fluoro-2-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(3-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
{2-fluoro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]phenyl}methanol;
5-(4-fluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(]pyrimidine; {3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl]phenyl}methanol;
5-(2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
5-[3-(methylsulfanyl)phenyl]-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
4-(morpholin-4-yl)-5-(pyridin-3-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidin-5-yl]isoquinoline;
5- (5-bromopyridin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
5-(2-chloro-5-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidine;
5-(3-methylphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(1-methyl-1/-/-pyrazol-3-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(]pyrimidine;
3-[4-(4-hydroxypiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c(]pyrimidin-5yljbenzonitrile;
3-methyl-5-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yl}benzonitrile;
3-[4-(6-oxa-3-azabicyclo[3.1.1]hept-3-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl]benzonitrile;
3- chloro-5-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
4- methoxy-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile;
5- (5-chloro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidine;
6- methyl-5-(1-methyl-1/-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidine;
3- methoxy-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
5-(1-methyl-1/7-pyrazol-4-yl)-4-(thiomorpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
-[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c(|pyrimidin-4-yl]piperidin-3-ol;
4- [(2S)-2-methylmorpholin-4-yl]-5-(1-methyl-1/-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3djpyrimidine;
4-[(2H)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3cdpyrimidine;
4-(3-fluoropiperidin-1 -y 1)-5-( 1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c(]pyrimidine;
{4-[5-(1-methyl-1/-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-4-yl]morpholin-2yljmethanol;
5-(1 -methyl-1 H-pyrazol-4-yl)-4-(2-{[(6-methylpyridin-3-yl)oxy]methyl}morpholin-4-yl)-7/-/- pyrrolo[2,3-d]pynrnidine;
A/,A/-dimethyl-5-(1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-4-amine;
A/-cyclopropyl-A/-methyl-5-(1-methyl-1/-/-pyrazol-4-yl)-7H-pyrrolo[2,3-d|pyrimidin-4amine;
3-(4-(3,3-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-[4-(3-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(2-{[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}morpholin-4-yl)-7/-/-pyrrolo[2)3c(]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(1,3-thiazol-2-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile;
3-[4-(4-oxopiperidin-1-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-{4-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
3-{4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-{4-[2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5yljbenzonitrile;
3-[4-(3,3-difluoropyrrolidin-1-yl)-7/-/-pyrrolo[2,3-d]pynmidin-5-yl]benzonitrile;
3-(4-{2-[(3-cyanophenoxy)methyl]morpholin-4-yl}-7/-/-pyrrolo[2,3-c/]pyrimidin-5yl)benzonitrile;
3-[4-(3-hydroxypiperidin-1-yl)-7/-/-pyrrolo[2,3-af]pyrimidin-5-yl]benzonitrile;
1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidine-3-carboxamide;
3-[4-(2-ethylmorpholin-4-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-{4-[2-(pyrimidin-4-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-{4-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
3-(4-{2-[(dimethylamino)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-c0pyrimidin-5yl)benzonitrile;
3-(4-(1 H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-(4-{2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]morpholin-4-yl}-7/-/-pyrrolo[2,3c/]pyrimidin-5-yl)benzonitrile;
3-{4-[3-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5yl}benzonitrile;
3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]-5-methoxybenzonitrile;
5-(1-ethyl-1/-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(5-chloropyridin-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-a(]pyrimidine;
5-(6-methoxypyrazin-2-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidine;
5-(1,3-dimethyl-1/7-pyrazol-4-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-a(|pyrimidine;
3-{4-[(3S)-3-methylmorpholin-4-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
2- fluoro-3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3- {4-[(3fî)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
1- [5-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/pyrrolo[2,3-d]pyrimidine;
2- fluoro-3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
4- (4-fluoropiperidin-1-yl)-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine;
5- (3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine;
3- [4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-c(]pyrimidin-5-yl]-2-fluorobenzonitrile;
1-[5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-c/|pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7/7-pyrrolo[2,3-d]pyrimidine;
1-[5-(3-fluoro-5-methoxyphenyl)-7H-pyrrolo[2,3-c/]pyrimidin-4-yl]piperidin-3-ol;
1- [5-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol;
2- fluoro-3-{4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-
d]pyrimidin-5-yl}benzonitrile;
2-fluoro-3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c(|pyrimidin-5yljbenzonitrile;
4- (azetidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-7H-pyrrolo[2,3-c/|pyrimidine;
4- [(2S)-2-methylmorpholin-4-yl]-5-(5-methylpyridin-3-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5- (3-fluorophenyl)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(3-fluorophenyl)-4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3cflpyrimidine;
5-(2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-d]pynmidine;
5-(2-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-c/|pyrirnidin-4-amine;
2-fluoro-3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
4- [(3S)-3-fluoropyrrolidin-1-yl]-5-(2-methoxyphenyl)-7H-pyrrolo[2,3-c/]pyrimidine;
5- (2-methoxyphenyl)-4-(pyrrolidin-1-yl)-7/7-pyrrolo[2,3-i/]pynmidine;
5-(3-fluoro-5-methoxyphenyl)-/V,A/-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3qjpyrimidine; 2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7/7-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile; 5-(5-fluoro-2-methoxyphenyl)-4-(3-fluoropiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(3-fluorophenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/7-pyrrolo[2,3-d]pyrimidine; 5-(5-fluoro-2-methoxyphenyl)-A/,A/-dimethyl-7H-pyrrolo[2,3-cf]pyrimidin-4-amine; 2-fluoro-3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-7/-/-pyrrolo[2,3-c(|pyrimidine;
2- fluoro-3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3d]pyrimidin-5-yl}benzonitrile;
5-(4-methyl-1,3-thiazol-2-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine; 5-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidine;
5-(2-fluoro-6-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-c/]pyrimidin-4-amine; 5-(2-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine; 5-(2,6-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(3-methyl-1,2-thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine; 5-(2-chloro-3-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine;
5-(4-methoxypyridin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
3- {4-[2-((5F?)-5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/7-pyrrolo[2,3-c/|pyrimidin-5yljbenzonitrile;
3-{4-[2-((5S)-5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
3-{4-[(2S)-2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
or a pharmaceutically acceptable sait thereof.
A fifteenth embodiment of a first aspect of the présent invention is a compound of the first embodiment of a first aspect selected from the group consisting of:
5- (1-methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine; 3-[6-rnethyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]pyridine-2-carbonitrile; 3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3- {4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
4- (morpholin-4-yl)-5-(1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
3-[4-(piperidin-1-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
2-fluoro-3-[4-(morpholin-4-yl)-7/-f-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitnle;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/|pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidine; 5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine; 5-(3-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine;
-[5-( 1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-4-yl]piperidin-3-ol; 5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-i/]pyrimidine;
2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile; 2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile;
2- fluoro-3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3c(|pyrimidin-5-yl}benzonitrile;
5-(3-methyl-1,2-thiazol-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine; and
3- {4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
or a pharmaceutically acceptable sait thereof.
A sixteenth embodiment of a first aspect of the présent invention is the compound of the first embodiment of the first aspect selected from the group consisting of:
3- [6-(difluoromethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile; 5-(5,6-dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(]pyrimidine; 5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
4- (morpholin-4-yl)-5-[3-(1,2,4-oxadiazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidine;
3- {4-[2-(3-methyl-1,2-oxazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
2-methyl-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
4- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl]pyridin-2(1/-/)-one;
5- (imidazo[2,1-b][1,3]thiazol-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine; re/-3-{4-[(3aS,6aS)-hexahydro-5/-/-furo[2,3-c]pyrrol-5-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5yljbenzonitrile;
re/-3-{4-[(3afî,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3/-/)-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-
5-yl}benzonitrile;
re/-3-{4-[(4afî,7aS)-hexahydrocyclopenta[b][1,4]oxazin-4(4aH)-yl]-7/-/-pyrrolo[2,3q]pyrimidin-5-yl}benzonitrile;
4- [5-(3-cyanophenyl)-7H-pyrrolo[2,3-c(]pyrimidin-4-yl]morpholine-2-carbonitrile;
3- [4-(2,2-dimethylmorpholin-4-yl)-7/-/-pyrrolo[2,3-<^pyrimidin-5-yl]benzonitrile;
5- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]thiophene-2-carbonitrile;
5- (imidazo[1,2-b]pyridazin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine; 2-fluoro-3-{4-[2(R)-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3d]pyrimidin-5-yl}benzonitrile;
2- fluoro-3-{4-[2(S)-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3cdpyrimidin-5-yl}benzonitrile;
6- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]pyridine-2-carboxamide;
4- (morpholin-4-yl)-5-(pyrazolo[1,5-a]pyrimidin-3-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
1-methyl-4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]-1 /-/-pyrrole-2-carbonitrile;
5- (6-methylimidazo[2,1-b][1,3]thiazol-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3c/]pyrimidine;
3- {4-[2-(1,2-oxazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile;
1-methyl-4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]-1 H-imidazole-2carbonitrile;
4- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]thiophene-2-carbonitrile;
4-(morpholin-4-yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
1,5-dimethyl-4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]-1/-/-pyrrole-2carbonitrile;
1-methyl-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]-1 /-/-pyrazole-5carbonitrile; and
3-{4-[2-(cyanomethyl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile; or a pharmaceutically acceptable sait thereof.
A first embodiment of a second aspect of the présent invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of the first through sixteenth embodiments of the first aspect of the invention, or a pharmaceutically acceptable sait thereof together with a pharmaceutically acceptable carrier.
A first embodiment of a third aspect of the présent invention is a method of
treating Parkinson’s dîsease in a patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable sait thereof according to any one of the first through sixteenth embodiments of the first aspect of the invention.
Another aspect of the présent invention is the compound or pharmaceutically acceptable sait thereof according to any one of the first through sixteenth embodiments of the first aspect of the invention for use in the treatment of Parkinson’s disease.
Another aspect of the présent invention is the use of any of the preceding compounds of formula I and their compositions for inhibiting LRRK2 kinase. In a further embodiment, the compounds of formula I or compositions thereof are useful for treating a neurodegenerative disease. In yet another embodiment, the neurodegenerative disease is Parkinson’s Disease.
Accordingly, the invention is also directed to methods of treating a patient (preferably a human) for diseases in which the LRRK2 kinase is involved, such as Parkinson’s Disease, by administering a therapeutically effective amount of a compound of any of the embodiments of formula I, or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier.
The invention is also directed to methods of inhibiting LRRK2 kinase activity, by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier, to a mammal or a patient in need thereof. The invention is also directed to methods of treating disorders responsive to the inhibition of LRRK2 kinase activity, such as neurological disorders (particularly Parkinson’s disease), certain cancers, and certain immunological disorders (such as Crohn’s disease and leprosy) by administering a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable sait thereof, and a pharmaceutically acceptable carrier, to a mammal or a patient in need thereof.
The invention is also directed to methods for treating conditions or diseases of the central nervous System and neurological disorders in which the LRRK2 kinase is involved, particularly Parkinson’s disease (but also including other neurological diseases which may include migraine; epilepsy; Alzheimer’s disease; brain injury; stroke; cerebrovascular diseases (including cérébral arteriosclerosis, cérébral amyloid
angiopathy, hereditary cérébral hemorrhage, and brain hypoxia-ischemia); cognitive disorders (including amnesia, senile dementia, HIV-associated dementia, Alzheimer’s disease, Huntington’s disease, Lewy body dementia, vascular dementia, drug-related dementia, tardive dyskinesia, myoclonus, dystonia, delirium, Pick's disease, Creutzfeldt5 Jacob disease, HIV disease, Gilles de la Tourette's syndrome, epilepsy, muscular spasms and disorders associated with muscular spasticity or weakness including tremors, and mild cognitive impairment); mental deficiency (including spasticity, Down syndrome and fragile X syndrome); sleep disorders (including hypersomnia, circadian rhythm sleep disorder, insomnia, parasomnia, and sleep deprivation) and psychiatrie 10 disorders such as anxiety (including acute stress disorder, generalized anxiety disorder, social anxiety disorder, panic disorder, post-traumatic stress disorder, agoraphobia, and obsessive-compulsive disorder); factitious disorder (including acute hallucinatory mania); impulse control disorders (including compulsive gambling and intermittent explosive disorder); mood disorders (including bipolar I disorder, bipolar II disorder, 15 mania, mixed affective state, major dépréssion, chronic dépréssion, seasonal dépréssion, psychotic dépréssion, seasonal dépréssion, premenstrual syndrome (PMS) premenstrual dysphorie disorder (PDD), and postpartum dépréssion); psychomotor disorder; psychotic disorders (including schizophrenia, schizoaffective disorder, schizophreniform, and delusional disorder); drug dependence (including narcotic 20 dependence, alcoholism, amphétamine dependence, cocaïne addiction, nicotine dependence, and drug withdrawal syndrome); eating disorders (including anorexia, bulimia, binge eating disorder, hyperphagia, obesity, compulsive eating disorders and pagophagia); sexual dysfunction disorders; urinary incontinence; neuronal damage disorders (including ocular damage, retinopathy or macular degeneration of the eye, 25 tinnitus, hearing impairment and loss, and brain edema) and pédiatrie psychiatrie disorders (including attention déficit disorder, attention deficit/hyperactive disorder, conduct disorder, and autism) in a mammal, preferably a human, comprising administering to said mammal a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable sait thereof.
The text révision of the fourth édition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV-TR) (2000, American Psychiatrie Association, Washington D.C.) provides a diagnostic tool for identifying many of the disorders described herein. The skilled artisan will recognize that there are alternative nomenclatures, nosologies,
and classification Systems for disorders described herein, including those as described in the DMS-IV-TR, and that terminology and classification Systems evolve with medical scientific progress.
Preferred methods are for treating a neurological disorder, most preferably Parkinson’s disease, (but also other neurological disorders such as migraine; epilepsy; Alzheimer’s disease; Niemann-Pick type C; brain injury; stroke; cerebrovascular disease; cognitive disorder; sleep disorder) or a psychiatrie disorder (such as anxiety; factitious disorder; impulse control disorder; mood disorder; psychomotor disorder; psychotic disorder; drug dependence; eating disorder; and pédiatrie psychiatrie disorder) in a mammal, preferably a human, comprising administering to said mammal a therapeutically effective amount of a compound of Formula I or pharmaceutically acceptable sait thereof. In addition, the compounds of Formula I and pharmaceutically acceptable salts thereof may also be employed in methods of treating other disorders associated with LRRK2 such as Crohn’s disease, leprosy and certain cancers, such as kidney, breast, lung, prostate, lung and blood cancer.
Also provided herein are compositions comprising a pharmaceutically effective amount of one or more of the compounds described herein and a pharmaceutically acceptable vehicle, carrier or excipient.
The présent invention is also directed to the use of a combination of a LRRK2 inhibitor compound of formula I, and one or more additional pharmaceutically active agent(s).
Other features and advantages of this invention will be apparent from this spécification and the appendent claims which describe the invention.
Définitions
The term alkyl” refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen); in one embodiment from one to six carbon atoms (i.e., CrC6alkyl); in another embodiment, from one to three carbon atoms (i.e., Ci-Cealkyl). Examples of such substituents include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl and te/t-butyl), pentyl, isoamyl, hexyl and the like.
The term alkoxy” refers to a linear or branched-chain saturated hydrocarbyl substituent (i.e., a substituent obtained from a hydrocarbon by removal of a hydrogen)
which is in turn attached to an oxygen atom; in one embodiment from one to six carbon atoms (i.e., CrCealkoxy); in another embodiment, from one to three carbon atoms (i.e., CrC3alkoxy). Examples of such substituents include methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, seobutoxy and tert-butoxy), pentoxy and the like.
The term cycloalkyl” refers to a carbocyclic substituent obtaîned by removing a hydrogen from a saturated carbocyclic molécule and having the specified number of carbon atoms. In one embodiment, a cycloalkyl substituent has three to seven carbon atoms (i.e., C3-C7cycloalkyl). Examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The term “cycloalkyl” includes mono-, bi- and tricyclic saturated carbocycles, as well as bridged and fused ring carbocycles, as well as spiro-fused ring Systems.
In some instances, the number of atoms in a cyclic substituent containing one or more heteroatoms (i.e., heteroaryl or heterocycloalkyl) is indicated by the prefix “x to y membered”, wherein x is the minimum and y is the maximum number of atoms forming the cyclic moiety of the substituent. The term “heterocycloalkyl” refers to a substituent obtaîned by removing a hydrogen from a saturated or partially saturated ring structure containing the specified number of ring atoms, wherein at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consîsting of carbon, oxygen, nitrogen, and sulfur. If the heterocycloalkyl substituent is in turn substituted with a group or substituent, the group or substituent may be bound to a nitrogen heteroatom, or it may be bound to a ring carbon atom, as appropriate. As used herein, the term “heterocycloalkyl” as used herein refers to a monocyclic ring System containing the heteroatoms N, O or S as specified. Thus, for example, “four to seven membered heterocycloalkyl” refers to a heterocycloalkyl containing from 4 to 7 atoms, including one or more heteroatoms, in the cyclic moiety of the heterocycloalkyl. The term “heterobicycloalkyl” as used herein refers to a non-spiro bicyclic ring System containing the heteroatoms N, O or S as specified. Thus, for example, “six to twelve membered heterobicycloalkyl” refers to a heterobicycloalkyl containing from 6 to 12 atoms, including one or more heteroatoms, in the cyclic moieties of the heterobicycloalkyl. The term “heterospirocycloalkyl” as used herein refers to a spirocyclic ring System containing the heteroatoms N, O or S as specified. For example, “six to twelve membered
heterospirocycloalkyl” means a six to twelve membered spirocyclic ring system which contains at least one heteroatom as specified.
The term “hydrogen” refers to a hydrogen substituent, and may be depicted as -H.
The term “hydroxy” or “hydroxyl” refers to -OH. Compounds bearing a carbon to which one or more hydroxy substituents are attached include, for example, alcohols, enols and phénol.
The term “halo” or “halogen” refers to fluoro (which may be depicted as -F), chloro (which may be depicted as -Cl), bromo (which may be depicted as -Br), or iodo (which may be depicted as -I).
The term “heteroaryl” refers to an aromatic ring structure containing the specified number of ring atoms in which at least one of the ring atoms is a heteroatom (i.e., oxygen, nitrogen, or sulfur), with the remaining ring atoms being independently selected from the group consisting of carbon, oxygen, nitrogen, and sulfur. A five to six membered heteroaryl is an aromatic ring system which has five or six ring atoms with at least one of the ring atoms being N, O or S. Similarly, a five to ten membered heteroaryl is an aromatic ring system which has five to ten ring atoms with at least one of the ring atoms being N, O or S. A heteroaryl may be a single ring or 2 fused rings. Examples of heteroaryl substituents include 6-membered ring substituents such as pyridyl, pyrazyl, pyrimidinyl, and pyridazinyl; 5-membered ring substituents such as triazolyl, imidazolyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5-membered fused ring substituents such as benzothiofuranyl, isobenzothiofuranyl, benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl; and 6/6-membered fused rings such as quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and 1,4-benzoxazinyl. In a group that has a heteroaryl substituent, the ring atom of the heteroaryl substituent that is bound to the group may be the at least one heteroatom, or it may be a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least one heteroatom. Similarly, if the heteroaryl substituent is in turn substituted with a group or substituent, the group or substituent may be bound to the at least one heteroatom, or it may be bound to a ring carbon atom, where the ring carbon atom may be in the same ring as the at least one heteroatom or where the ring carbon atom may be in a different ring from the at least
one heteroatom. The term “heteroaryl” also includes pyridyl /V-oxides and groups containing a pyridine /V-oxide ring.
Examples of single-ring heterocycloalkyls include azetidinyl, oxetanyl, thietanyl, dihydrofuranyl, tetrahydrofuranyl, dihydrothiophenyl, tetrahydrothiophenyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, thiazolinyl, isothiazolinyl, thiazolidinyl, isothiazolidinyl, dihydropyranyl, piperidinyl, morpholinyl, piperazinyl, azepinyl, oxepinyl, thiepinyl, and diazepinyl.
Examples of 2-fused-ring heteroaryls include, indolizinyl, pyranopyrrolyl, 4/-/-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b]-pyridinyl, or pyrido[4,3-b]-pyridinyl), and pteridinyl, indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl, benzopyranyl, benzothiopyranyl, benzoxazolyl, indoxazinyl, anthranilyl, benzodioxolyl, benzodioxanyl, benzoxadiazolyl, benzofuranyl, isobenzofuranyl, benzothienyl, isobenzothienyl, benzothiazolyl, benzothiadiazolyl, benzimidazolyl, benzotriazolyl, benzoxazinyl, benzisoxazinyl, pyrrolopyridinyl, pyrazolopyridinyl and imidazothiazolyl.
Other examples of fused-ring heteroaryls include benzo-fused heteroaryls such as indolyl, isoindolyl, indoleninyl, isoindazolyl, benzazinyl (including quinolinyl or isoquinolinyl), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl or quinazolinyl).
The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-2-yl (C-attached).
If substituents are described as being “independently selected” from a group, each instance of a substituent is selected independent of the other. Each substituent therefore may be identical to or different from the other substituent(s).
As used herein the term “formula I” or “Formula I” may be referred to as a “compound(s) of the invention.” Such terms are also defined to include ail forms of the compound of formula I, including hydrates, solvatés, isomers, crystalline and noncrystalline forms, isomorphs, polymorphs, and métabolites thereof. For example, the compounds of the invention, or pharmaceutically acceptable salts thereof, may exist in unsolvated and solvated forms. When the solvent or water is tightly bound, the complex
will hâve a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvatés and hygroscopic compounds, the water/solvent content will be dépendent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
The compounds of the invention may exist as clathrates or other complexes. Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein the drug and host are présent in stoichiometric or nonstoichiometric amounts. Also included are complexes of the compounds of the invention containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J. Pharm. Soi., 64 (8), 1269-1288 by Haleblian (August 1975).
The compounds of the invention may hâve asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the invention may be depicted herein using a solid line (-----), a solid wedge or a dotted wedge (.........111 ). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers (e.g., spécifie enantiomers, racemic mixtures, etc.) at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of Formula I may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that ail possible stereoisomers are meant to be included. For example, unless stated otherwise, it is intended that the compounds of Formula I can exist as enantiomers and diastereomers or as racemates and mixtures thereof. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of Formula I and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is présent.
Stereoisomers of Formula I include cis and trans isomers, optical isomers such as R and S enantiomers, diastereomers, géométrie isomers, rotational isomers, conformational isomers, and tautomers of the compounds of the invention, including compounds exhibiting more than one type of isomerism; and mixtures thereof (such as racemates and diastereomeric pairs). Also included are acid addition or base addition
salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.
When any racemate crystallizes, crystals of two different types are possible. The first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts. The second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
The présent invention comprises the tautomeric forms of compounds of the invention. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism (‘tautomerism’) can occur. This can take the form of proton tautomerism in compounds of the invention containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism. The various ratios of the tautomers in solid and liquid form is dépendent on the various substituents on the molécule as well as the particular crystallization technique used to isolate a compound.
The compounds of this invention may be used in the form of salts derived from inorganic or organic acids. Depending on the particular compound, a sait of the compound may be advantageous due to one or more of the salt’s physical properties, such as enhanced pharmaceutical stability in differing températures and humidities, or a désirable solubility in water or oil. In some instances, a sait of a compound also may be used as an aid in the isolation, purification, and/or resolution of the compound.
Where a sait is intended to be administered to a patient (as opposed to, for example, being used in an in vitro context), the sait preferably is pharmaceutically acceptable. The term pharmaceutically acceptable sait refers to a sait prepared by combining a compound of formula I with an acid whose anion, or a base whose cation, is generally considered suitable for human consumption. Pharmaceutically acceptable salts are particularly useful as products of the methods of the présent invention because of their greater aqueous solubility relative to the parent compound. For use in medicine, the salts of the compounds of this invention are non-toxic “pharmaceutically acceptable salts.” Salts encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
Suitable pharmaceutically acceptable acid addition salts of the compounds of the présent invention when possible include those derived from inorganic acids, such as hydrochloric, hydrobromic, hydrofluoric, boric, fluoroboric, phosphoric, metaphosphoric, nitric, carbonic, sulfonic, and sulfuric acids, and organic acids such as acetic, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isothionic, lactic, lactobionic, maleic, malic, methanesulfonic, trifluoromethanesulfonic, succinic, toluenesulfonic, tartaric, and trifluoroacetic acids. Suitable organic acids generally include, for example, aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids.
Spécifie examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate, maleate, fumarate, pyruvate, aspartate, glutamate, benzoate, anthranilic acid, stéarate, salicylate, p-hydroxybenzoate, phenylacetate, mandelate, embonate (pamoate), methanesulfonate, ethanesulfonate, benzenesulfonate, pantothenate, toluenesulfonate, 2-hydroxyethanesulfonate, sufanilate, cyclohexylaminosulfonate, β-hydroxybutyrate, galactarate, galacturonate, adipate, alginate, butyrate, camphorate, camphorsulfonate, cyclopentanepropionate, dodecylsulfate, glycoheptanoate, glycérophosphate, heptanoate, hexanoate, nicotinate,
2-naphthalesulfonate, oxalate, palmoate, pectinate, 3-phenylpropionate, picrate, pivalate, thiocyanate, and undecanoate.
Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali métal salts, i.e., sodium or potassium salts; alkaline earth métal salts, e.g., calcium or magnésium salts; and salts formed with suitable organic ligands, e.g., quaternary ammonium salts. In another embodiment, base salts are formed from bases which form non-toxic salts, including aluminum, arginine, benzathine, choline, diethylamine, diolamine, glycine, lysine, meglumine, olamine, tromethamine and zinc salts.
Organic salts may be made from secondary, tertiary or quaternary amine salts, such as tromethamine, diethylamine, Λ/,Λ/’-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (/V-methylglucamine), and procaine. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl (CrCe) halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (i.e., dimethyl, diethyl, dibutyl, and diamyl sulfates), long
chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), arylalkyl halides (e.g., benzyl and phenethyl bromides), and others.
In one embodiment, hemisalts of acids and bases may also be formed, for example, hemisulfate and hemicalcium salts.
Also within the scope of the présent invention are so-called “prodrugs” of the compound of the invention. Thus, certain dérivatives of the compound of the invention which may hâve little or no pharmacological activity themselves can, when administered into or onto the body, be converted into the compound of the invention having the desired activity, for example, by hydrolytic cleavage. Such dérivatives are referred to as “prodrugs.” Further information on the use of prodrugs may be found in “Pro-drugs as Novel Delivery Systems, Vol. 14, ACS Symposium Sériés (T. Higuchi and V. Stella) and “Bioreversible Carriers in Drug Design,” Pergamon Press, 1987 (ed. E. B. Roche, American Pharmaceutical Association). Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities présent in the compounds of any of formula I with certain moieties known to those skilled in the art as “pro-moieties” as described, for example, in “Design of Prodrugs” by H. Bundgaard (Elsevier, 1985).
The présent invention also includes isotopically labeled compounds, which are identical to those recited in formula I, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be încorporated into compounds of the présent invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, such as 2H, 3H, 13C, 11C, 14C, 15N, 18O, 17O, 32P, 35S, 18F, and 36CI, respectively. Compounds of the présent invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the présent invention, for example those into which radioactive isotopes such as 3H and 14C are încorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of préparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or
reduced dosage requirements and, hence, may be preferred in some circumstances.
Isotopically labeled compounds of formula I of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Préparations below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
DETAILED DESCRIPTION OF THE INVENTION
Typically, a compound of the invention is administered in an amount effective to treat a condition as described herein. The compounds of the invention are administered by any suitable route in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. Therapeutically effective doses of the compounds required to treat the progress of the medical condition are readily ascertained by one of ordinary skill in the art using preclinical and clinical approaches familiar to the médicinal arts.
The term treating, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term treatment, as used herein, unless otherwise indicated, refers to the act of treating as treating is defined immediately above. The term “treating” also includes adjuvant and neo-adjuvant treatment of a subject.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed, by which the compound enters the blood stream directly from the mouth.
In another embodiment, the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internai organ. Suitable means for parentéral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parentéral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
In another embodiment, the compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. In another embodiment, the compounds of the invention can also be administered
intranasally or by inhalation. In another embodîment, the compounds of the invention may be administered rectally or vaginally. In another embodîment, the compounds of the invention may also be administered directly to the eye or ear.
The dosage regimen for the compounds and/or compositions containing the compounds is based on a variety of factors, including the type, âge, weight, sex and medical condition of the patient; the severity of the condition; the route of administration; and the activity of the particular compound employed. Thus the dosage regimen may vary widely. Dosage levels of the order from about 0.01 mg to about 100 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions. In one embodîment, the total daily dose of a compound of the invention (administered in single or divided doses) is typically from about 0.01 to about 100 mg/kg. In another embodîment, the total daily dose of the compound of the invention is from about 0.1 to about 50 mg/kg, and in another embodîment, from about 0.5 to about 30 mg/kg (i.e., mg compound of the invention per kg body weight). In one embodîment, dosing is from 0.01 to 10 mg/kg/day. In another embodîment, dosing is from 0.1 to 1.0 mg/kg/day. Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound will be repeated a plurality of times in a day (typically no greater than 4 times). Multiple doses per day typically may be used to increase the total daily dose, if desired.
For oral administration, the compositions may be provided in the form of tablets containing from about 0.01 mg to about 500 mg of the active ingrédient, or in another embodîment, from about 1 mg to about 100 mg of active ingrédient. Intravenously, doses may range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
Suitable subjects according to the présent invention include mammalian subjects. Mammals according to the présent invention include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodîment, humans are suitable subjects. Human subjects may be of either gender and at any stage of development.
In another embodîment, the invention comprises the use of one or more compounds of the invention for the préparation of a médicament for the treatment of the conditions recited herein.
For the treatment of the conditions referred to above, the compound of the invention can be administered as compound per se. Alternatively, pharmaceutically acceptable salts are suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
In another embodiment, the présent invention comprises pharmaceutical compositions. Such pharmaceutical compositions comprise a compound of the invention presented with a pharmaceutically acceptable carrier. The carrier can be a solid, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compounds. A compound of the invention may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances can also be présent.
The compounds of the présent invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and compositions, for example, may be administered orally, rectally, parenterally, or topically.
Oral administration of a solid dose form may be, for example, presented in discrète units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the présent invention. In another embodiment, the oral administration may be in a powder or granule form. In another embodiment, the oral dose form is sub-lingual, such as, for example, a lozenge. In such solid dosage forms, the compounds of formula I are ordinarily combined with one or more adjuvants. Such capsules or tablets may contain a controlled-release formulation. In the case of capsules, tablets, and pills, the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
In another embodiment, oral administration may be in a liquid dose form. Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable émulsions, solutions, suspensions, syrups, and élixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also may comprise adjuvants, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
In another embodiment, the présent invention comprises a parentéral dose form. Parentéral administration includes, for example, subcutaneous injections, intravenous injections, intraperitoneal injections, intramuscular injections, intrasternal injections, and infusion. Injectable préparations (e.g., stérile injectable aqueous or oleaginous suspensions) may be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents.
In another embodiment, the présent invention comprises a topical dose form. Topical administration includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration. Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams. A topical formulation may include a compound which enhances absorption or pénétration of the active ingrédient through the skin or other affected areas. When the compounds of this invention are administered by a transdermal device, administration will be accomplished using a patch either of the réservoir and porous membrane type or of a solid matrix variety. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, minerai oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Pénétration enhancers may be incorporated; see, for example, J. Pharm. Sci., 88 (10), 955-958, by Finnin and Morgan (October 1999).
Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier. A typical formulation suitable for ocular or aurai administration may be in the form of drops of a micronized suspension or solution in isotonie, pH-adjusted, stérile saline. Other formulations suitable for ocular and aurai administration include ointments, biodégradable (e.g., absorbable gel sponges, collagen) and nonbiodegradable (e.g., silicone) implants, wafers, lenses and particulate or vesicular Systems, such as niosomes or liposomes. A polymer such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, (hydroxypropyl)methyl cellulose, hydroxyethyl cellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together
with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aérosol spray présentation from a pressurized container or a nebulizer, with the use of a suitable propellant. Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aérosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
In another embodiment, the présent invention comprises a rectal dose form. Such rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Other carrier materials and modes of administration known in the pharmaceutical art may also be used. Pharmaceutical compositions of the invention may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures. The above considérations in regard to effective formulations and administration procedures are well known in the art and are described in standard textbooks. Formulation of drugs is discussed in, for example, Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania, 1975; Liberman étal., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.
The compounds of the présent invention can be used, alone or in combination with other therapeutic agents, in the treatment of various conditions or disease states. The compound(s) of the présent invention and other therapeutic agent(s) may be may be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially.
Two or more compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomie sites or using different routes of administration.
The phrases “concurrent administration,” “co-administration,” “simultaneous administration,” and “administered simultaneously” mean that the compounds are administered in combination.
The présent invention includes the use of a combination of a LRRK2 inhibitor compound as provided in formula I and one or more additional pharmaceutically active agent(s). If a combination of active agents is administered, then they may be administered sequentially or simultaneously, in separate dosage forms or combined in a single dosage form. Accordingly, the présent invention also includes pharmaceutical compositions comprising an amount of: (a) a first agent comprising a compound of formula I or a pharmaceutically acceptable sait of the compound; (b) a second pharmaceutically active agent; and (c) a pharmaceutically acceptable carrier, vehicle or diluent.
Various pharmaceutically active agents may be selected for use in conjunction with the compounds of Formula I, depending on the disease, disorder, or condition to be treated. For example, a pharmaceutical composition for use in treating Parkinson’s disease may comprise a compound of formula I or a pharmaceutically acceptable sait thereof together with another agent such as a dopamine (levodopa, either alone or with a DOPA decarboxylase inhibitor), a monoamine oxidase (MAO) inhibitor, a catechol Omethyltransferase (COMT) inhibitor or an anticholinergic agent, or any combination thereof. Particularly preferred agents to combine with the compounds of formula I for use in treating Parkinson’s disease include levodopa, carbidopa, tolcapone, entacapone, selegiline, benztropine and trihexyphenidyl, or any combination thereof. Pharmaceutically active agents that may be used in combination with the compounds of formula I and compositions thereof include, without limitation:
(i) levodopa (or its methyl or ethyl ester), alone or in combination with a DOPA decarboxylase inhibitor (e.g., carbidopa (SINEMET, CARBILEV, PARCOPA), benserazide (MADOPAR), α-methyldopa, monofluoromethyldopa, difluoromethyldopa, brocresine, or m-hydroxybenzylhydrazine);
(n) anticholinergics, such as amitriptyline (ELAVIL, EN DEP), butriptyline, benztropine mesylate (COGENTIN), trihexyphenidyl (ARTANE), diphenhydramine (BENADRYL), orphenadrine (NORFLEX), hyoscyamine, atropine (ATROPEN), scopolamine (TRANSDERM-SCOP), scopolamine methylbromide (PARMINE), dicycloverine (BENTYL, BYCLOMINE, DIBENT, DILOMINE), tolterodine (DETROL), oxybutynin (DITROPAN, LYRINEL XL, OXYTROL), penthienate bromide, propantheline (PRO-BANTHINE), cyclizine, imipramine hydrochloride (TOFRANIL), imipramine maleate (SURMONTIL), lofepramine, desipramine (NORPRAMIN), doxepin (SINEQUAN, ZONALON), trimipramine (SURMONTIL), and glycopyrrolate (ROBINUL);
(iii) catechol O-methyltransferase (COMT) inhibitors, such as nitecapone, tolcapone (TASMAR), entacapone (COMTAN), and tropolone;
(iv) monoamine oxidase (MAO) inhibitors, such as selegiline (EMSAM), selegiline hydrochloride (l-deprenyl, ELDEPRYL, ZELAPAR), dimethylselegiline, brofaromine, phenelzine (NARDIL), tranylcypromine (PARNATE), moclobemide (AURORIX, MANERIX), befloxatone, safinamide, isocarboxazid (MARPLAN), nialamide (NIAMID), rasagiline (AZILECT), iproniazide (MARSILID, IPROZID, IPRONID), iproclozide, toloxatone (HUMORYL, PERENUM), bifemelane, desoxypeganine, harmine (also known as telepathine or banasterine), harmaline, linezolid (ZYVOX, ZYVOXID), and pargyline (EUDATIN, SUPIRDYL);
(v) acetylcholinesterase inhibitors, such as donepezil hydrochloride (ARICEPT®, MEMAC), physostigmine salicylate (ANTILIRIUM®), physostigmine sulfate (ESERINE), ganstigmine, rivastigmine (EXELON®), ladostigil, NP-0361, galantamine hydrobromide (RAZADYNE®, REMINYL®, NIVALIN®), tacrine (COGNEX®), tolserine, memoquin, huperzine A (HUP-A; Neuro-Hitech), phenserine, bisnorcymserine (also known as BNC), and INM-176;
(vi) amyloid-β (or fragments thereof), such as AB^s conjugated to pan HLA DRbinding epitope (PADRE®), ACC-001 (Elan/Wyeth), and Affitope;
(vii) antibodies to amyloid-B (or fragments thereof), such as ponezumab, solanezumab, bapineuzumab (also known as AAB-001), AAB-002 (Wyeth/Elan), Gantenerumab, intravenous Ig (GAMMAGARD®), LY2062430 (humanized m266; Lilly), and those disclosed in International Patent Publication Nos WO04/032868, W005/025616, W006/036291, W006/069081, WO06/118959, in
US Patent Publication Nos US2003/0073655, US2004/0192898,
US2005/0048049, US2005/0019328, in European Patent Publication Nos EP0994728 and 1257584, and in US Patent No 5,750,349;
(viii) amyloid-lowering or -inhibiting agents (including those that reduce amyloid production, accumulation and fibrillization) such as eprodisate, celecoxib, lovastatin, anapsos, colostrinin, pioglitazone, clioquinol (also known as PBT1), PBT2 (Prana Biotechnology), flurbiprofen (ANSAID®, FROBEN®) and its Renantiomer tarenflurbil (FLURIZAN®), nitroflurbiprofen, fenoprofen (FENOPRON, NALFON®), ibuprofen (ADVIL®, MOTRIN®, NUROFEN®), ibuprofen lysinate, meclofenamic acid, meclofenamate sodium (MECLOMEN®), indomethacin (INDOCIN®), diclofenac sodium (VOLTAREN®), diclofenac potassium, sulindac (CLINORIL®), sulindac sulfide, diflunisal (DOLOBID®), naproxen (NAPROSYN®), naproxen sodium (ANAPROX®, ALEVE®), insulin-degrading enzyme (also known as insulysin), the gingko biloba extract EGb-761 (ROKAN®, TEBONIN®), tramiprosate (CEREBRIL®, ALZHEMED®), KIACTA®), neprilysin (also known as neutral endopeptidase (NEP)), scyllo-inositol (also known as scyllitol), atorvastatin (LIPITOR®), simvastatin (ZOCOR®), ibutamoren mesylate, BACE inhibitors such as LY450139 (Lilly), BMS-782450, GSK-188909; gamma secretase modulators and inhibitors such as ELND-007, BMS-708163 (Avagacestat), and DSP8658 (Dainippon); and RAGE (receptor for advanced glycation end-products) inhibitors, such as TTP488 (Transtech) and TTP4000 (Transtech), and those disclosed in US Patent No 7,285,293, including PTI-777;
(ix) alpha-adrenergic receptor agonists, and beta-adrenergic receptor blocking agents (beta blockers); anticholinergics; anticonvulsants; antipsychotics; calcium channel blockers; catechol O-methyltransferase (COMT) inhibitors; central nervous System stimulants; corticosteroids; dopamine receptor agonists and antagonists; dopamine reuptake inhibitors; gamma-aminobutyric acid (GABA) receptor agonists; immunosuppressants; interferons; muscarinic receptor agonists; neuroprotective drugs; nicotinic receptor agonists; norepinephrine (noradrenaline) reuptake inhibitors; quinolines; and trophic factors;
(x) histamine 3 (H3) antagonists, such as PF-3654746 and those disclosed in US Patent Publication Nos US2005-0043354, US2005-0267095, US2005-0256135, US2008-0096955, US2007-1079175, and US2008-0176925; International Patent
Publication Nos W02006/136924, W02007/063385, W02007/069053,
W02007/088450, W02007/099423, W02007/105053, W02007/138431, and W02007/088462; and US Patent No 7,115,600);
(xi) /V-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine (NAMENDA, AXURA, EBIXA), amantadine (SYMMETREL), acamprosate (CAMPRAL), besonprodil, ketamine (KETALAR), delucemine, dexanabinol, dexefaroxan, dextromethorphan, dextrorphan, traxoprodil, CP-283097, himantane, idantadol, ipenoxazone, L-701252 (Merck), lancicemine, levorphanol (DROMORAN), methadone, (DOLOPHINE), neramexane, perzinfotel, phencyclidine, tianeptine (STABLON), dizocilpine (also known as MK-801), ibogaine, voacangine, tiletamine, riluzole (RILUTEK), aptiganel (CERESTAT), gavestinel, and remacimide;
(xii) phosphodiesterase (PDE) inhibitors, including (a) PDE1 inhibitors; (b) PDE2 inhibitors; (c) PDE3 inhibitors; (d) PDE4 inhibitors; (e) PDE5 inhibitors; (f) PDE9 inhibitors (e.g., PF-04447943, BAY 73-6691 (Bayer AG) and those disclosed in US Patent Publication Nos US2003/0195205, US2004/0220186,
US2006/0111372, US2006/0106035, and USSN 12/118,062 (filed May 9, 2008)); and (g) PDE10 inhibitors such as 2-({4-[1-methyl-4-(pyridin-4-yl)-1/-/-pyrazol-3yl]phenoxy}methyl)quinoline (PF-2545920);
(xiii) serotonin (5-hydroxytryptamine) 1A (5-HTia) receptor antagonists, such as spiperone, /evo-pindolol, lecozotan;
(xiv) serotonin (5-hydroxytryptamine) 2C (5-HT2c) receptor agonists, such as vabicaserin, and zicronapine; serotonin (5-hydroxytryptamine) 4 (5-HT4) receptor agonists/antagonists, such as PRX-03140 (Epix) and PF-04995274;
(xv) serotonin (5-hydroxytryptamine) 3C (5-HT3c) receptor antagonists, such as Ondansetron (Zofran);
(xvi) serotonin (5-hydroxytryptamine) 6 (5-HT6) receptor antagonists, such as mianserin (TOLVON, BOLVIDON, NORVAL), methiothepin (also known as metitepine), ritanserin, SB-271046, SB-742457 (GlaxoSmithKIine), Lu AE58054 (Lundbeck A/S), SAM-760, and PRX-07034 (Epix);
(xvii) serotonin (5-HT) reuptake inhibitors such as alaproclate, citalopram (CELEXA, CIPRAMIL), escitalopram (LEXAPRO, CIPRALEX), clomipramine (ANAFRANIL), duloxetine (CYMBALTA), femoxetine (MALEXIL), fenfluramine (PONDIMIN),
norfenfluramine, fluoxetine (PROZAC), fluvoxamme (LUVOX), indalpine, milnacipran (IXEL), paroxetine (PAXIL, SEROXAT), sertraline (ZOLOFT, LUSTRAL), trazodone (DESYREL, MOLIPAXIN), venlafaxine (EFFEXOR), zimelidine (NORMUD, ZELMID), bicifadine, desvenlafaxine (PRISTIQ), brasofensine, vilazodone, cariprazine and tesofensine;
(xviii) Glycine transporter-1 inhîbitors such as paliflutine, ORG-25935, and ORG-26041 ; and mGluR modulators such as AFQ-059 and amantidine;
(xix) AMPA-type glutamate receptor modulators such as perampanel, mibampator, selurampanel, GSK-729327, and /V-[(3S,4S)-4-[4-(5-cyanothiophen-2yl)phenoxy]tetrahydrofuran-3-yl}propane-2-sulfonamide;
(xx) P450 inhîbitors, such as ritonavir;
(xxi) tau therapy targets, such as davunetide;
and the like.
The présent invention further comprises kits that are suitable for use in performing the methods of treatment described above. In one embodiment, the kit contains a first dosage form comprising one or more of the compounds of the présent invention and a container for the dosage, in quantities sufficient to carry out the methods of the présent invention.
In another embodiment, the kit of the présent invention comprises one or more compounds of the invention.
General Synthetic Schemes
The compounds of Formula I may be prepared by the methods described below, together with synthetic methods known in the art of organic chemistry, or modifications and transformations that are familiar to those of ordinary skill in the art. The starting materials used herein are commercially available or may be prepared by routine methods known in the art [such as those methods disclosed in standard reference books such as the Compendium of Organic Synthetic Methods, Vol. I-XII (published by Wiley-lnterscience)]. Preferred methods include, but are not limited to, those described below.
During any of the following synthetic sequences it may be necessary and/or désirable to protect sensitive or reactive groups on any of the molécules concerned.
This can be achieved by means of conventional protecting groups, such as those described in T. W. Greene, Protective Groups in Organic Chemistry, John Wiley & Sons, 1981; T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1991; and T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Chemistry, John Wiley & Sons, 1999, which are hereby incorporated by reference.
Compounds of Formula I, or their pharmaceutically acceptable salts, can be prepared according to the reaction Schemes discussed herein below. Unless otherwise indicated, the substituents in the Schemes are defined as above. Isolation and purification of the products is accomplished by standard procedures, which are known to a chemist of ordinary skill.
One skilled in the art will recognize that in many cases, the compounds in Schemes 1 through 4 will be generated as a mixture of diastereomers and/or enantiomers; these may be separated at various stages of the synthetic schemes using conventional techniques or a combination of such techniques, such as, but not limited to, crystallization, normal-phase chromatography, reversed phase chromatography and chiral chromatography, to afford the single enantiomers of the invention.
It will be understood by one skilled in the art that the various symbols, superscripts and subscripts used in the schemes, methods and examples are used for convenience of représentation and/or to reflect the order in which they are introduced in the schemes, and are not intended to necessarily correspond to the symbols, superscripts or subscripts in the appended daims. The schemes are représentative of methods useful in synthesizing the compounds of the présent invention. They are not to constrain the scope of the invention in any way.
The reactions for preparing compounds of the invention can be carried out in suitable solvents, which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at the températures at which the reactions are carried out, e.g., températures which can range from the solvent's freezing température to the solvent's boiling température. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.
Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic résonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographie methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).
DETAILED DESCRIPTION OF THE INVENTION
Compounds of Formula I and intermediates thereof may be prepared according to the following reaction schemes and accompanying discussion. Unless otherwise indicated, R1, R2, R3, R4 and R5 in the reaction schemes and discussions that follow are as defined hereinabove. In general, the compounds of this invention may be made by processes which include processes analogous to those known in the chemical arts, particularly in light of the description contained herein. Certain processes for the manufacture of the compounds of this invention and intermediates thereof are provided as further features of the invention and are illustrated by the following reaction schemes. Other processes may be described in the experimental section. The schemes and examples provided herein (including the corresponding description) are for illustration only, and not intended to limit the scope of the présent invention.
Scheme 1 refers to préparation of compounds of Formula I. Referring to Scheme 1, compounds of Formula 1-1 and 1-2 [wherein X is a leaving group such as Br or I, and Pg is a suitable protecting group, such as 2-(trimethylsilyl)ethoxymethyl (SEM), ptoluenesulfonyl (tosyl) or te/ï-butoxycarbonyl (BOC)] are commercially available or can be made by methods described herein or other methods well known to those skilled in the art.
A compound of Formula 1-3 can be prepared by coupling a compound of Formula 1-1 with a compound of Formula 1-2, for example, by heating a mixture of a compound of Formula 1-1 with a compound of Formula 1-2 in the presence of a base, such as /V,/V-diisopropylethylamine, in an appropriate solvent, such as n-butanol, at températures ranging between 50 °C and 200 °C. Suitable reaction times are typically from 20 minutes to 48 hours. Alternatively, a metal-catalyzed (such as using a palladium or copper catalyst) coupling may be employed to accomplish the aforesaid coupling. In this variant of the coupling, a mixture of a compound of Formula 1-1 and a
compound of Formula 1-2 can be heated at températures ranging between 50 °C and 120 °C in the presence of a base [such as césium carbonate], a métal catalyst [such as a palladium catalyst, e.g., palladium(ll) acetate], and a ligand [such as 1,1'binaphthalene-2,2'-diylbis(diphenylphosphane) (BINAP)] in an appropriate solvent, such as 1,4-dioxane. Suitable reaction times are typically from 30 minutes to 48 hours.
A compound of Formula 1-3 can subsequently be reacted with a compound of Formula R3-M [wherein M can be B(OH)2; B(OR)2 wherein each R is independently H or Ci-6 alkyl, or wherein two (OR) groups, together with the B atom to which they are attached, form a 5- to 10-membered heterocyclic ring optionally substituted with one or more Ci-6 alkyl; a trialkyltin moiety; or the like] by a metal-catalyzed (such as using a palladium catalyst) coupling reaction to obtain a compound of Formula 1-4. Compounds of Formula R3-M are commercially available or can be prepared by methods analogous to those described in the chemical art. Altematively, a compound of Formula 1-3 can be converted to a compound of Formula 1-5 [wherein M is defined as above]. A compound of Formula 1-5 can then be reacted with a compound of Formula R3-X [wherein X is defined as above] by a metal-catalyzed (such as using a palladium catalyst) coupling reaction to obtain a compound of Formula I. Compounds of Formula R3-X are commercially available or can be prepared by methods analogous to those described in the chemical art. The type of reaction employed dépends on the sélection of X and M. For example, when X is halogen or triflate and the R3-M reagent is a boronic acid or boronic ester, a Suzuki reaction may be used [A. Suzuki, J. Organomet. Chem. 1999, 576, 147-168; N. Miyaura and A. Suzuki, Chem. Rev. 1995, 95, 2457-2483; A. F. Littke et al., J. Am. Chem. Soc. 2000, 122, 4020-4028]. Altematively, when X is halogen or triflate and M is trialkyltin, a Stille coupling may be employed [V. Farina et al., Organic Reactions 1997, 50, 1-652]. Where X is Br, I or triflate and M is Zn or Mg, a Negishi coupling or Kumada coupling may be used [E. Erdik, Tetrahedron 1992, 48, 9577-9648; T. Banno et al., J. Organomet. Chem. 2002, 653, 288-291]. Removal of the protecting group from compounds of Formula 1-4 under conditions well known to those skilled in the art affords compounds of Formula I.
Scheme 2 also refers to préparation of compounds of Formula I. Referring to
Scheme 2, compounds of Formula I may be prepared utilizing analogous chemical 5 transformations to those described in Scheme 1, but with a different ordering of steps.
A compound of Formula 1-1 (as in Scheme 1) can be converted to a compound of Formula 2-1 either directly or after conversion to a compound of Formula 2-2 using methods analogous to those described in Scheme 1. A compound of Formula 2-1 may then be coupled to a compound of Formula 1-2 as in Scheme 1, to produce a 10 compound of Formula 1-4. The coupling conditions employed may be analogous to those described for the préparation of a compound of Formula 1-3 in Scheme 1.
Scheme 2
2-2
Scheme 3 refers to a préparation of a compound of Formula 1-1. Referring to Scheme 3, compounds of Formula 3-1 are commercially available or can be made by methods described herein or other methods well known to those skilled in the art. A compound of Formula 3-1 can be treated with a strong base and the intermediate can be subsequently reacted with an electrophile to obtain a compound of Formula 1-1 Examples of suitable reaction conditions for the reaction include mixing a compound of Formula 3-1 with a suitable base, such as lithium diisopropylamide, in a suitable reaction solvent such as tetrahydrofuran. This is followed by addition of an electrophile 10 such as an alkyl iodide or bromide. Suitable températures for the aforesaid reaction are typically between -78 °C and 30 °C. Suitable reaction times typically are from 20 minutes to 48 hours. A compound of Formula 1-1 can be converted to a compound of Formula I using chemistry described in Schemes 1 and 2.
Scheme 3
Scheme 4 refers to a préparation of a compound of Formula 4-5, wherein X is a leaving group such as Br or I. Referring to Scheme 4, compounds of Formula 4-1 (wherein each R is independently H or Ci-β alkyl) and Formula 4-2 are commercially available or can be made by methods described herein or other methods well known to those skilled in the art.
A compound of Formula 4-3 can be prepared by condensation of a compound of
Formula 4-1 with a compound of Formula 4-2, for example, through heating a compound of Formula 4-1 and a compound of Formula 4-2 in the presence of a base, such as sodium methoxide, in an appropriate solvent, such as éthanol, at températures ranging between 50 °C and 100 °C. Suitable reaction times are typically between 1 and
24 hours. A compound of Formula 4-3 can be converted to a compound of Formula 4-4 by treatment with a chlorinating agent, such as phosphorus oxychloride, either in the presence of a suitable solvent or neat, at a température ranging between 70 °C and 120 °C and a reaction time of between 1 and 24 hours. A compound of Formula 4-4 may then be treated with an appropriate halogenating agent, such as /V-iodosuccinimide, in a suitable solvent, such as dichloromethane, to produce a compound of Formula 4-5. Suitable reaction températures range from 0 °C to 50 °C, and suitable reaction times are typically from 30 minutes to 24 hours. A compound of Formula 4-5 can be protected (i.e. the pyrrole ring nitrogen is protected) by methods well known in the art and then the corresponding protected compound can be converted to a compound of Formula I using chemistry described in Schemes 1,2 and 3.
Scheme 4
4-1
4-2
4-3
4-4
4-5
Experimental Procedures and Workinq Examples
The following illustrate the synthesis of various compounds of the présent invention. Additional compounds within the scope of this invention may be prepared using the methods illustrated in these Examples, either alone or in combination with techniques generally known in the art.
Experiments were generally carried out under inert atmosphère (nitrogen or argon), particularly in cases where oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were generally used without further purification, including anhydrous solvents where appropriate. In some cases, Sure-Seal™ products from the Aldrich Chemical Company, Milwaukee, Wisconsin were used. In other cases, commercial solvents were passed through columns packed with 4Â molecular sieves, until the following QC standards for water were attained: a) <100 ppm for dichloromethane, toluene, A/,/V-dimethylformamide and tetrahydrofuran; b) <180 ppm for methanol, éthanol, 1,4-dioxane and diisopropylamine. For very sensitive reactions, solvents were further treated with metallic sodium, calcium hydride or molecular sieves, and distilled just prior to use.
Products were generally dried under vacuum before being carried on to further reactions or submitted for biological testing. Mass spectrometry data is reported from either liquid chromatography-mass spectrometry (LCMS), atmospheric pressure chemical ionization (APCI) or gas chromatography-mass spectrometry (GCMS) instrumentation. Chemical shifts for nuclear magnetic résonance (NMR) data are expressed in parts per million (ppm, δ) referenced to residual peaks from the deuterated solvents employed.
For synthèses referencing procedures in other Examples or Methods, reaction conditions (length of reaction and température) may vary. In general, reactions were followed by thin layer chromatography or mass spectrometry, and subjected to work-up when appropriate. Purifications may vary between experiments: in general, solvents and the solvent ratios used for eluents/gradients were chosen to provide appropriate RfS or rétention times.
Préparation P1
5-lodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/|pyrimidine
Step 1. Synthesis of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3djpyrimidine (C1).
A solution of 4-chloro-5-iodo-7/-/-pyrrolo[2,3-d]pyrimidine (9.8 g, 35 mmol) in tetrahydrofuran (250 mL) was cooled to 0 °C and treated with sodium hydride (60% in oil, 1.54 g, 38.5 mmol) in three portions. After the reaction mixture had stirred at 0 °C for 1 hour, 2-(trimethylsilyl)ethoxymethyl chloride (6.4 g, 38 mmol) was added drop-wise, and the reaction mixture was warmed to room température and allowed to stir for 3 hours. The reaction was quenched with saturated aqueous sodium chloride solution (250 mL), and the organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (Eluent: 10:1 petroleum ether / ethyl acetate) afforded the product as a white solid. Yield: 8 g, 20 mmol, 57%. 1H NMR (400 MHz, DMSO-cfe) δ 8.69 (s, 1H), 8.14 (s, 1H), 5.60 (s, 2H), 3.51 (t, J=8 Hz, 2H), 0.82 (t, J=8 Hz, 2H), -0.10 (s, 9H).
Step 2. Synthesis of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-d]pyrimidine (P1).
Morpholine (2.45 g, 28.1 mmol) and A/,/V-diisopropylethylamine (6.63 g, 51.3 mmol) were added to a solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}7/-/-pyrrolo[2,3-c/]pyrimidine (C1) (10.5 g, 25.6 mmol) in n-butanol (300 mL), and the reaction mixture was heated at reflux for 18 hours, then concentrated under reduced pressure. Aqueous hydrochloric acid (0.1 M, 100 mL) was added and the resulting solid was collected by filtration, washed with water (20 mL) and dried under vacuum to provide the product as a yellow solid. Yield: 8.0 g, 17 mmol, 66%. LCMS m/z 461.2
[Μ+Η+]. Ή NMR (400 MHz, DMSO-d6) δ 8.39 (s, 1H), 7.81 (s, 1H), 5.52 (s, 2H), 3.803.86 (m, 4H), 3.46-3.53 (m, 6H), 0.77-0.84 (m, 2H), -0.10 (s, 9H).
Préparation P2
4-(Morpholin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-{[2- (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-i/]pyrimidine (P2)
To a solution of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-d]pyrimidine (P1) (500 mg, 1.09 mmol) and 4,4,5,5-tetramethyl-1,3,2dioxaborolane (543 mg, 4.24 mmol) in 1,4-dioxane (20 mL) was added tris(dibenzylideneacetone)dipalladium(0) (99.7 mg, 0.109 mmol), triethylamine (439 mg, 4.34 mmol) and 2-dicyclohexylphosphino-2',4,,6,-triisopropylbiphenyl (XPhos, 51.8 mg, 0.109 mmol), and the reaction mixture was heated at 95 °C for 18 hours. After cooling to room température, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via silica gel chromatography (Gradient: 0% to 30% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 415 mg, 0.901 mmol, 83%. LCMS m/z461.3 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.45 (s, 1H), 7.73 (s, 1H), 5.59 (s, 2H), 3.87-3.93 (m, 4H), 3.68-3.74 (m, 4H), 3.49-3.56 (m, 2H), 1.35 (s, 12H), 0.87-0.93 (m, 2H), -0.06 (s, 9H).
Préparation P3
5-Bromo-4-chloro-7-[(4-methylphenyl)sulfonyl]-7/-/-pyrrolo[2,3-d|pyrimidine (P3)
4-Methylbenzenesulfonyl chloride (5.21 g, 27.3 mmol) was added to a suspension of 5-bromo-4-chloro-7H-pyrrolo[2,3-c/]pyrimidine (6.34 g, 27.3 mmol) in acetone (70 mL). After addition of an aqueous solution of sodium hydroxide (1.11 g, 27.8 mmol in 15 mL water), the reaction mixture was stirred at room température for 16 hours. The mixture was then diluted with water (125 mL), stirred for 10 minutes, and filtered. The collected solids were washed with water to afford the product as a solid. Yield: 8.88 g, 23.0 mmol, 84%. LCMS m/z 385.9, 387.9, 389.8 [M+H+]. 1H NMR (400 MHz, DMSO-de) δ 8.84 (s, 1H), 8.42 (s, 1H), 8.06 (br d, J=8.4 Hz, 2H), 7.46-7.51 (m, 2H), 2.37 (brs, 3H).
Préparation P4
7-[(4-Methylphenyl)sulfonyl]-4-(3-methylpiperidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-7/-/-pyrrolo[2,3-d]pyrimidine (P4)
5-Bromo-7-[(4-methylphenyl)sulfonyl]-4-(3-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3cflpyrimidine (racemic version of C15, see Example 7) (1.44 g, 3.20 mmol) was added to a solution of triethylamine (1.3 g, 13 mmol) in 1,4-dioxane (15 mL). 4,4,5,5-Tetramethyl-
1,3,2-dioxaborolane (1.64 g, 12.8 mmol) was then slowly added, and the mixture was
degassed by bubbling nitrogen through it for 5 minutes. 2-Dicyclohexylphosphino2,,4',6,-triisopropylbiphenyl (XPhos, 137 mg, 0.287 mmol) and tris(dibenzylideneacetone)dipalladium(0) (146 mg, 0.160 mmol) were then introduced, and the reaction mixture was heated at 95 °C for 18 hours. After cooling, the mixture was filtered through cotton and the filtrate was concentrated in vacuo. Chromatography on silica gel (Gradient: 0% to 75% ethyl acetate in heptane) afforded the product as a solid. Yield: 1.25 g, 2.52 mmol, 79%. 1H NMR (400 MHz, CDCI3) δ 8.41 (s, 1H), 8.10 (br d, J=8.4 Hz, 2H), 7.95 (s, 1H), 7.30 (br d, J=8.6 Hz, 2H), 4.28 (br d, J=13 Hz, 1H), 4.184.24 (m, 1H), 2.99 (ddd, J=13, 11, 4 Hz, 1H), 2.70 (dd, J=12.9, 10.9 Hz, 1H), 2.40 (s, 3H), 1.77-1.85 (m, 1H), 1.56-1.70 (m, 4H), 1.35 (s, 12H), 0.88 (d, J=6.6 Hz, 3H).
Préparation P5
5-lodo-4-[(3S)-3-methylpiperidin-1-yl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-
djpyrimidine (P5) | ||
î1 1 kN^N Ό C1 | H | 1 1 w kN^N P5 O |
/r | < /sr |
4-Chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c0pyrimidine (C1) was converted to the product using the method described for synthesis of 5-bromo-
7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidine (C15) in Example 7. Yield: 7.38 g, 15.6 mmol, 80%. LCMS m/z 473.1 [M+H+]. 1H NMR (400 MHz, CDCIs) δ 8.42 (s, 1H), 7.34 (s, 1H), 5.55 (s, 2H), 4.06-4.17 (m, 2H), 3.503.57 (m, 2H), 2.91 (ddd, J=12.6, 11.5, 3.5 Hz, 1H), 2.58 (dd, J=12.6, 10.8 Hz, 1H), 1.952.07 (m, 1H), 1.76-1.95 (m, 3H), 1.11-1.23 (m, 1H), 0.96 (d, J=6.8 Hz, 3H), 0.88-0.94 (m, 2H), -0.04 (s, 9H).
Préparation P6
4-Chloro-5-(1 -methyl-1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine (P6)
Step 1. Synthesis of 4-chloro-5-(1 -methyl-1 /-/-pyrazol-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (C2).
To a solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/7pyrrolo[2,3-c/]pyrimidine (C1) (4.1 g, 10 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-1 H-pyrazole (2.1 g, 10 mmol) and potassium carbonate (2.8 g, 20 mmol) in aqueous 1,4-dioxane was added dichlorobis(triphenylphosphine)palladium(ll) (350 mg, 0.50 mmol). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After heating at reflux for 18 hours, the reaction mixture was cooled to room température, diluted with water (200 mL) and extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (500 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification by chromatography on silica gel (Gradient: 0% to 10% ethyl acetate in petroleum ether) afforded the product as a white solid. Yield: 2.0 g, 5.5 mmol, 55%. 1H NMR (400 MHz, CDCI3) δ 8.66 (s, 1H), 7.68 (d, J=0.5 Hz, 1H), 7.62 (br s, 1H), 7.36 (s, 1H), 5.68 (s, 2H), 3.99 (s, 3H), 3.54-3.59 (m, 2H), 0.91-0.97 (m, 2H), -0.03 (s, 9H).
Step 2. Synthesis of 4-chloro-5-(1-methyl-1/-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine (P6).
4-Chloro-5-(1-methyl-1/-/-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-c/]pyrimidine (C2) was converted to the product using the method described for synthesis of 3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin-5yl]benzonitrile (2) in Example 2. In this case the product, obtained as a yellow solid, was purified by recrystallization from ethyl acetate, rather than via préparative HPLC. Yield: 1.0 g, 4.3 mmol, 43% over two steps. LCMS m/z234.0 [M+H+]. 1H NMR (400 MHz,
DMSO-cfe) δ 12.66 (brs, 1H), 8.58 (s, 1H), 7.91 (s, 1H), 7.69 (d, J=2.5 Hz, 1H), 7.63 (d,
J=0.7 Hz, 1 H), 3.89 (s, 3H).
Préparation P7
A/,/V-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-{[2 (trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-d]pyrimidin-4-amine (P7)
°'B'°
H
5-lodo-A/,A/-dimethyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3d]pyrimidin-4-amine [C3, prepared from 4-chloro-5-iodo-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c(]pyrimidine (C1) according to the method described for synthesis of 3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-d]pyrimidin-5yl]benzonitrile (5) in Example 5] was converted to the product according to the method described for synthesis of 4-(morpholin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/7-pyrrolo[2,3-c/]pyrimidine (P2) in Préparation P2. The product was obtained as a yellow solid. Yield: 342 mg, 0.817 mmol, 69%. LCMS m/z419.3 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.37 (s, 1H), 7.57 (s, 1H), 5.56 (s, 2H), 3.49-3.57 (m, 2H), 3.25 (s, 6H), 1.36 (s, 12H), 0.86-0.94 (m, 2H), -0.06 (s, 9H).
Example 1
5-(1 -Methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine (1 )
Step 1. Synthesis of 5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-d]pyrimidine (C4).
To a solution of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/5 pyrrolo[2,3-c(|pyrimidine (P1) (500 mg, 1.1 mmol) and 1-methyl-4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1 H-pyrazole (272 mg, 1.31 mmol) in a mixture of éthanol and water (4:1, 10 mL) were added dichlorobis(triphenylphosphine)palladium(ll) (41 mg, 58 pmol) and potassium carbonate (447 mg, 3.23 mmol). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three 10 times. It was then heated at 100 °C for 18 hours. After concentration in vacuo, the residue was purified via chromatography on silica gel (Eluent: 1:1 ethyl acetate / petroleum ether) to provide the product as a yellow solid. Yield: 200 mg, 0.48 mmol, 44%. 1H NMR (400 MHz, DMSO-c/6) δ 8.39 (s, 1H), 7.86 (s, 1H), 7.59 (s, 1H), 7.52 (s, 1H), 5.57 (s, 2H), 3.90 (s, 3H), 3.50-3.58 (m, 6H), 3.20-3.27 (m, 4H), 0.83 (dd, J=8.0, 15 7.9 Hz, 2H), -0.09 (s, 9H).
Step 2. Synthesis of [5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3d]pyrimidin-7-yl]methanol (C5).
A solution of 5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (C4) (200 mg, 0.48 mmol) in 20 trifluoroacetic acid (5 mL) was stirred at room température for 2 hours. The reaction
mixture was concentrated under reduced pressure to afford the product as a yellow oil, which was used for the next step without additional purification.
Step 3. Synthesis of 5-(1-methyl-1H-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine (1).
A solution of [5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3c(|pyrimidin-7-yl]methanol (C5) (material from the previous step, <0.48 mmol) in methanol (5 mL) was brought to a pH of >12 via addition of solid potassium carbonate. The reaction mixture was stirred for 30 minutes, filtered, and concentrated in vacuo. Purification via préparative HPLC (Column: Agella Venusil ASB C18, 5 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; Eluent: 13% B) provided the product as a yellow solid. Yield over two steps: 90 mg, 0.32 mmol, 67%. LCMS m/z285.1 [M+H+]. 1H NMR (400 MHz, DMSO-cfe) δ 12.96 (brs, 1H), 8.47 (s, 1H), 7.85 (s, 1H), 7.57 (s, 1H), 7.52 (d, J=2.5 Hz, 1H), 3.90 (s, 3H), 3.53-3.59 (m, 4H), 3.453.51 (m, 4H).
Example 2
3-[6-Methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (2)
Step 1. Synthesis of 4-chloro-5-iodo-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7Hpyrrolo[2,3-d]pyrimidine (C6).
To a -78 °C solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-c(|pyrimidine (C1) (15.0 g, 36.6 mmol) in tetrahydrofuran (500 mL) was added lithium diisopropylamide (2 M solution in heptane / tetrahydrofuran / ethylbenzene, 183 mL, 366 mmol), and the reaction mixture was stirred at -20 °C for 2 hours, then re-cooled to -78 °C. lodomethane (52.1 g, 367 mmol) was added at -78 °C, and the reaction mixture was allowed to stir at -20 °C for 2 hours. Saturated aqueous ammonium chloride solution was added, and the mixture was extracted with ethyl acetate (3 x 500 mL). The combined organic layers were washed with water (100 mL) and with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via chromatography on silica gel (Eluent: 10:1 petroleum ether / ethyl acetate) afforded the product as a yellow oil. Yield: 10 g, 24 mmol, 66%. LCMS m/z 424.1 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.58 (s, 1H), 5.69 (s, 2H), 3.48-3.54 (m, 2H), 2.60 (s, 3H), 0.88-0.95 (m, 2H), -0.05 (s, 9H).
Step 2. Synthesis of 3-(4-chloro-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile (C7).
To a solution of 4-chloro-5-iodo-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7Hpyrrolo[2,3-c/]pyrimidine (C6) (300 mg, 0.71 mmol) and (3-cyanophenyl)boronic acid (104 mg, 0.708 mmol) in a mixture of 1,2-dimethoxyethane and water (5:1, 10 mL) was added potassium carbonate (193 mg, 1.40 mmol) and [1,1’bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (17 mg, 23 pmol). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After heating at reflux for 18 hours, the reaction mixture was cooled to room température and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried
over sodium sulfate, filtered and concentrated in vacuo. Purification via silica gel chromatography (Gradient: 0% to 20% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 140 mg, 0.351 mmol, 50%. LCMS m/z 399.2 [M+H+].
Step 3. Synthesis of 3-[6-methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}7H-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile (C8).
To a solution of 3-(4-chloro-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7Hpyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile (C7) (140 mg, 0.351 mmol) in n-butanol (5 mL) was added morpholine (30.6 mg, 0.351 mmol) and /\/,/V-diisopropylethylamine (90.9 mg, 0.703 mmol). The reaction mixture was heated at 100 °C for 18 hours, then concentrated in vacuo to provide the product as a yellow solid. Yield: 125 mg, 0.278 mmol, 79%. LCMS m/z 450.3 [M+H+].
Step 4. Synthesis of 3-[7-(hydroxymethyl)-6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3c/]pyrimidin-5-yl]benzonitrile (C9).
A solution of 3-[6-methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile (C8) (125 mg, 0.278 mmol) in trifluoroacetic acid (10 mL) was stirred at room température for 2 hours, then concentrated in vacuo to provide the product as a yellow solid (125 mg). This was used in the next step without additional purification. LCMS m/z 349.9 [M+H+].
Step 5. Synthesis of 3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5yl]benzonitrile (2).
A solution of 3-[7-(hydroxymethyl)-6-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3d]pyrimidin-5-yl]benzonitrile (C9) (from the previous step, 125 mg, <0.278 mmol) in acetonitrile (5 mL) was adjusted to a pH of >11 by addition of solid potassium carbonate. The mixture was filtered and concentrated in vacuo; purification via préparative HPLC (Column: Boston Symmetrix ODS-H, 5 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; Gradient: 19% to 39% B) afforded the product as a yellow solid. Yield: 54 mg, 0.17 mmol, 61% over two steps. LCMS m/z 319.9 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 12.17 (brs, 1H), 8.34 (s, 1H), 7.77-7.83 (m, 2H), 7.65-7.74 (m, 2H), 3.27-3.33 (m, 4H), 2.98-3.06 (m, 4H), 2.36 (s, 3H).
Example 3
6-[4-(Morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]pyridine-2-carbonitrile (3)
/Si- -Si-
Step 1. Synthesis of 6-[4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-c(lpyrimidin-5-yl]pyridine-2-carbonitrile (C10).
To a solution of 6-bromopyridine-2-carbonitrile (80 mg, 0.44 mmol) and 4(morpholin-4-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/|pyrimidine (P2) (241 mg, 0.523 mmol) in 1,4-dioxane (2.5 mL) and water (0.5 mL) was added tetrakîs(triphenylphosphine)palladium(0) (51 mg, 44 pmol) and sodium carbonate (140 mg, 1.32 mmol). The reaction mixture was heated at 120 °C under microwave irradiation for 15 minutes, then diluted with water (30 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo', purification via préparative thin layer chromatography (Eluent: 1:1 petroleum ether / ethyl acetate) afforded the product as a brown oil. Yield: 110 mg, 0.252 mmol, 57%. 1H NMR (400 MHz, CDCI3) δ 8.52 (s, 1H), 7.84-7.93 (m, 2H), 7.74 (s, 1H), 7.59 (dd, J=7.0, 1.2 Hz, 1H), 5.66 (s, 2H), 3.56-3.65 (m, 6H), 3.34-3.40 (m, 4H), 0.93 (dd, J=8.3, 8.0 Hz, 2H), -0.05 (s, 9H).
Step 2. Synthesis of 6-[7-(hydroxymethyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d|pyrimidin-
5-yl]pyridine-2-carbonitrile (C11).
A solution of 6-[4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/7pyrrolo[2,3-d|pyrirnidin-5-yl]pyridine-2-carbonitrile (C10) (110 mg, 0.252 mmol) in trifluoroacetic acid (3 mL) was stirred at room température for 2 hours. The reaction mixture was concentrated in vacuo to provide the product as a yellow oil, which was used for the next step without additional purification.
Step 3. Synthesis of 6-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-a(]pyrimidin-5-yl]pyridine-2carbonitrile (3).
A solution of 6-[7-(hydroxymethyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidin5-yl]pyridine-2-carbonitrile (C11) (from the previous step, 85 mg, <0.25 mmol) in acetonitrile (3 mL) was brought to a pH of >12 via addition of solid potassium carbonate. After 30 minutes at room température, the reaction mixture was filtered and concentrated in vacuo. Purification via préparative HPLC (Column: Phenomenex Gemini C18, 8 pm; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 10% to 50% B) afforded the product as a white solid. Yield: 15.2 mg, 49.6 pmol, 20% over two steps. LCMS m/z 307.2 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.13 (dd, J=8.1,7.7 Hz, 1H), 7.96 (br d, J=8 Hz, 1H), 7.89 (br d, J=8 Hz, 1H), 7.86 (s, 1H), 3.50-3.55 (m, 4H), 3.19-3.24 (m, 4H).
Example 4
3-[4-(Morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile (4)
Step 1. Synthesis of 3-(4-chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3 cflpyrimidin-5-yl)benzonitrile (C12).
To a stirred mixture of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-d]pyrimidine (C1) (8.2 g, 20 mmol), (3-cyanophenyl)boronic acid (3.2 g, 22 mmol) and potassium carbonate (8.3 g, 60 mmol) in a mixture of 1,2-dimethoxyethane and water (4:1 ratio, 250 mL) was added [1,1’bis(diphenylphosphino)ferrocene]dichloropalladium(ll) (731 mg, 1.00 mmol). The reaction mixture was degassed and then charged with nitrogen; this procedure was carried out a total of three times. The reaction mixture was heated at reflux for 3 hours, then cooled to room température and diluted with saturated aqueous sodium chloride solution (100 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification via silica gel column chromatography (Eluent: 10:1 petroleum ether / ethyl acetate) provided the product as a yellow oil. Yield: 5.0 g, 12 mmol, 60%. 1H NMR (400 MHz, DMSO-afe) δ 8.75 (s, 1H), 8.13 (s, 1H), 8.008.02 (m, 1H), 7.84-7.92 (m, 2H), 7.68 (dd, J=7.Q, 7.8 Hz, 1H), 5.70 (s, 2H), 3.60 (dd, J=8.0, 8.0 Hz, 2H), 0.86 (dd, J=8.0, 8.0 Hz, 2H), -0.08 (s, 9H).
Step 2. Synthesis of 3-[4-chloro-7-(hydroxymethyl)-7/-/-pyrrolo[2,3-ûf|pyrimidin-5yl]benzonitrile (C13).
A solution of 3-(4-chloro-7-[[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3c/]pyrimidin-5-yl)benzonitrile (C12) (3.8 g, 9.9 mmol) in trifluoroacetic acid (25 mL) was stirred at room température for 2 hours. The reaction mixture was concentrated in vacuo to afford the product (4 g, >100% mass recovery) as a yellow oil, which was used in the next step without further purification.
Step 3. Synthesis of 3-(4-chloro-7/7-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile (C14).
A solution of 3-[4-chloro-7-(hydroxymethyl)-7/7-pyrrolo[2,3-d]pyrimidin-5yl]benzonitrile (C13) (4 g from the previous step, <9.9 mmol) in methanol (100 mL) was adjusted to pH >12 by addition of solid potassium carbonate. Solvent was removed in vacuo and the residue was mixed with water (100 mL). The resulting solid was isolated via filtration and washed with water, providing the product as a white solid. Yield: 1.3 g, 5.1 mmol, 52% over two steps. LCMS m/z 255.0 [M+H+].
Step 4. Synthesis of 3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile (4).
Morpholine (871 mg, 10 mmol) and A/,A/-diisopropylethylamine (2.6 g, 20 mmol) were added to a solution of 3-(4-chloro-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl)benzonitrile (C14) (2.5 g, 9.8 mmol) in n-butanol (100 mL), and the reaction mixture was heated at
reflux for 3 hours. Solvents were removed m vacuo and the residue was purified using chromatography on silica gel (Eluent: 1:1 ethyl acetate / petroleum ether). Subséquent recrystallization from ethyl acetate and te/t-butyl methyl ether afforded the product as a white solid. Yield: 770 mg, 2.52 mmol, 26%. LCMS m/z 306.0 [M+H+]. 1H NMR (400 MHz, DMSO-dg) δ 12.34 (br s, 1 H), 8.41 (s, 1H), 7.99-8.02 (m, 1H), 7.89 (br d, J=8 Hz, 1H), 7.76 (br d, J=7.5 Hz, 1H), 7.71 (s, 1H), 7.68 (dd, J=7.8, 7.8 Hz, 1H), 3.44-3.50 (m, 4H), 3.11-3.17 (m, 4H).
Example 5
3-[4-(Dimethylamino)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile (5)
A mixture of 3-(4-chloro-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl)benzonitrile (C14) (157 mg, 0.616 mmol), dimethylamine (189 mg, 4.19 mmol) and triethylamine (182 mg, 1.80 mmol) in n-butanol (12 mL) was heated under microwave irradiation at 150 °C for 25 minutes. After concentration in vacuo, the residue was purified by préparative HPLC (Column: Phenomenex Gemini C18, 8 pm; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 25% to 65% B) to give the product as a white solid. Yield: 72.1 mg, 0.274 mmol, 44%. LCMS m/z 263.8 [M+H+]. 1H NMR (400 MHz, DMSO-ofe) δ 12.15 (br s, 1H), 8.28 (s, 1H), 7.93 (br s, 1H), 7.78 (br d, J=7.8 Hz, 1H), 7.73 (br d, J=7.8 Hz, 1 H), 7.62 (br dd, J=8.0, 7.8 Hz, 1 H), 7.57 (br s, 1 H), 2.73 (s, 6H).
Example 6
3-{4-[(2S)-2-Methylmorpholin-4-yl]-7H-pyrrolo[2,3-c(|pyrimidin-5-yl}benzonitrile (6)
To a solution of 3-(4-chloro-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile (C14) (100 mg, 0.393 mmol) and (2S)-2-methylmorpholine (54 mg, 0.53 mmol) in n-butanol (20 mL) was added /V,A/-diisopropylethylamine (152 mg, 1.18 mol), and the reaction mixture was heated at 100 °C for 18 hours. The reaction mixture was then concentrated 5 in vacuo; purification via préparative HPLC (Column: Phenomenex Gemini C18, 8 pm;
Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 27% to 47% B) provided the product as a white solid. Yield: 17.5 mg, 54.8 pmol, 14%. LCMS m/z 320.2 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 10.71 (br s, 1H), 8.53 (br s, 1H), 7.737.89 (m, 2H), 7.51-7.69 (m, 2H), 7.28 (s, 1H, assumed; partially obscured by solvent 10 peak), 3.56-3.77 (m, 3H), 3.39-3.54 (m, 2H), 2.86-2.98 (m, 1 H), 2.53-2.65 (m, 1 H), 0.931.03 (m, 3H).
Example 7 (3-{4-[(3S)-3-Methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl}phenyl)methanol (7)
Step 1. Synthesis of 5-bromo-7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1yl]-7H-pyrrolo[2,3-c(]pyrimidine (C15).
5-Bromo-4-chloro-7-[(4-methylphenyl)sulfonyl]-7/-/-pyrrolo[2,3-c/|pyrimidine (P3) was reacted with the hydrochloride sait of (3S)-3-methylpiperidine according to the 20 method described for préparation of 3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3d]pyrimidin-5-yl}benzonitrile (6) in Example 6. In this case, purification was effected via
silica gel chromatography (Eluent: 5:1 petroleum ether / ethyl acetate), providing the product as a white solid. Yield: 4.3 g, 9.6 mmol, 92%.
Step 2. Synthesis of (3-{7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1-yl]-7Hpyrrolo[2,3-d]pyrimidin-5-yl}phenyl)methanol (C16).
A mixture of 5-bromo-7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-1-yl]7/-/-pyrrolo[2,3-d]pyrimidine (C15) (0.225 g, 0.501 mmol), [3(hydroxymethyl)phenyl]boronic acid (0.104 g, 0.684 mmol), sodium carbonate (0.159 g, 1.50 mmol) and dichlorobis(triphenylphosphine)palladium(ll) (36 mg, 51 pmol) in acetonitrile (2 mL) and water (2 mL) was heated to 150 °C under microwave irradiation for 15 minutes. The reaction was concentrated in vacuo to afford the product (0.35 g, >100%), which was used directly in the following step without additional purification. Step 3. Synthesis of (3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5yl}phenyl)methanol (7).
To a stirred solution of (3-{7-[(4-methylphenyl)sulfonyl]-4-[(3S)-3-methylpiperidin-
1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}phenyl)methanol (C16) from the previous step (<0.50 mmol) in 2-propanol (20 mL) was added lithium hydroxide monohydrate (0.42 g, 10 mmol) and water (3 mL) and the reaction mixture was stirred at room température for 18 hours. After concentration in vacuo, the residue was purified by préparative HPLC (Column: Waters XBridge; Mobile phase A: 0.1% ammonia in water; Mobile phase B: acetonitrile; Gradient: 44% to 60% B) to provide the product as a white solid. Yield: 130 mg, 0.403 mmol, 80% over two steps. LCMS m/z 323.4 [M+H+]. 1H NMR (400 MHz, CD3OD) Ô 8.24 (s, 1 H), 7.46 (br s, 1 H), 7.35-7.43 (m, 2H), 7.30 (br d, J=6 Hz, 1 H), 7.23 (s, 1H), 4.67 (s, 2H), 3.89 (br d, J=13 Hz, 1H), 3.79 (br d, J=12 Hz, 1H), 2.58-2.69 (m, 1H), 2.27 (dd, J=12.0, 11.0 Hz, 1H), 1.62-1.71 (m, 1H), 1.30-1.52 (m, 3H), 0.87-1.01 (m, 1H), 0.60 (d, J=6.5 Hz, 3H).
Example 8
4-(Morpholin-4-yl)-5-(1/7-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidine, formate sait (8)
Step 1. Synthesis of 1-(tetrahydro-2/-/-pyran-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2dioxaborolan-2-yl)-1 /7-pyrazole (C17).
3,4-Dihydro-2H-pyran (5.6 g, 67 mmol) and trifluoroacetic acid (1.17 g, 10.3 mmol) were added to a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 Hpyrazole (10.0 g, 51.5 mmol) in toluene (200 mL), and the reaction mixture was heated to 90 °C for 2 hours. After cooling to room température, the reaction mixture was partitioned between ethyl acetate (200 mL) and saturated aqueous sodium bicarbonate 10 solution (100 mL), and the aqueous layer was extracted with ethyl acetate (100 mL).
The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. Silica gel chromatography (Gradient: 10% to 50% ethyl acetate in petroleum ether) provided the product as a white solid. Yield: 13.4 g, 48.2 mmol, 94%. 1H NMR (400 MHz, CDCI3)
δ 7.94 (s, 1 Η), 7.83 (s, 1 Η), 5.41 (dd, J=9.5, 2.5 Hz, 1H), 4.01-4.08 (m, 1H), 3.65-3.74 (m, 1H), 1.98-2.18 (m, 3H), 1.6-1.76 (m, 3H), 1.32 (s, 12H).
Step 2. Synthesis of 4-chloro-5-[1-(tetrahydro-2/-/-pyran-2-yl)-1/-/-pyrazol-4-yl]-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-d]pyrimidine (C18).
A mixture of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3djpyrimidine (C1) (2.0 g, 4.9 mmol), 1-(tetrahydro-2/-/-pyran-2-yl)-4-(4,4,5,5-tetramethyl-
1,3,2-dioxaborolan-2-yl)-1/7-pyrazole (C17) (1.91 g, 6.87 mmol), potassium phosphate (4.0 g, 19 mmol) and tetrakis(triphenylphosphîne)palladium(0) (0.10 g, 87 pmol) was degassed several times with nitrogen and irradiated in a microwave synthesizer at 130 °C for 1.5 hours. The reaction mixture was partitioned between ethyl acetate (400 mL) and water (60 mL), and the aqueous layer was extracted with ethyl acetate (200 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Chromatography on silica gel (Gradient: 10% to 80% ethyl acetate in petroleum ether) afforded the product as a brown oil. Yield: 1.33 g, 3.06 mmol, 62%. 1H NMR (400 MHz, CDCI3) δ 8.67 (s, 1H), 7.87 (s, 1H), 7.76 (s, 1H), 7.38 (s, 1H), 5.68 (s, 2H), 5.46 (dd, J=9.4, 2.9 Hz, 1H), 4.08-4.15 (m, 1H), 3.71-3.79 (m, 1H), 3.57 (dd, J=8.3, 8.0 Hz, 2H), 2.04-2.24 (m, 3H), 1.61-1.79 (m, 3H), 0.94 (dd, J=8.3, 8.3 Hz, 2H), -0.03 (s, 9H).
Step 3. Synthesis of 4-(morpholin-4-yl)-5-[1-(tetrahydro-2/-/-pyran-2-yl)-1/-/-pyrazol-4-yl]-
7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/]pyrimidine (C19).
A solution of 4-chloro-5-[1-(tetrahydro-2H-pyran-2-yl)-1/-/-pyrazol-4-yl]-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/]pyrimidine (C18) (3.3 g, 7.6 mmol), morpholine (0.99 g, 11 mmol) and Λ/,/V-diisopropylethylamine (6 mL, 34 mmol) in nbutanol (15 mL) was irradiated in a microwave synthesizer at 100 °C for 30 minutes. After removal of solvents in vacuo, the residue was purified by silica gel chromatography (Gradient: 10% to 50% ethyl acetate in petroleum ether) to provide the product as a brown oil. Yield: 2.6 g, 5.4 mmol, 71%. 1H NMR (400 MHz, CDCI3) δ 8.50 (s, 1H), 7.79 (s, 1H), 7.71 (s, 1H), 7.17 (s, 1H), 5.62 (s, 2H), 5.44 (dd, J=6.5, 6.0 Hz,
1H), 4.08-4.15 (m, 1H), 3.71-3.79 (m, 1H), 3.62-3.67 (m, 4H), 3.58 (dd, J=8.5, 8.0 Hz,
2H), 3.33-3.39 (m, 4H), 2.06-2.19 (m, 3H), 1.62-1.79 (m, 3H), 0.93 (dd, J=8.5, 7.5 Hz,
2H), -0.04 (s, 9H).
Step 4. Synthesis of 4-(morpholin-4-yl)-5-(1 /-/-pyrazol-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-J]pyrimidine (C20).
To a solution of 4-(morpholin-4-yl)-5-[1-(tetrahydro-2/-/-pyran-2-yl)-1/-/-pyrazol-4yl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/]pyrimidine (C19) (4.0 g, 8.2 mmol) in dichloromethane (20 mL) was added a solution of hydrogen chloride in 1,4dioxane (4 M, 100 mL). The reaction mixture was stirred at room température for 2 hours, then poured into a mixture of ethyl acetate (300 mL) and saturated aqueous sodium bicarbonate solution (300 mL). The aqueous layer was extracted with ethyl acetate (2 x 300 mL), and the combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification via silica gel chromatography (Gradient: 10% to 80% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 2.18 g, 5.44 mmol, 66%. LCMS m/z 401.3 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 8.51 (s, 1H), 7.78 (s, 2H), 7.19 (s, 1H), 5.64 (s, 2H), 3.56-3.66 (m, 6H), 3.343.40 (m, 4H), 0.91-0.98 (m, 2H), -0.03 (s, 9H).
Step 5. Synthesis of [4-(morpholin-4-yl)-5-(1/-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin7-yl]methanol (C21).
4-(Morpholin-4-yl)-5-(1H-pyrazol-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/7pyrrolo[2,3-c/]pyrimidine (C20) (0.13 g, 0.32 mmol) was dissolved in trifluoroacetic acid (10 mL) and stirred at room température for 2 hours. Removal of solvent in vacuo provided the product (100 mg) as a brown solid; this was used in the next step without further purification. LCMS m/z 301.2 [M+H+].
Step 6. Synthesis of 4-(morpholin-4-yl)-5-(1/-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine, formate sait (8).
To a solution of [4-(morpholin-4-yl)-5-(1/-/-pyrazol-4-yl)-7H-pyrrolo[2,3c/]pyrimidin-7-yl]methanol (C21) (from the previous step, 0.10 g, <0.32 mmol) in acetonitrile (10 mL) was added potassium carbonate (0.34 g, 2.5 mmol) and the reaction mixture was stirred at room température for 30 minutes. The mixture was filtered and the filter cake was washed with ethyl acetate (3 x 20 mL). The combined filtrâtes were concentrated in vacuo- purification via préparative HPLC (Column: DIKMA Diamonsil(2) C18, 5 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; Gradient: 0% to 17% B) afforded the product as a pale solid. Yield: 36 mg, 0.11 mmol, 34% over 2 steps. LCMS m/z271.2 [M+H+]. 1H NMR (400 MHz, CDCI3) δ
10.72 (br s, 1 H), 8.47 (s, 1 H), 7.78 (s, 2H), 7.19 (s, 1 H), 3.60-3.67 (m, 4H), 3.41 -3.48 (m, 4H).
Example 9
3-[2-Methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (9)
Step 1. Synthesis of 4-chloro-5-iodo-2-methyl-7/-/-pyrrolo[2,3-d]pyrimidine (C22).
To a solution of 4-chloro-2-methyl-7/-/-pyrrolo[2,3-d]pyrimidine (400 mg, 2.4 mmol) in dichloromethane (10 mL) was added /V-iodosuccinimide (537 mg, 2.39 mmol).
The mixture was stirred at room température for 2 hours, then washed with aqueous sodium sulfite solution, dried over sodium sulfate, filtered, and concentrated in vacuo to provide the product as a brown solid. Yield: 330 mg, 1.12 mmol, 47%. LCMS m/z 293.8 [M+H+],
Step 2. Synthesis of 4-chloro-5-iodo-2-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/15 pyrrolo[2,3-d]pyrimidine (C23).
4-Chloro-5-iodo-2-methyl-7/-/-pyrrolo[2,3-d]pyrimidine (C22) was converted to the product according to the method used for synthesis of 4-chloro-5-iodo-7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-c/]pyrimidine (C1) in Préparation P1. The product was obtained as a yellow oil. Yield: 400 mg, 0.94 mmol, 84%. LCMS m/z 424.0 [M+H+].
Step 3. Synthesis of 5-iodo-2-methyl-4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-cflpyrimidine (C24).
The product was prepared from 4-chloro-5-iodo-2-methyl-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine (C23) according to the method described for synthesis of 3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-
5-yl}benzonitrile (6) in Example 6. In this case, purification was carried out via silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 300 mg, 0.63 mmol, 67%. LCMS m/z475.2 [M+H+]. Step 4. Synthesis of 3-[2-methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (C25).
To a solution of 5-iodo-2-methyl-4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c(|pyrimidine (C24) (100 mg, 0.21 mmol), (3-cyanophenyl)boronic acid (62 mg, 0.42 mmol) and potassium carbonate (100 mg, 0.72 mmol) in a mixture of éthanol and water (4:1,5 mL) was added dichlorobis(triphenylphosphine)palladium (15 mg, 21 pmol). The reaction mixture was degassed and purged with nitrogen; this procedure was carried out a total of three times. After the reaction mixture had heated at 90 °C for 3 hours, it was allowed to cool and concentrated in vacuo. Purification via préparative thin layer chromatography (Eluent: 1:1 petroleum ether / ethyl acetate) provided the product as a yellow oil. Yield: 52 mg, 0.12 mmol, 57%. LCMS m/z451.3 [M+H+].
Step 5. Synthesis of 3-[2-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5yl]benzonitrile (9).
3-[2-Methyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3c/]pyrimidin-5-yl]benzonitrile (C25) was converted to the product using the method described for synthesis of 5-(1-methyl-1/-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/pyrrolo[2,3-c/]pyrimidine (1) in Example 1. In this case, préparative HPLC purification was carried out using a Phenomenex Gemini C18 column, 8 pm; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 30% to 50% B. The product was obtained as a white solid. Yield: 17.3 mg, 54.2 pmol, 45% over 2 steps. LCMS m/z 320.1 [M+H+]. 1H NMR (400 MHz, CD3OD) δ 7.91-7.93 (m, 1H), 7.85-7.88
(m, 1H), 7.60-7.69 (m, 2H), 7.38 (s, 1H), 3.51-3.55 (m, 4H), 3.24-3.28 (m, 4H), 2.59 (s,
3H).
Example 10 s {3-[4-(Dimethylamino)-7H-pyrrolo[2,3-c/|pyrimidin-5-yl]phenyl}methanol (10)
Step 1. Synthesis of {3-[4-(dimethylamino)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-c/|pyrimidin-5-yl]phenyl}methanol (C26).
A solution of 5-iodo-/V,/V-dimethyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H10 pyrrolo[2,3-c/|pyrimidin-4-amine (C3) (418 mg, 1.00 mmol), [3(hydroxymethyl)phenyl]boronic acid (228 mg, 1.50 mmol), tetrakis(triphenylphosphine)palladîum(0) (115 mg, 0.100 mmol), and césium carbonate (625 mg, 1.92 mmol) in 1,4-dioxane (6 mL) and water (1.5 mL) was purged with nitrogen, then heated under microwave irradiation at 120 °C for 20 minutes. The 15 reaction mixture was diluted with saturated aqueous sodium chloride solution (50 mL) and extracted with dichloromethane (3 x 60 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Chromatography on silica gel (Gradient: 2% to 17% ethyl acetate in petroleum ether) afforded the product as a brown oil. Yield: 369 mg, 0.926 mmol, 93%. LCMS m/z 399.0 [M+H+].
Step 2. Synthesis of 3-[4-(dimethylamino)-7-(hydroxymethyl)-7/-/-pyrrolo[2,3-c(]pyrimidin-
5-yl]benzyl trifluoroacetate (C27).
A solution of {3-[4-(dimethylamino)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-d]pyrimidin-5-yl]phenyl}methanol (C26) (397 mg, 0.996 mmol) in
trifluoroacetic acid (10 mL) was stirred at room température for 2 hours. The reaction mixture was concentrated in vacuo to provide the product (400 mg) as a brown oil. This material was taken directly into the following step. LCMS m/z 395.1 [M+H+].
Step 3. Synthesis of {3-[4-(dimethylamino)-7H-pyrrolo[2,3-c/]pyrimidin-5yl]phenyl}methanol (10).
A mixture of 3-[4-(dimethylamino)-7-(hydroxymethyl)-7/-/-pyrrolo[2,3-c(]pyrimidin-
5-yl]benzyl trifluoroacetate (C27) (from the previous step, 400 mg, ^0.996 mmol) and potassium carbonate (500 mg, 3.6 mmol) in methanol (10 mL) was stirred at 80 °C for 30 minutes. The reaction mixture was diluted with saturated aqueous sodium chloride solution (50 mL) and extracted with dichloromethane (3 x 60 mL); the combined organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via préparative HPLC (Column: Phenomenex Gemini C18, 8 pm; Mobile phase A: ammonia in water, pH 10; Mobile phase B: acetonitrile; Gradient: 21% to 33% B) afforded the product as a white solid. Yield: 77.7 mg, 0.290 mmol, 29% over two steps. LCMS m/z 268.9 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 10.83 (br s, 1H), 8.39 (s, 1H), 7.50 (brs, 1H), 7.38-7.42 (m, 2H), 7.29-7.34 (m, 1H), 7.11 (s, 1H), 4.78 (s, 2H), 2.84 (s, 6H).
Example 198 3-[6-(Difluoromethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-G(]pyrimidin-5-yl]benzonitrile (198)
/ \
ÔH
Step 1. Synthesis of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3d]pyrimidine-6-carbaldehyde (C28).
A solution of diisopropylamine (2.9 g, 29 mmol) in tetrahydrofuran (30 mL) was cooled to -78 °C and treated drop-wise with n-butyllithium (2.5 M, 11.6 mL, 29 mmol).
The reaction mixture was stirred at 0 °C for 1 hour, and then cooled to -78 °C. A solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3djpyrimidine (C1) (8.0 g, 20 mmol) in tetrahydrofuran (10 mL) was added drop-wise, and stirred was continued at -78 °C for 1 hour. After drop-wise addition of a solution of ethyl 10 formate (2.6 g, 35 mmol) in tetrahydrofuran (10 mL) to the -78 °C reaction mixture, it was allowed to warm to room température and stir for 18 hours. It was then cooled to 0 °C, and the reaction was quenched by addition of saturated aqueous ammonium chloride solution (20 mL), then extracted with ethyl acetate (3 x 50 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), 15 dried over sodium sulfate, filtered, and concentrated. Purification via silica gel chromatography (Gradient: 0% to 25% ethyl acetate in petroleum ether) afforded the
product as a yellow oil. Yield: 5.0 g, 11 mmol, 55%. 1H NMR (400 MHz, CDCI3) δ 10.11 (s, 1H), 8.80 (s, 1H), 6.05 (s, 2H), 3.55-3.62 (m, 2H), 0.89-0.96 (m, 2H), -0.05 (s, 9H). Step 2. Synthesis of 5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-c/|pyrimidine-6-carbaldehyde (C29).
Morpholine (1.09 g, 12.5 mmol) and Λ/,/V-diisopropylethylamine (2.94 g, 22.7 mmol) were added to a solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}7/-/-pyrrolo[2,3-af|pyrimidine-6-carbaldehyde (C28) (5.0 g, 11 mmol) in acetonitrile (20 mL). The reaction mixture was stirred at reflux for 16 hours, whereupon it was cooled and concentrated in vacuo; the residue was purified by chromatography on silica gel (Gradient: 0% to 20% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 4.0 g, 8.2 mmol, 74%. 1H NMR (400 MHz, CDCI3) δ 9.99 (s, 1H), 8.54 (s, 1H), 6.01 (s, 2H), 3.92-3.98 (m, 4H), 3.70-3.75 (m, 4H), 3.58-3.65 (m, 2H), 0.91-0.96 (m, 2H), -0.05 (s, 9H).
Step 3. Synthesis of 3-[6-formyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (C30).
5-lodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3c/]pyrimidine-6-carbaldehyde (C29) was converted to the product using the method described for synthesis of 3-(4-chloro-6-methyl-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/« pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile (C7) in Example 2. The product was obtained as a yellow solid. Yield: 1.5 g, 3.2 mmol, 78%. 1H NMR (400 MHz, CDCI3) δ 9.75 (s, 1H), 8.60 (s, 1H), 7.77-7.83 (m, 2H), 7.72-7.76 (m, 1H), 7.67 (br dd, J=8, 8 Hz, 1H), 6.09 (s, 2H), 3.66-3.71 (m, 2H), 3.38-3.44 (m, 4H), 3.23-3.28 (m, 4H), 0.94-1.01 (m, 2H), -0.03 (s, 9H).
Step 4. Synthesis of 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (C31).
A solution of 3-[6-formyl-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile (C30) (200 mg, 0.43 mmol) and (diethylamino)sulfur trifluoride (276 mg, 1.71 mmol) in dichloromethane (10 mL) was stirred at 40 °C for 16 hours. The reaction mixture was poured into saturated aqueous sodium bicarbonate solution (10 mL) and extracted with dichloromethane (3 x 20 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated; purification by préparative thin-layer chromatography on silica gel (Eluent: 1:1 ethyl acetate /
petroleum ether) afforded the product as a yellow solid. Yield: 150 mg, 0.31 mmol, 72%. 1H NMR (400 MHz, CDCI3) δ 8.58 (s, 1H), 7.76 (ddd, J=7.3, 1.6, 1.5 Hz, 1H), 7.72-7.74 (m, 1H), 7.61-7.70 (m, 2H), 6.74 (t, JHf=52.5 Hz, 1H), 5.86 (s, 2H), 3.65-3.72 (m, 2H), 3.34-3.42 (m, 4H), 3.15-3.21 (m, 4H), 0.95-1.02 (m, 2H), -0.02 (s, 9H).
Step 5. Synthesis of 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin5-yl]benzonitrile (198).
A solution of 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile (C31) (10 mg, 21 pmol) in trifluoroacetic acid (2 mL) was stirred at room température for 24 hours. The reaction mixture was concentrated and purified by préparative reversed phase highperformance liquid chromatography (Column: DIKMA Diamonsil(2) C18, 5 pm; Eluent: 22% acetonitrile in water containing 0.225% formic acid) to provide the product as a white solid. Yield: 2.0 mg, 5.6 pmol, 27%. LCMS m/z 355.9 [M+H+]. 1H NMR (400 MHz, DMSO-cfe) δ 13.06 (br s, 1 H), 8.47 (s, 1 H), 7.92 (ddd, J=6.7, 2.1, 1.7 Hz, 1 H), 7.83-7.85 (m, 1H), 7.69-7.76 (m, 2H), 7.02 (t, JHf=52.5 Hz, 1H), 3.22-3.30 (m, 4H), 3.03-3.10 (m, 4H).
Example 199 and Example 200
5-(5,6-Dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine (199) and
5-(3,4-Dihydro-2H-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine (200)
Step 1. Synthesis of 3-(4-chloro-7/-/-pyrrolo[2,3-c/Jpyrimidin-5-yl)tetrahydro-2/-/-pyran-3ol (C32).
To a -78 °C solution of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1.5 g, 5.4 mmol) in tetrahydrofuran (50 mL) was added n-butyllithium (2.5 M, 6.4 mL, 16.1 mmol) drop-wise. After the reaction mixture had been stirred at -78 °C for 2 hours, it was treated with dihydro-2/7-pyran-3(4/-/)-one (1.61 g, 16.1 mmol), warmed to room température, and stirred for 18 hours. The reaction was quenched with water (50 mL), and the aqueous layer was extracted with ethyl acetate (3 x 30 mL); the combined organic layers were washed with saturated aqueous sodium chloride solution (100 mL), dried over sodium sulfate, filtered, and concentrated. Silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 200 mg, 0.79 mmol, 15%. LCMS m/z 254.0 [M+H+].
Step 2. Synthesis of 3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]tetrahydro2/-/-pyran-3-ol (C33).
To a solution of 3-(4-chloro-7/7-pyrrolo[2,3-d]pyrimidin-5-yl)tetrahydro-2/-/-pyran3-ol (C32) (200 mg, 0.79 mmol) and morpholine (134 mg, 1.54 mol) in n-butanol (10 mL) was added /V,/V-diisopropylethylamine (305 mg, 2.36 mol), and the reaction mixture was heated at 70 °C for 2 hours. After concentration in vacuo, préparative reversed phase high-performance liquid chromatography (Column: Phenomenex Gemini C18, 8 pm; Mobile phase A: aqueous ammonia, pH 10; Mobile phase B: acetonitrile; Gradient: 9% to 29% B) provided the product as a white solid. Yield: 180 mg, 0.59 mmol, 75%. LCMS m/z 305.1 [M+H+]. 1H NMR (400 MHz, CDCI3 + D2O) δ 8.73 (s, 1H), 7.52 (s, 1H), 3.92-4.03 (m, 4H), 3.74-3.88 (m, 4H), 3.32-3.40 (m, 2H), 3.15-3.24 (m, 2H), 2.07-2.16 (m, 1H), 1.88-2.06 (m, 2H), 1.57-1.68 (m, 1H).
Step 3. Synthesis of 5-(5,6-dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine (199) and 5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine (200).
Triethylsilane (10 mL) and trifluoroacetic acid (10 mL) were added over 10 minutes to a solution of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidin-5-yl]tetrahydro2/-/-pyran-3-ol (C33) (40 mg, 0.13 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at room température for 2 hours, whereupon it was concentrated in vacuo. Préparative reversed phase high-performance liquid chromatography (Column: Boston Symmetrix ODS-H, 5 pm; Mobile phase A: water containing 0.225% formic acid; Mobile phase B: acetonitrile; Gradient: 11% to 31% B) afforded 199 as a white solid
(Yield: 11.3 mg, 39.5 pmol, 30%) and 200, also as a white solid (Yield: 7.0 mg, 24 pmol, 18%).
199: LCMS m/z287.0 [M+H+]. 1H NMR (400 MHz, DMSO-d6) δ 11.97 (br s, 1 H), 8.29 (s, 1H), 7.31 (s, 1H), 5.87-5.93 (m, 1H), 4.30-4.36 (m, 2H), 3.68-3.78 (m, 6H), 3.36-3.43 (m, 4H), 2.21-2.29 (m, 2H).
200: LCMS m/z287.0 [M+H+], 1H NMR (400 MHz, DMSO-d6) δ 11.83 (br s, 1 H), 8.26 (s, 1H), 7.18 (s, 1 H), 6.65 (s, 1 H), 3.92-3.97 (m, 2H), 3.69-3.76 (m, 4H), 3.40-3.46 (m, 4H), 2.29-2.36 (m, 2H), 1.88-1.96 (m, 2H).
Example 201
4-(Morpholin-4-yl)-5-[3-(1,2,4-oxadiazol-3-yl)phenyl]-7/-/-pyrrolo[2,3-d]pyrimidine (201 )
Step 1. Synthesis of 3-[4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7Hpyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (C34).
3-[4-(Morpholin-4-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile (4) was converted to the product using the method described for synthesis of 4-chloro-5-iodo-7{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-d]pyrimidine (C1) in Préparation P1. The product was obtained as a yellow solid. Yield: 0.90 g, 2.1 mmol, 70%. 1H NMR (400 MHz, CDCI3) δ 8.55 (s, 1H), 7.86 (br s, 1H), 7.79 (br d, J=7.6 Hz, 1H), 7.63 (br d, J=7.6 Hz, 1H), 7.57 (dd, J=7.6, 7.6 Hz, 1H), 7.29 (s, 1H), 5.67 (s, 2H), 3.58-3.64 (m, 2H), 3.52-3.58 (m, 4H), 3.27-3.32 (m, 4H), 0.92-0.98 (m, 2H), -0.03 (s, 9H).
Step 2. Synthesis of /V'-hydroxy-3-[4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzenecarboximidamide (C35).
Hydroxylamine hydrochloride (278 mg, 4.00 mmol) and sodium carbonate (318 mg, 3.00 mmol) were added to a stirred solution of 3-[4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (C34) (436 mg, 1.00 mmol) in éthanol (10 mL) and water (5 mL). The reaction mixture was heated at reflux for 2 hours, then concentrated in vacuo, poured into water (25 mL), and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (25 mL), dried over sodium sulfate, filtered, and concentrated, affording the product as a white solid. Yield: 280 mg, 0.60 mmol, 60%. 1H NMR (400 MHz, DMSO-de) δ 9.67 (s, 1 H), 8.43 (s, 1 H), 7.89 (br s, 1 H), 7.72 (s, 1H), 7.64 (br d, J=7.8 Hz, 1H), 7.53 (br d, J=7.8 Hz, 1H), 7.46 (dd, J=7.6, 7.6 Hz, 1H), 5.89 (br s, -1.6H), 5.61 (s, 2H), 3.53-3.61 (m, 2H), 3.39-3.47 (m, 4H), 3.13-3.21 (m, 4H), 0.81-0.88 (m, 2H), -0.09 (s, 9H).
Step 3. Synthesis of 4-(morpholin-4-yl)-5-[3-(1,2,4-oxadiazol-3-yl)phenyl]-7/7pyrrolo[2,3-c/]pyrimidine (201).
Triethyl orthoformate (760 mg, 5.1 mol) and boron trifluoride diethyl etherate (370 mg, 2.6 mol) were added to a 0 °C solution of A/'-hydroxy-3-[4-(morpholin-4-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzenecarboximidamide (C35) (600 mg, 1.3 mmol) in tetrahydrofuran (25 mL). The reaction mixture was heated at 40 °C for 18 hours, then poured into water (50 mL) and extracted with ethyl acetate (3 x 25 mL). The combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL), dried over sodium sulfate, filtered, and concentrated. Purification via préparative reversed phase high-performance liquid chromatography (Column: Phenomenex Gemini C18, 8 pm; Mobile phase A: aqueous ammonia, pH 10; Mobile phase B: acetonitrile; Gradient: 30% to 50% B) provided the product as a yellow solid. Yield: 62 mg, 0.18 mmol, 14%. LCMS m/z 349.0 [M+H+]. 1H NMR (400 MHz, DMSO-cfe) δ 9.77 (s, 1H), 8.40 (s, 1H), 8.24 (br s, 1H), 7.98 (br d, J=7.5 Hz, 1H), 7.82 (br d, J=7.3 Hz, 1H), 7.63-7.70 (m, 2H), 3.39-3.45 (m, 4H), 3.13-3.20 (m, 4H).
Example 202
3-{4-[2-(3-Methyl-1,2-oxazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile (202)
Step 1. Synthesis of 4-benzyl-2-(3-methyl-1,2-oxazol-5-yl)morpholin-2-ol (C36).
A solution of 2-bromo-1-(3-methyl-1,2-oxazol-5-yl)ethanone (2.50 g, 12.2 mmol) and 2-(benzylamino)ethanol (3.70 g, 24.5 mmol) in acetonitrile (25 mL) was stirred at 35 °C for 18 hours. The reaction mixture was concentrated in vacuo and purified using silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) to provide the product as a yellow oil. Yield: 1.2 g, 4.4 mmol, 36%. 1H NMR (400 MHz, CDCI3) δ 7.27-7.38 (m, 5H), 6.22 (s, 1H), 4.11-4.19 (m, 1H), 3.76-3.84 (m, 1H), 3.60 (AB quartet, JAB=13.0 Hz, ΔνΑΒ=13.2 Hz, 2H), 2.99 (br d, J=11.0 Hz, 1H), 2.71-2.79 (m, 1 H), 2.55 (d, J=11.0 Hz, 1 H), 2.42 (ddd, J=11.7, 11.5, 3.6 Hz, 1 H), 2.29 (s, 3H). Step 2. Synthesis of 4-benzyl-2-(3-methyl-1,2-oxazol-5-yl)morpholine (C37).
Trimethylsilyl trifluoromethanesulfonate (2.9 g, 13 mmol) and triethylsilane (2.6 g, 22 mmol) were added to a solution of 4-benzyl-2-(3-methyl-1,2-oxazol-5-yl)morpholin-2ol (C36) (1.2 g, 4.4 mmol) in dichloromethane (15 mL), and the reaction mixture was heated at 80 °C for 2 hours. The reaction mixture was then adjusted to a pH of ~5 to 6 via addition of saturated aqueous sodium bicarbonate solution. After extraction with dichloromethane (3 x 20 mL), the combined organic layers were washed with saturated aqueous sodium chloride solution (25 mL), dried over sodium sulfate, filtered, and concentrated. Purification via silica gel chromatography (Gradient: 0% to 50% ethyl acetate in petroleum ether) afforded the product as a yellow oil. Yield: 500 mg, 1.9
mmol, 43%. LCMS m/z 258.9 [M+H+]. 1H NMR (400 MHz, CDCI3) δ 7.27-7.37 (m, 5H), 6.07 (s, 1H), 4.75 (dd, 7=9.7, 2.3 Hz, 1H), 3.96 (ddd, J=11.3, 2.8, 2.4 Hz, 1H), 3.81 (ddd, 7=11.3, 10.8, 2.5 Hz, 1H), 3.52-3.61 (m, 2H), 3.02 (brd, 7=11.4 Hz, 1H), 2.68-2.75 (m, 1H), 2.29 (s, 3H), 2.27-2.37 (m, 2H).
Step 3. Synthesis of 2-(3-methyl-1,2-oxazol-5-yl)morpholine (C38).
Ammonium cerium(IV) nitrate (442 mg, 0.806 mmol) was added to a solution of
4-benzyl-2-(3-methyl-1,2-oxazol-5-yl)morpholine (C37) (100 mg, 0.39 mmol) in acetonitrile / water (5:1 mixture, 6 mL). The reaction mixture was stirred at 25 °C for 4 hours, then concentrated in vacuo; préparative thin-layer chromatography on silica gel (Eluent: 10:1 dichloromethane / methanol) provided the product as a yellow oil. Yield: 40 mg, 0.24 mmol, 62%. 1H NMR (400 MHz, CDCI3) δ 6.11 (s, 1H), 4.79 (dd, 7=10.0, 2.4 Hz, 1H), 4.01 (ddd, 7=11.8, 2.5, 2.4 Hz, 1H), 3.81-3.89 (m, 1H), 3.35 (dd, 7=12.7, 2.5 Hz, 1H), 2.99-3.07 (m, 3H), 2.30 (s, 3H).
Step 4. Synthesis of 3-{4-[2-(3-methyl-1,2-oxazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3d]pyrimidin-5-yl}benzonitrile (202).
To a solution of 2-(3-methyl-1,2-oxazol-5-yl)morpholine (C38) (20 mg, 0.12 mmol) in n-butanol (7 mL) was added 3-(4-chloro-7/-/-pyrrolo[2,3-d]pyrimidin-5yl)benzonitrile (C14) (36.2 mg, 0.142 mol), and the reaction mixture was placed in a sealed tube and heated at 150 °C in a microwave reactor for 2 hours. After removal of solvent, the residue was purified by préparative reversed phase high-performance liquid chromatography (Column: YMC-Actus Triart C18, 5 pm; Mobile phase A: water containing 0.225% formic acid; Mobile phase B: acetonitrile; Gradient: 33% to 53% B) to afford the product as a white solid. Yield: 0.78 mg, 2.0 pmol, 2%. LCMS m/z 387.0 [M+H+]. 1H NMR (400 MHz, DMSO-cfe), characteristic peaks: δ 12.45 (br s, 1H), 8.45 (s, 1H), 8.00-8.03 (m, 1H), 7.85 (br d, 7=8 Hz, 1H), 7.76 (br d, 7=8 Hz, 1H), 7.72 (d, 7=2.8 Hz, 1H), 7.66 (dd, 7=8, 8 Hz, 1H), 6.25 (s, 1H), 4.58-4.63 (m, 1H), 3.71-3.83 (m, 2H), 3.01-3.09 (m, 1H), 2.88-2.97 (m, 1H), 2.20 (s, 3H).
Methods
Method A
Introduction of a 4-amino substituent onto 3-(4-chloro-7/-/-pyrrolo[2,3-û(]pyrimidin-5yl)benzonitrile via chloride displacement
RlN.R*
I H
CN
A solution of 3-(4-chloro-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile (C14) in dimethyl sulfoxide (0.1 M, 500 pL, 50 pmol) was added to a vial containing the appropriate amine (150 pmol). After addition of césium fluoride (23 mg, 150 pmol), the reaction mixture was shaken at 100 °C for 16 hours, then purified via préparative HPLC using an appropriate gradient with one of the following Systems: 1) Column: DIKMA Diamonsil(2) C18, 5 pm; Mobile phase A: 0.1% trifluoroacetic acid in water; Mobile phase B: acetonitrile; 2) Column: Boston Symmetrix ODS-H, 5 pm or Phenomenex Synergi C18, 4 pm or Agella Venusil ASB C18, 5 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile.
Method B
Synthesis of 5-substituted-4-[(3S)-3-methylpiperidin-1 -yl]-7/-/-pyrrolo[2,3-c(]pyrimidines via Suzuki reaction
Step 1. Suzuki reaction
A solution of the appropriate boronic ester in aqueous 1,4-dioxane (1:5 v/v water / 1,4-dioxane) (0.3 M, 400 pL, 120 pmol) was combined with a solution of 5-iodo-4[(3S)-3-methylpiperidin-1-yl]-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3c/Jpyrimidine (P5) (0.25 M in 1:5 water / 1,4-dioxane; 400 pL, 100 pmol). The solution was treated with césium carbonate (65 mg, 200 pmol) and degassed by bubbling nitrogen through it. [1,1'-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(ll) (3
mg, 5 pmol) was added to the reaction mixture, which was again degassed with nitrogen, then shaken at 150 °C for 4 hours. After removal of solvent using a Speedvac® concentrator, the products were purified via préparative thin layer chromatography in an appropriate solvent System and taken to the following step. Step 2. Deprotection
The product from the previous step was treated with a solution of trifluoroacetic acid in dichloromethane (1:5 v/v; 2 mL), and the reaction mixture was shaken at 30 °C for 2 hours. After concentration using the Speedvac®, the residue was treated with a solution of ammonium hydroxide in methanol (1:4 v/v; 2 mL) and shaken at 30 °C for 16 hours. Solvents were removed on the Speedvac® and the product was purified via préparative HPLC using an appropriate gradient (Column: DIKMA Diamonsil(2) C18, 5 pm or Agella Venusil ASB C18, 5 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile).
Method C
Synthesis of 5-substituted-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidines via Suzuki reaction
Step 1. Suzuki reaction
A solution of
5-iodo-4-(morpholin-4-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/pyrrolo[2,3-c/|pyrimidine (P1) in 1,4-dioxane (0.20 M, 400 pL, 80 pmol) was combined with a solution of the appropriate boronic acid in 1,4-dioxane (0.50 M, 200 pL, 100 pmol). An aqueous solution of potassium phosphate (0.80 M, 200 pL, 160 pmol) was added, followed by [1,1'-bis(di-te/ï-butylphosphino)ferrocene]dichloropalladium(ll) (3 mg, 5 pmol), and the reaction mixture was shaken at 100 °C for 16 hours. The mixture was filtered and the filtrate was concentrated on a Speedvac®. The residue was partitioned between dichloromethane and saturated aqueous sodium carbonate solution, and the aqueous layer was extracted with dichloromethane (2 x 1 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated using the Speedvac® to afford the crude product, which was used directly in the next step.
Step 2. Deprotection
The product of the preceding reaction was treated with a solution of concentrated hydrochloric acid in éthanol (1:6 v/v; 1 mL), and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvents on the Speedvac®, the residue was purified via préparative HPLC using an appropriate gradient with one of the following Systems: 1) Column: Kromasil Eternity-5-C18, 5 pm or Boston Symmetrix ODS-H, 5 pm or Phenomenex Synergi C18, 4 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile; 2) Column: Phenomenex Gemini C18, 8 pm; Mobile phase A: aqueous ammonium hydroxide, pH 10; Mobile phase B: acetonitrile.
Method D
Introduction of a 4-amino substituent onto 7H-pyrrolo[2,3-d]pyrimidines via chloride displacement
A solution of the 4-chloro-7/-/-pyrrolo[2,3-c(]pyrimidine substrate in dimethyl sulfoxide (0.5 M, 200 pL, 100 pmol) was added to a solution of the appropriate amine in dimethyl sulfoxide (0.8 M, 200 pL, 160 pmol). A/,/\/-Diisopropylethylamine (120 pL, 700 pmol) was added, and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvents using a Speedvac®, the product was purified via préparative HPLC using an appropriate gradient with one of the following Systems: 1) Column: Phenomenex Gemini C18, 8 pm or Agela Durashell C18, 5 pm; Mobile phase A: aqueous ammonium hydroxide, pH 10; Mobile phase B: acetonitrile; or 2) Column: DIKMA Diamonsil(2) C18, 5 pm or Phenomenex Synergi C18, 4 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile.
Method E
Synthesis of 4-amino-substituted, 5-substituted-7/-/-pyrrolo[2,3-c/|pyrimidines from 4chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidine
Step 1. Amine displacement reaction
A solution of 4-chloro-5-iodo-7-{[2-(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3djpyrimidine (C1) in /V,/V-dimethylformamide (0.25 M, 500 pL, 125 pmol) was added to the appropriate amine (150 pmol). Triethylamine (35 pL, 250 pmol) was added, and the reaction mixture was shaken at 100 °C for 16 hours. This solution was used directly in the following step.
Step 2. Suzuki reaction
The product solution from the preceding step (£125 pmol) was mixed with a solution of the appropriate boronic acid in A/,A/-dimethylformamide (0.25 M, 500 pL, 125 pmol). An aqueous solution of césium carbonate (1.25 M, 200 pL, 250 pmol) was added, followed by [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(ll) (1.6 mg, 2.5 pmol), and the reaction mixture was shaken at 120 °C for 4 hours. Removal of solvent using a Speedvac® provided a residue, which was used directly in the following step.
Step 3. Deprotection
The product from the previous step (<125 pmol) was treated with a solution of concentrated hydrochloric acid in éthanol (1:6 v/v; 2 mL), and the reaction mixture was shaken at 80 °C for 16 hours. After removal of solvent via the Speedvac®, the residue was taken up in a solution of ammonium hydroxide (30% aqueous) in methanol (1:4 v/v, 2 mL). The mixture was shaken at 30 °C for 16 hours, concentrated on the Speedvac® and purified via préparative HPLC using an appropriate gradient (Column: DIKMA
Diamonsil(2) C18, 5 pm or Agella Venusil ASB C18, 5 pm; Mobile phase A: 0.225% formic acid in water; Mobile phase B: acetonitrile).
Method F
Introduction of a 5-substituent onto 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c/]pyrimidin-4-amines via Suzuki reaction
Step 1. Suzuki reaction
A solution of the 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-7-{[2(trimethylsilyl)ethoxy]methyl}-7/-/-pyrrolo[2,3-c0pyrimidine substrate in 1,4-dioxane (0.1 M, 1 mL, 100 pmol) was added to the appropriate aryl or heteroaryl halide (100 pmol). An aqueous solution of césium carbonate (1.0 M, 200 pL, 200 pmol) was added, followed by [1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(ll) (1.3 mg, 2.0 pmol), and the reaction mixture was shaken at 120 °C for 4 hours. Removal of solvent using a Speedvac® provided a residue, which was used directly in the following step. Step 2. Deprotection
Protecting group removal and purification were carried out as described in the final step of Method E.
The following table (Table 1) provides Examples 11-197 and Examples 203-225 of the présent invention, the structure of the compound, reference to the method of préparation and characterizing data for the compound. Certain of the compounds depicted in the table are racemic and others are depicted as single enantiomers with the absolute stereochemistry as shown. In certain cases the racemic compound has been separated into the individual enantiomers, although the absolute stereochemistry of the single enantiomer(s) may not hâve been determined. In the table the individual separated enantiomers may be referred to as ENT-1 or ENT-2, which are abbreviations for the separated enantiomer-1 and enantiomer-2, respectively. It is to be understood
that one of the compounds designated as ENT-1 or ENT-2 will hâve the (R) absolute stereochemistry at the chiral center while the other will hâve the (S) absolute stereochemistry.
Table 1
Example # | Structure | Method of Préparation; Noncommercial starting materials | 1H NMR (400 MHz, DMSO-d6) δ (ppm); Mass spectrum, observed ion m/z (M+H+) or HPLC rétention time; Mass spectrum m/z (M+H+) (unless otherwise indicated) |
11 | f'V-CN yj w H | Ex 6 | 12.20 (brs, 1H), 8.32 (s, 1H), 7.90 (dd, J=1.8, 1.5 Hz, 1H), 7.83 (ddd, J=8.0, 1.5, 1.3 Hz, 1H), 7.76 (ddd, J=8, 1.5, 1 Hz, 1H), 7.65 (dd, J=7.8, 7.5 Hz, 1H), 7.59 (d, J=2.3 Hz, 1H), 2.96-3.03 (m, 4H), 1.20-1.27 (m, 2H), 1.10-1.19 (m, 2H), 0.87 (s, 6H); 331.9 |
12 | O r>cN V W W H | Ex 6 | 12.21 (br s, 1 H), 8.35 (s, 1 H), 7.95 (br s, 1 H), 7.85 (br d, J=7.5 Hz, 1 H), 7.74 (br d, J=7.5 Hz, 1H), 7.61-7.67 (m, 2H), 3.13-3.19 (m, 4H), 1.40-1.48 (m, 2H), 1.29-1.38 (m, 4H); 303.9 |
13 | NH, Yo H | Ex 6 | 12.05 (brs, 1H), 8.31 (s, 1H), 7.37-7.50 (m, 5H), 7.24-7.31 (m, 1H), 7.08 (brs, 1H), 6.73 (br s, 1 H), 3.93 (br d, J=12.4 Hz, 1 H), 3.65 (brd, J=12.4 Hz, 1H), 2.74 (dd, J=12.4, 11.7 Hz, 1H), 2.5-2.58 (m, 1H, assumed; partially obscured by solvent peak), 2.21-2.31 (m, 1 H), 1.68-1.78 (m, 1 H), 1.26-1.44 (m, 2H), 1.15-1.26 (m, 1H), 322.2 |
14 | ÏJ rVCN n ys/ W | Ex 5 | ’H NMR (400 MHz, CDCI3), characteristic peaks: δ 10.44 (br s, 1H), 8.46 (s, 1H), 7.82 (dd, J=1.5, 1.3 Hz, 1H), 7.75 (ddd, 4=7.7, 1.5, 1.5 Hz, 1H), 7.62 (ddd, J=7.8, 1.5, 1.3 Hz, 1H), 7.54 (dd, J=8.0, 7.5 Hz, 1H), 7.28 (d, J=2.5 Hz, 1H), 4.83 (br s, 1H), 4.14 (br d, 4=14 Hz, 1H), 3.95-4.00 (m, 1H), 3.45 (dd, J=13.9, 2.4 Hz, 1H), 3.13-3.21 (m, 1H), 2.82- 2.91 (m, 1H), 1.13-1.22 (m, 1H); 320.2 |
15 | On N \=^ nY-Y N H | Ex 71 | 1H NMR (400 MHz, CD3OD) δ 8.25 (s, 1H), 7.38-7.49 (m, 4H), 7.27-7.33 (m, 1H), 7.21 (s, 1 H), 3.91 (br d, J=13 Hz, 1 H), 3.78 (br d, J=13 Hz, 1H), 2.63 (ddd, J=12.6, 12.6, 3.0 Hz, 1H), 2.25 (dd, J=12.6, 11.0 Hz, 1H), 1.62-1.70 (m, 1H), 1.31-1.52 (m, 3H), 0.881.00 (m, 1H), 0.59 (d, J=6.5 Hz, 3H); 293.3 |
16 | ry cn N νΎΥ Y^N H | Ex 6 | 1H NMR (400 MHz, CDCI3) δ 10.55 (br s, 1 H), 8.49 (s, 1 H), 7.83 (br s, 1 H), 7.75 (br d, 4=7.5 Hz, 1H), 7.61 (br d, 4=7.5 Hz, 1H), 7.54 (dd, J=8.0, 7.5 Hz, 1H), 7.23 (s, 1H), 3.84 (brd, J=13 Hz, 1H), 3.77 (brd, J=13 Hz, 1H), 2.61-2.70 (m, 1H), 2.34 (dd, J=12.0, 11.5 Hz, 1 H), 1.65-1.77 (m, 1 H), 1.29-1.55 (m, 3H), 0.91-1.03 (m, 1H), 0.68 (d, J=6.5 Hz, 3H); 318.3 |
17 | W N nYY Y^Y H | Ex 7* | 1H NMR (400 MHz, CD3OD) δ 8.23 (s, 1H), 7.71 (s, 1H), 7.57 (s, 1H), 7.19 (s, 1H), 3.95 (s, 3H), 3.88-3.95 (m, 1H), 3.83 (br d, 4=-12 Hz, 1H), 2.66-2.74 (m, 1H), 2.33 (dd, 4=12, 11 Hz, 1H), 1.71-1.79 (m, 1H), 1.40-1.62 (m, 3H), 0.96-1.08 (m, 1H), 0.72 (d, J=6.8 Hz, 3H), 297.6 |
18 | ο ο n y^ ôS Ν Η | Ex 6 | 3.10 minutes3; 265.1 |
19 | JDH όη n y^ | Ex 6 | 12.02 (brs, 1H), 8.29 (s, 1H), 7.45-7.51 (m, 2H), 7.37-7.45 (m, 3H), 7.24-7.30 (m, 1H), 4.39 (t, J=5.1 Hz, 1H), 3.82 (br d, J=12.4 Hz, 2H), 3.11-3.18 (m,2H), 2.61 (brdd, J=12, 11 Hz, 2H), 1.35-1.46 (m, 3H), 0.88-1.03 (m, 2H); 309.1 |
20 | Ό θ^°Η Ν'^γΑ Η | Ex 7 | 1H NMR (400 MHz, CD30D) δ 8.34 (s, 1H), 7.50 (br s, 1H), 7.43-7.46 (m, 2H), 7.32-7.35 (m, 1H), 7.30 (s, 1H), 4.70 (s, 2H), 3.64-3.71 (m, 1H), 3.46-3.54 (m, 1H), 3.21-3.27 (m, 1H), 3.09-3.18 (m, 1H), 2.85-2.92 (m, 1H), 1.82-1.91 (m, 1H), 1.67-1.77 (m, 1H), 1.41- 1.51 (m, 1H), 1.19-1.31 (m, 1H); 334.3 |
21 | T j fVCN n y=/ | Ex 7 | 1H NMR (400 MHz, CD30D) δ 8.39 (s, 1H), 7.92 (brs, 1H), 7.87 (brd, J=7 Hz, 1H), 7.63- 7.72 (m, 2H), 7.47 (s, 1H), 3.58-3.70 (m, 2H), 3.06-3.19 (m, 2H), 2.96-3.04 (m, 1H), 1.74-1.92 (m, 2H), 1.38-1.50 (m, 1H), 1.17- 1.30 (m, 1 H); 329.4 |
22 | n y=/ | Ex 72 | 1H NMR (400 MHz, CD30D) δ 8.23 (s, 1H), 7.69 (s, 1H), 7.55 (s, 1H), 7.18 (s, 1H), 3.94 (s, 3H), 3.89 (br d, J=12 Hz, 2H), 2.20 (dd, J=12.0, 11.5 Hz, 2H), 1.73 (brd, J=12.6 Hz, 1H), 1.48-1.62 (m, 2H), 0.74 (d, J=7.0 Hz, 6H), 0.65 (dt, J=12, 12 Hz, 1H); 311.5 |
23 | όΉ V w n'xS^C/° il X / N H | Ex 34’5’6; P4 | qH NMR (300 MHz, DMS0-de), characteristic peaks: δ 12.01 (brs, 1H), 8.26 (s, 1H), 7.81 (dd, J=8.4, 2.1 Hz, 1H), 7.68 (d, J=2.1 Hz, 1H), 7.36 (d, J=2.1 Hz, 1H), 7.26 (d, J=9.1 Hz, 1H), 3.82 (s, 3H), 3.74-3.84 (m, 1H), 3.57-3.66 (m, 1H), 2.17 (dd, J=12.5, 11.2 Hz, |
1H), 1.56-1.66 (m, 1H), 1.38-1.50 (m, 1H), 1.05-1.24 (m, 2H), 0.80-0.96 (m, 1H), 0.55 (d, J=6.3 Hz, 3H); 348.2 | |||
24 | ΝΟχ /0 w H | Ex 11,7 | 8.17 (s, 1H), 7.80 (dd, J=8.5, 2.5 Hz, 1H), 7.70 (d, J=2.0 Hz, 1H), 7.30 (s, 1H), 7.22 (d, J=9.0 Hz, 1 H), 3.80 (s, 3H), 2.73 (s, 6H); 293.8 |
25 | CL /0 w H | Ex 71,8 | 11.88 (br s, 1H), 8.16 (s, 1 H), 7.30-7.35 (m, 2H), 7.25 (d, J=2.6 Hz, 1H), 7.06 (d, J=8.5 Hz, 1H), 3.71 (s, 3H), 2.75 (s, 6H); 303.2 |
26 | /=\ HN^N M fVCN .CFgCOOH w H H | Method A | 2.07 minutes9; 370 |
27 | O '''θ f°VCN v w ν'Ά-Ά w | Method A | 2.58 minutes9; 348 |
28 | 'Cft -y. V yJ νΆγΆ w | Ex 6 | 12.29 (br s, 1 H), 8.37 (s, 1 H), 7.92 (dd, J=1.5, 1.5 Hz, 1H), 7.86 (ddd, J=7.5, 1.5, 1.5 Hz, 1H), 7.77 (ddd, J=7.5, 1.5, 1.5 Hz, 1H), 7.62-7.68 (m, 2H), 3.23-3.28 (m, 2H), 3.19 (s, 2H), 2.95-3.00 (m, 2H), 2.25-2.32 (m, 2H), 2.14-2.23 (m, 2H), 2.13 (s, 3H), 1.741.82 (m, 2H), 1.45-1.54 (m, 2H); 389.2 |
29 | °Ό r>cN ν y# SA N H | Method A | 2.46 minutes9; 334 |
30 | o T) r>CN V yJ N H | Method A | 2.42 minutes9; 350 |
31 | l< o<S rvcN ^NH W n^'S-A ^hTN N H | Method A | 2.23 minutes9; 335 |
32 | N ^==7 ™ H | Method A | 2.78 minutes9; 340 |
33 | F O fVCN N ^=7 ^hTN H | Method A | 2.27 minutes10; 322 |
33A | F Cj rycN N ^=7 N'^Sr N H | Ex 6 | 1H NMR (400 MHz, CDCI3) δ 10.65 (br s, 1 H), 8.51 (s, 1 H), 7.84 (s, 1 H), 7.76 (br d, J=7.5 Hz, 1 H), 7.62 (br d, J=8 Hz, 1 H), 7.55 (brdd, J=8, 7.5 Hz, 1H), 7.24-7.30 (1H, assumed, obscured by solvent peak), 4.75 (br d, JHf=48 Hz, 1 H), 3.32-3.51 (m, 4H), 1.65-1.84 (m, 4H, assumed; partially obscured by water peak); 322.2 |
34 | σ Cj rycN N H | Method A | 2.33 minutes9; 370 |
35 | O ry-θΝ N H | Method A | 2.33 minutes9; 308 |
36 | hn-n VG i j r>cN v y# N GA N H | Method A | 2.33 minutes9; 372 |
37 | HN-n ^ΌΓ/γ0Ν V y/ N H | Method A | 2.42 minutes9; 370 |
38 | O h Ί0 r^ycN V yZ N GA n H | Method A | 2.15 minutes9; 370 |
39 | I L 1 /GrCN ^Ah y/ N GA N H | Method A | 2.08 minutes9; 333 |
40 | HN—. 0=<^0 ΓΑΝ W y/ n ΑΛ w IN H | Method A | 2.27 minutes9; 373 |
41 | 'Ό ΓνθΝ ΕΝΤ-2 ΙΝ Η | Ex611·12 | 1H NMR (400 MHz, CD3OD) δ 8.30 (s, 1H), 7.84 (brs, 1H), 7.81 (brd, J=7.5 Hz, 1H), 7.66 (br d, J=7.5 Hz, 1 H), 7.61 (dd, J=8.0, 7.5 Hz, 1H), 7.39 (s, 1H), 3.81 (brd, J=13.0 Hz, 1H), 3.70 (brd, J=12.6 Hz, 1H), 2.65 (ddd, J=12.6,12.3, 2.8 Hz, 1H), 2.29 (dd, J=12.6, 11.0 Hz, 1H), 1.65-1.74 (m 1H), 1.47-1.56 (m, 1H), 1.31-1.46 (m, 2H), 0.91- 1.04 (m, 1H), 0.64 (d, J=6.5 Hz, 3H); 318.0 |
42 | ο Ί Λ>ον ^ΝΗ Ν Η | Method A | 1.99 minutes9; 349 |
43 | <brykNJ y# ^hTN H | Method A | 2.47 minutes9; 360 |
44 | 0 hnA cb r0cN v y/ N H | Method A | 2.13 minutes9; 361 |
45 | . H/N'N W N^rA N H | Method B | 2.06 minutes10; 333 |
46 | /=χΛ'ΝΗ2 nta IN H | Method B | 2.32 minutes9; 372 |
47 | Όη N y=< ï I F H | Method B | 2.53 minutes10; 311 |
48 | N | Method B | 2.15 minutes10; 333 |
49 | ΤχΑ N N'Vi W 1 H | Method B | 2.39 minutes10; 326 |
50 | 0 yAh Vy | Method B | 1.86 minutes10; 348 |
51 | Ko N N | Method B | 2.04 minutes9; 294 |
52 | Oo IN H | Method B | 1.69 minutes10; 308 |
53 | ΊΟ m5 \__ÿ N 1 H | Method B | 2.02 minutes10; 333 |
54 | OçF H | Method B | 1.96 minutes10; 348 |
55 | ^<0 nXJnh W ,N H | Method B | 1.11 minutes10; 333 |
56 | OH Όό w H | Method B | 2.11 minutes10; 309 |
57 | H2V° O <5 n IN H | Method B | 2.17 minutes9; 336 |
58 | T( γύ°η N \=^ | Method B | 2.66 minutes13; 309 |
59 | yjh n \=X JL 7 ci H | Method B | 2.31 minutes10; 342 |
60 | ΎΊ/Μ W y=/ nh2 n'VA | Ex17·14; P5 | characteristicpeaks, 12.09 (brs, 1H), 8.31 (s, 1H), 7.99-8.03 (m, 2H), 7.79 (br d, J=7.5 Hz, 1 H), 7.62 (br d, J=7.5 Hz, 1 H), 7.47-7.52 (m, 2H), 7.36 (br s, 1 H), 3.75 (br d, J=13 Hz, 1H), 3.68 (brd, J=12 Hz, 1H), 2.21 (dd, J=12, 11 Hz, 1H), 1.54-1.61 (m, 1H), 1.33- 1.43 (m, 2H), 1.19-1.32 (m, 1 H), 0.81 -0.95 (m, 1H), 0.54 (d, J=7.0 Hz, 3H); 336.2 |
61 | Ρχ^ r>cN V yJ N^rA w N H | Ex 6 | 8.35 (s, 1 H), 7.92 (br s, 1 H), 7.82 (br d, J=8 Hz, 1H), 7.74 (br d, J=7.5 Hz, 1H), 7.60-7.66 (m, 2H), 4.60 (br d, JHf=47 Hz, 1 H), 3.26-3.4 (m, 2H, assumed; partially obscured by water peak), 3.16-3.25 (m, 1H), 3.01-3.10 (m, 1H), 1.71-1.87 (m, 1H), 1.59-1.70 (m, 1H), 1.48-1.58 (m, 1H), 1.11-1.21 (m, 1H); 322.2 |
62 | cS r>cn W yJ w | Ex 6 | 12.83 (br s, 1 H), 8.44 (s, 1 H), 7.96 (br s, 1 H), 7.83 (br d, J=8 Hz, 1 H), 7.80 (br d, J=8 Hz, 1H), 7.75 (d, J=2.5 Hz, 1H), 7.67 (dd, J=8.0, 7.5 Hz, 1H), 3.75 (br d, J=13 Hz, 2H), 2.84 (br dd, J=13, 12 Hz, 2H), 1.42-1.55 (m, 3H), 0.91-1.03 (m, 2H), 0.83 (d, J=6.0 Hz, 3H); 318.2 |
63 | ΌζΚ IN H | Ex 17,14; P5 | ’H NMR (400 MHz, CDCI3), characteristic peaks: δ 8.42 (s, 1H), 8.28-8.31 (m, 1H), 8.09 (br d, J=7 Hz, 1 H), 7.69 (br d, J=7 Hz, 1H), 7.52-7.58 (m, 1H), 3.90-4.03 (m, 2H), 2.63-2.73 (m, 1H), 2.32-2.41 (m, 1H), 0.65 (d, J=6 Hz, 3H); 337.0 |
64 | /TV^CN ^NH \=d W N H | Ex 6 | 11.94 (br s, 1 H), 8.22 (s, 1 H), 7.86 (dd, J=1.5, 1.5 Hz, 1H), 7.73-7.78 (m, 2H), 7.64 (dd, J=7.8, 7.5 Hz, 1H), 7.35 (s, 1H), 5.76 (q, J=4.6 Hz, 1H), 2.90 (d, J=4.8 Hz, 3H); 250.1 |
65 | γγΆ V Ο ότΟ' Ν N | Ex 4 | 1H NMR (400 MHz, CD3OD) δ 8.24 (s, 1 H), 7.72 (dd, J=8.7, 2.1 Hz, 1 H), 7.65 (d, J=2.0 Hz, 1H), 7.28 (s, 1H), 7.23 (d, J=8.8 Hz, 1H), 3.87 (s, 3H), 3.83 (brd, J=12 Hz, 2H), 2.13 (dd, J=12.0,12.0 Hz, 2H), 1.68 (br d, J=13 Hz, 1H), 1.25-1.37 (m, 2H), 0.68 (d, J=6.5 Hz, 6H), 0.60 (dt, J=12,12 Hz, 1H); 362.1 |
66 | V W W ΙΝ Η | Ex17,14; P5 | 1H NMR (400 MHz, CDCI3) δ 10.70 (br s, 1H), 8.42 (s, 1H), 7.61-7.67 (m, 2H), 7.257.29 (m, 1 H, assumed; partially obscured by solvent peak), 7.03 (d, J=8.5 Hz, 1 H), 3.89 (s, 3H), 3.87-3.96 (m, 1H), 3.81 (br d, J=13 Hz, 1H), 2.61 (ddd, J=13, 13, 3 Hz, 1H), 2.29 (dd, J=12.6, 11.0 Hz, 1H), 1.66-1.75 (m, 1H), 1.45-1.54 (m 1H), 1.18-1.37 (m, 2H), 0.89- 1.00 (m, 1H), 0.65 (d, J=7.0 Hz, 3H); 348.2 |
67 | ΥΊ rycN Ν ν< 1 / F ΙΝ Η | Ex 17·14; P5 | 1H NMR (400 MHz, CDCI3), characteristic peaks: δ 10.36 (brs, 1H), 8.45 (s, 1H), 7.70 (ddd, J=7.5, 7.5, 1.8 Hz, 1H), 7.59 (ddd, J=7.8, 5.5, 1.8 Hz, 1H), 7.31-7.37 (m, 2H), 3.76-3.88 (m, 2H), 2.66 (ddd, J=13, 12, 2.5 Hz, 1 H), 2.36 (dd, J=12.7, 11.2 Hz, 1 H), 1.46-1.54 (m, 1H), 1.35-1.45 (m, 1H), 1.22- 1.34 (m, 1H), 0.92-1.03 (m, 1H), 0.69 (d, J=6.5 Hz, 3H), 336.2 |
68 | ν Ο Ναυ> Ν η | Ex 11·7; C3 | 1H NMR (400 MHz, CDCI3) δ 8.39 (s, 1H), 7.48 (br d, J=8 Hz, 2H), 7.41 (br dd, J=8, 8 Hz, 2H), 7.30-7.34 (m, 1H), 7.09 (s, 1H), 2.84 (s, 6H); 239.1 |
69 | •f'V-CN N W N H | Ex11·7; C3 | 12.24 (brs, 1H), 8.25 (s, 1H), 7.84-7.91 (m, 1H), 7.75-7.82 (m, 1H), 7.51 (brs, 1H), 7.47 (dd, J=8.0, 7.5 Hz, 1H), 2.73 (s, 6H); 282.2 |
70 | o rycN N H | Ex 5 | 8.35 (s, 1 H), 7.92 (s, 1 H), 7.85 (d, J=7.5 Hz, 1H), 7.76 (d, J=7.5 Hz, 1H), 7.63 (dd, J=8.0, 7.5 Hz, 1H), 7.57 (brs, 1 H), 3.19-3.3 (brm, 4H), 1.70-1.79 (br m, 4H); 290.1 |
71 | 'H Pvcn N AA JL·/ ent-2 N N 1 H | Ex 515·12 | 1H NMR (400 MHz, CD30D) δ 8.15 (s, 1H), 7.78-7.80 (m, 1 H), 7.73 (ddd, J=7.8, 1.6, 1.3 Hz, 1H), 7.69 (ddd, J=7.8, 1.5, 1.2 Hz, 1H), 7.58 (dd, J=7.8, 7.8 Hz, 1H), 7.19 (s, 1H), 3.36-3.44 (m, 2H), 3.21-3.30 (m, 1H), 2.75 (dd, J=10.4, 8.2 Hz, 1H), 2.05-2.15 (m, 1H), 1.82-1.91 (m, 1H), 1.30-1.41 (m, 1H), 0.90 (d, J=6.5 Hz, 3H); 304.1 |
72 | NC__ O w F | ΕχΓ·7; C3 | 1H NMR (400 MHz, CD30D) δ 8.23 (s, 1H), 7.87 (dd, J=6.9, 2.1 Hz, 1H), 7.76 (ddd, J=8.5, 4.5, 2.3 Hz, 1H), 7.37-7.42 (m, 2H), 2.85 (s, 6H); 282.1 |
73 | J tv» n n | Ex 6 | 1H NMR (400 MHz, DMSO-d6+ D20) δ 8.29 (s, 1 H) 7.88-7.90 (m, 1 H), 7.84 (br d, J=8.5 Hz, 1H), 7.71 (brd, J=8.0 Hz, 1H), 7.61 (dd, J=8.0, 7.5 Hz, 1H), 7.56 (s, 1H), 3.20 (q, J=7.0 Hz, 4H), 0.88 (t, J=7.0 Hz, 6H); 292.0 |
74 | nô r>cN V yJ ri εν™ H | Ex 616,17 | 1H NMR (400 MHz, CDCI3) δ 11.17 (br s, 1 H), 8.52 (s, 1 H), 7.83 (br s, 1 H), 7.76 (br d, J=8.0 Hz, 1H), 7.64 (brd, J=7.5 Hz, 1H), 7.57 (dd, J=8.0, 7.5 Hz, 1H), 7.29 (s, 1H), 3.73-3.84 (m, 2H), 3.63 (br d, J=13.6 Hz, 1H), 3.51-3.59 (m, 1H), 3.47 (ddd, J=12.0, 11.5, 2.5 Hz, 1H), 3.30 (s, 3H), 3.20-3.30 (m, 2H), 2.96 (ddd, J=13, 12, 3.5 Hz, 1H), 2.79 (dd, J=12.8, 10.8 Hz, 1H); 350.2 |
75 | CN 'Ν'- Çl F Nôu> H | Ex11’7; C3 | 8.31 (s, 1H), 7.81-7.83 (m, 1H), 7.71-7.76 (m, 1H), 7.67 (s, 1H), 7.64-7.69 (m, 1H), 2.76 (s, 6H); 282.1 |
76 | hn-n rr™ V yJ ? ify ENT-2 | Ex 618,12 | 1H NMR (400 MHz, CDCI3), characteristic peaks: δ 8.51 (br s, 1H), 7.84 (s, 1H), 7.77 (br d, J=7.5 Hz, 1H), 7.62 (br d, J=8 Hz, 1H), 7.56 (dd, J=8.0, 7.5 Hz, 1H), 7.51 (brs, 1H), 6.06 (br s, 1 H), 4.55 (br d, J=10 Hz, 1 H), 3.99 (brd, J=13 Hz, 1H), 3.84-3.91 (m, 1H), 3.60-3.75 (m, 2H), 3.02-3.13 (m, 2H); 372.1 |
77 | o fvcn N itA L II Z ENT-1 %|^N N H | Ex 515,17 | 1H NMR (400 MHz, CD30D) δ 8.19 (s, 1H), 7.82 (br s, 1H), 7.71-7.77 (m, 2H), 7.61 (dd, J=7.5, 7.5 Hz, 1H), 7.29 (s, 1H), 3.40-3.49 (m, 2H), 3.24-3.3 (m, 1 H, assumed; partially obscured by solvent peak), 2.76 (dd, J=9.5, 9.0 Hz, 1H), 2.10-2.22 (m, 1H), 1.88-1.98 (m, 1H), 1.36-1.48 (m, 1H), 0.91 (d, J=6.5 Hz, 3H), 304.0 |
78 | i J rVCN N \=< | Ex 17 | 8.38 (s, 1H), 7.80-7.90 (m, 2H), 7.64 (d, J=1.0 Hz, 1H), 7.52 (dd, J=8.0, 7.5 Hz, 1H), 3.35-3.41 (m, 4H), 3.09-3.15 (m, 4H); 323.9 |
79 | *O (TVCN n \=^ n'^A IN H | Ex 6 | 1H NMR (400 MHz, CDCI3) δ 11.02 (br s, 1H), 8.53 (s, 1H), 7.85 (s, 1H), 7.78 (d, J=7.0 Hz, 1H), 7.53-7.68 (m, 2H), 7.30 (s, 1H), 3.57-3.77 (m, 3H), 3.39-3.54 (m, 2H), 2.92 (br dd, J=12, 12 Hz, 1 H), 2.59 (dd, J=11.5, 11.0 Hz, 1 H), 0.98 (d, J=6.0 Hz, 3H); 319.9 |
80 | 0 NÇ 0 V w F w N H | Ex 17 | 1H NMR (400 MHz, DMSO-d6+ D2O) δ 8.35 (s, 1H), 7.97 (dd, J=7.0, 2.0 Hz, 1H), 7.817.87 (m, 1H), 7.61 (s, 1H), 7.53 (dd, J=9.0, 9.0 Hz, 1H), 3.36-3.42 (m, 4H), 3.08-3.15 (m, 4H); 324.2 |
81 | F ô «Ή n W nOA w | Ex 42’4 | 1H NMR (400 MHz, DMSO-d6+ D2O) δ 8.36 (s, 1H), 7.81 (s, 1H), 7.54 (s, 1H), 7.46 (s, 1H), 4.84 (br d, JHf=48 Hz, 1H), 3.85 (s, 3H), 3.43-3.58 (m, 4H), 1.58-1.88 (m, 4H); 301.1 |
82 | On n y=y 1 / CN nVA ^N^N IN H | Method C | 2.27 minutes9; 306 |
83 | 0 m n y# nOO w H | Method C | 2.39 minutes10; 315 |
84 | /O on n y=< 1 J F ^iOn H | Method C | 2.39 minutes9; 299 |
85 | ΠΚ Ψ CH n^Vy, ^n^n N H | Method C | 2.54 minutes9; 329 |
86 | AFH c ^n N V=\ 1 / F ^1\TN H | Method C | 2.46 minutes9; 317 |
87 | /0 C JfV 1 / f n H | Method C | 2.47 minutes9; 317 |
88 | 0 ck ûb n Vy F W H | Method C | 2.38 minutes10; 333 |
89 | A r7H UyÇ H | Method C | 2.07 minutes9; 329 |
90 | r% A o N \=< 1 J F nta W N H | Method C | 2.46 minutes9; 317 |
91 | /O OfVF n y^7 1N H | Method C | 2.46 minutes9; 299 |
92 | AF>=x Up N TA ^hTN IN H | Method C | 2.57 minutes9; 317 |
93 | Op IN H | Method C | 2.40 minutes9; 281 |
94 | η N ï I o^· IN H | Method C | 2.41 minutes9; 329 |
95 | /0 O N \=< ï / ci IN H | Method C | 2.46 minutes9; 315 |
96 | on N V=\ N ^<4 IN H | Method C | 2.51 minutes9; 313 |
97 | A C )ry°x N \=^ IN H | Method C | 2.42 minutes9; 311 |
98 | ,0H F ob M H | Method C | 2.18 minutes9; 329 |
99 | r% A (An n y=7 N H | Method C | 2.44 minutes9; 299 |
100 | O^0H IN H | Method C | 2.11 minutes9; 311 |
101 | ο \ | Method C | 2.36 minutes9; 311 |
102 | C J CYS n 'y-A N H | Method C | 2.34 minutes9; 327 |
103 | Γ°Ί /Νβ\ W N γΑ vQ | Method C | 1.44 minutes9; 282 |
104 | ûm n ypy n ya IN H | Method C | 1.96 minutes9; 332 |
105 | Ô «>Br n y=v N TA H | Method C | 2.34 minutes9; 360 |
106 | c n yy JL 7 ci n vA h | Method C | 2.14 minutes10; 329 |
107 | Oça H | Method C | 2.30 minutes9; 295 |
108 | Ô VN nAA ^n^n IN H | Ex319 | 1H NMR (400 MHz, CDCI3) δ 9.70 (br s, 1 H), 8.45 (s, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.33 (d, J=2.0 Hz, 1H), 6.43 (d, J=2.0 Hz, 1H), 3.99 (s, 3H), 3.66 (dd, J=4.8, 4.8 Hz, 4H), 3.42 (dd, J=4.9, 4.4 Hz, 4H); 285.2 |
109 | OH ô rycN N \V N 'SA W IN H | Ex 5 | 1H NMR (400 MHz, CDCI3), characteristic peaks: δ 10.64 (br s, 1 H), 8.50 (s, 1 H), 7.847.86 (m, 1H), 7.77 (ddd, J=7.7, 1.8, 1.4 Hz, 1H), 7.61 (ddd, half of ABXY pattern, J=7.8, 1.5, 1.5 Hz, 1 H), 7.55 (dd, half of ABX pattern, J=7.8, 7.8 Hz, 1H), 3.77-3.85 (m, 1H), 3.67-3.76 (m, 2H), 3.03 (ddd, J=13.2, 9.8, 3.0 Hz, 2H), 1.71-1.80 (m, 2H), 1.351.46 (m, 2H); 319.8 |
110 | J*? o Z | Ex 5 | characteristic peaks: 12.35 (brs, 1H), 8.43 (s, 1H), 8.01 (brs, 1H), 7.69-7.81 (m, 3H), 7.59 (dd, J=7.5, 7.5 Hz, 1H), 4.94 (br d, J=8 Hz, 1H), 3.91 (brd, J=13.5 Hz, 1H), 3.62- 3.70 (m, 1H), 3.43-3.51 (m, 1H), 2.88-2.97 (m, 1 H), 2.35 (s, 3H); 388.2 |
111 | (^yrycN V yJ NVS Ά*^Ν N H | Ex 3 | 8.39 (s, 1 H), 7.81 (br s, 1 H), 7.71 (br s, 1 H), 7.68 (s, 1H), 7.57 (brs, 1H), 3.46 (dd, J=4.5, 4.5 Hz, 4H), 3.10-3.16 (m, 4H), 2.43 (s, 3H); 320.2 |
112 | P~N N V) rycN N \==^ νζ\Λ w H | Ex 520 | characteristic peaks: 8.43 (s, 1 H), 8.00 (br s, 1 H), 7.85 (br d, J=8.0 Hz, 1 H), 7.75 (br d, J=7.5 Hz, 1H), 7.71 (s, 1H), 7.65 (dd, J=7.5, 7.5 Hz, 1H), 4.65-4.70 (m, 1H), 3.82-3.88 (m, 1H), 3.68-3.75 (m, 1H), 3.43-3.51 (m, 1H), 3.19 (dd, J=13, 10 Hz, 1H), 2.85-2.94 (m, 1 H), 2.57 (s, 3H); 388.2 |
113 | R) /rA^CN N'Sd, IN H | Ex 5 | 12.21 (brs, 1H), 8.32 (s, 1H), 7.92-7.94 (m, 1 H), 7.81 (br d, J=8 Hz, 1 H), 7.75 (br d, J=8 Hz, 1H), 7.60 (dd, J=8.0, 7.5 Hz, 1H), 7.55 (d, J=2.5 Hz, 1H), 4.36 (br d, J=6.0 Hz, 2H), 3.72 (d, J=12.6 Hz, 2H), 3.43 (d, J=12.6 Hz, 2H), 2.91-2.98 (m, 1H), 1.89 (d, J=8.5 Hz, 1H); 318.1 |
114 | 0 ck Q ^|\T^N N H | Ex 3 | 8.41 (s, 1 H), 8.04 (br s, 1 H), 7.97 (br s, 1 H), 7.90 (brs, 1H), 7.83 (s, 1H), 3.49-3.56 (m, 4H), 3.10-3.17 (m,4H); 340.1 |
115 | O NCx 0 Ô w H | Ex 3 | 8.33 (s, 1H), 7.82 (dd, J=8.5, 2.0 Hz, 1H), 7.73 (d, J=2.0 Hz, 1H), 7.48 (s, 1H), 7.28 (d, J=9.0 Hz, 1H), 3.85 (s, 3H), 3.3-3.38 (m, 4H, assumed; partially obscured by water peak), 3.08-3.15 (m, 4H); 336.2 |
116 | /=2 X /—\ / \ o | Ex 3 | 1H NMR (400 MHz, DMSO-d6+ D2O) 8 8.29 (s, 1H), 7.41 (s, 1H), 7.33 (dd, half of ABX pattern, J=8.5, 2.8 Hz, 1H), 7.30 (d, half of AB quartet, J=2.5 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H), 3.74 (s, 3H), 3.33-3.39 (m, 4H), 3.08- 3.14 (m, 4H); 345.2 |
117 | /=H X /—\ T \ | Ex 22 | 11.89 (br s, 1 H), 8.25 (s, 1 H), 7.74 (s, 1 H), 7.48 (s, 1H), 3.90 (s, 3H), 3.43-3.49 (m, 4H), 3.08-3.15 (m, 4H), 2.31 (s, 3H); 299.1 |
118 | o 4 Ô PrCN N νΑΛ w H | Ex 3 | 1H NMR (400 MHz, DMSO-d6+ D2O) 8 8.36 (s, 1H), 7.67 (s, 1H), 7.54-7.57 (m, 1H), 7.39-7.42 (m, 1H), 7.30-7.33 (m, 1H), 3.86 (s, 3H), 3.43-3.50 (m, 4H), 3.10-3.16 (m, 4H); 335.9 |
100
119 | Ô n y^ IN H | Method D21; P6 | 2.06 minutes9; 301 |
120 | ΤΊ Λ n y^ A^N H | Method D21; P6 | 1.90 minutes13; 299 |
121 | C ) Ù n W nAA | Method D21; P6 | 1.96 minutes9; 299 |
122 | Y) h n y^ nAA w H | Method D21; P6 | 1.96 minutes9; 299 |
123 | ΡΊΟ Λ< n W n^vA w H | Method D21; P6 | 2.02 minutes9; 301 |
124 | OH Sô h n w nAA A^n H | Method D21; P6 | 1.80 minutes13; 315 |
125 | 0 X | Method D21; P622 | 1.89 minutes9; 406 |
101
126 | \ n-n x y W H H | Method D21; P6 | 1.76 minutes9; 243 |
127 | \ A /n'n y w IN H | Method D21; P6 | 1.92 minutes9; 269 |
128 | fJO rycN N 0=7 nAL w 1 H | Method D; C14 | 2.49 minutes13; 340 |
129 | h2n^. _ LJ rVCN n y= w H | Method D; C14 | 2.05 minutes13; 319 |
130 | WfrJ îVcn f ο-n yjr H | Method D; C1423 | 2.43 minutes13; 438 |
131 | A : c>cn S? y/ N H | Method D; C14 | 2.39 minutes13; 389 |
132 | 0 m ry™ N 0=7 Nyy w IN H | Method D; C14 | 2.13 minutes13; 318 |
102
133 | HO N nYY H | Method D; C14 | 2.03 minutes9; 352 |
134 | OH όγ°Ί T j rycN n y^7 N H | Method D; C14 | 2.36 minutes9; 398 |
135 | Y °'n\°> T J fVCN N H | Method D; C1424 | 2.49 minutes9; 414 |
136 | F F Y rycn N X^7 Y^N H | Method D; C14 | 2.08 minutes10; 326 |
137 | cXXn V) rycN n y*7 nYY Y*Y H | Method D; C1425 | 2.43 minutes10; 437 |
138 | T j rycN N X^7 n\4 Y^N IN H | Method D; C14 | 2.00 minutes9; 320 |
103
139 | 0 ΗζνΛΟ rycN w | Method D; C14 | 1.93 minutes9; 347 |
140 | Ÿ) rycN IN H | Method D; C14 | 2.39 minutes9; 334 |
141 | N^i L'L·), N Ύ Ί #^y-cN kisr y=i nva 'Al | Method D; C1426 | 2.22 minutes9; 384 |
142 | -r-N ν·Λλ Ύ ΊΓΥCN n yF w H | Method D; C14 | 2.61 minutes9; 414 |
143 | VO O-CN n yF N'Sr'Â w IN H | Method D; C14 | 1.87 minutes9; 363 |
144 | N==, r-^ HN Ί ΓΥΰΝ y=/ w N H | Method D; C14 | 1.86 minutes9; 302 |
145 | 0-^ NyN L) Fr™ n y=Y IN H | Method D; C1427 | 2.25 minutes9; 402 |
104
146 | Y Ά) TV™ N TA W H | Method D; C14 | 2.17 minutes9; 386 |
147 | / YA-cn W N TA W N H | Ex 3 | 1H NMR (400 MHz, CDCI3) δ 11.32 (br s, 1H), 8.46 (s, 1H), 7.39-7.43 (m, 1H), 7.27- 7.30 (m, 1 H), 7.24 (s, 1 H), 7.08-7.11 (m, 1H), 3.88 (s, 3H), 2.88 (s, 6H); 294.1 |
148 | C} YY n W nW | C2028 | 2.07 minutes9; 299 |
149 | Û<v n y^7 Λτ K Y | Ex 3 | 8.59 (br d, J=1.5 Hz, 1H), 8.39 (s, 1H), 8.33- 8.36 (m, 1H), 7.73-7.76 (m, 1H), 7.63 (s, 1 H), 3.4-3.47 (m, 4H, assumed; partially obscured by water peak), 3.12-3.17 (m, 4H), 2.38 (s 3H); 296.0 |
150 | ô (N>CI W yJ όθ> h | Ex 3 | 8.78 (brs, 1H), 8.54 (brd, J=2 Hz, 1H), 8.42 (s, 1H), 8.07-8.10 (m, 1H), 7.80 (s, 1H), 3.46-3.54 (m, 4H), 3.11-3.18 (m, 4H); 316.1 |
151 | 0 A N An n y4 W N H | Ex 329 | 8.48 (s, 1H), 8.36 (s, 1H), 8.13 (s, 1H), 7.87 (s, 1H), 3.99 (s, 3H), 3.49-3.56 (m, 4H), 3.21-3.27 (m,4H); 313.1 |
152 | AA X r ί n~m V y< N 'VT H | Ex 3 | 8.30 (s, 1H), 7.61 (s, 1H), 7.22 (s, 1H), 3.80 (s, 3H), 3.4-3.48 (m, 4H, assumed; partially obscured by water peak), 3.15-3.21 (m, 4H), 2.13 (s, 3H); 299.2 |
105
153 | y θ' IN H | Ex 5 | characteristic peaks: 8.40 (s, 1H), 8.00 (br s, 1H), 7.90 (br d, J=8 Hz, 1H), 7.76 (br d, J=7 Hz, 1H), 7.65-7.70 (m, 2H), 3.60-3.74 (m, 2H), 0.93 (d, J=6.5 Hz, 3H); 320.1 |
154 | C } rVCN n y\ IN H | ΕχΓ | 1H NMR (400 MHz, CD3OD) δ 7.80-7.86 (m, 1H), 7.70-7.75 (m, 1H), 7.47 (dd, J=7.8, 7.8 Hz, 1H), 7.39 (d, J=1 Hz, 1H), 3.45-3.50 (m, 4H), 3.24-3.28 (m, 4H), 2.58 (s, 3H); 338.2 |
155 | ΗΟ,,./χ LJ ΓΥ0Ν n y*7 N H | Ex 6 | characteristic peaks: 12.21 (br s, 1H), 8.33 (s, 1 H), 7.94 (br s, 1 H), 7.82 (br d, J=8 Hz, 1H), 7.73 (br d, J=8 Hz, 1H), 7.60-7.66 (m, 2H), 4.71 (d, J=4.5 Hz, 1H), 3.70-3.79 (m, 1H), 3.44-3.52 (m, 1H), 2.60-2.70 (m, 1H), 1.73-1.82 (m, 1H), 1.38-1.48 (m, 1H), 1.121.26 (m, 2H); 320.1 |
156 | HCy^ ofV n y^7 N^S-Â ^hT^N H | Method E | 2.48 minutes9; 313 |
157 | 1 \ 7 o \ | Method E20 | 2.66 minutes9; 411 |
158 | F A ry™ n y< N ΤΆ w IN H | Method E | 2.41 minutes10; 340 |
106
159 | 0-0 O \ | Method E | 2.66 minutes9; 327 |
160 | y | Method E | 2.60 minutes10; 345 |
161 | cW n y=< IN H | Method E | 2.92 minutes9; 358 |
162 | ΗΟϊΊ /N=vVy N H | Method E | 1.88 minutes9; 310 |
163 | z^ru M O O \ | Method E | 2.47 minutes10; 345 |
164 | hc\^FX-\ ury°x N \=/ H | Method E | 2.54 minutes9; 343 |
107
165 | un n yA n ta w N H | Method E | 2.41 minutes9; 325 |
166 | An Ύ Ί A-™ N \=< νΆα N ™ H | Method E | 2.65 minutes13; 406 |
167 | A U rycN n y=\ 1 J F n'VA N H | Method E | 2.58 minutes9; 368 |
168 | / \ 7Π O \ | Method E | 2.17 minutes9; 299 |
169 | Τ°Ί ΓνU y N TA An N H | Method E | 1.74 minutes9; 310 |
170 | ory n yA nSA N N H | Method E | 2.02 minutes10; 283 |
171 | An Ά ΓΑ n yA nAA ,N H | Method E20 | 2.43 minutes9; 381 |
108
172 | οο ν \==( ϊ J 0 | Method Ε | 2.27 minutes9; 325 |
173 | Çt ^γΟν ΙΝ Η | Method Ε | 2.12 minutes9; 269 |
174 | Y OCN νΟΟ F ΙΝ Η | Method Ε | 2.13 minutes9; 326 |
175 | bn Ν - W Ν Η | Method Ε | 2.22 minutes9; 313 |
176 | Οθ ο \ | Method Ε | 2.24 minutes9; 295 |
177 | ^ιΟν ΙΝ Η | Method Ε | 2.24 minutes9; 287 |
178 | ΊΟ tvcn ν \=< νχΑ ^|Ον Ν Η | Method Ε | 2.04 minutes9; 338 |
109
179 | -Ab UU 1 J o- H H | Method E | 2.31 minutes9; 343 |
180 | C) fVCN n | Method E | 2.27 minutes9; 338 |
181 | bn V w nZ^ïa o— w n H | Method E | 2.13 minutes10; 345 |
182 | 'V0\ rv OfV IN H | Method E | 2.14 minutes10; 313 |
183 | F\^x 'n-' Ça _ N TA H H | Method E | 2.15 minutes9; 287 |
184 | O rycN n \=\ n pA H | Method E | 2.12 minutes9; 308 |
185 | Vp I J n τΛ N H | Method E | 2.26 minutes9; 331 |
110
186 | N\°) rVCN n y=< n N H | Method E20 | 2.36 minutes9; 406 |
187 | Ocr Ôa N N | Method F; P2 | 2.07 minutes9; 302 |
188 | y w H | Method F; P2 | 1.84 minutes9; 296 |
189 | N X U 1 7 H | Method F; P7 | 2.29 minutes9; 287 |
190 | C°>YY ï AJ sy | Method F; P2 | 2.33 minutes9; 329 |
191 | ï Ar uv | Method F; P2 | 2.35 minutes9; 317 |
192 | ôS V Vs Ôa N H | Method F; P2 | 2.18 minutes9; 302 |
111
193 | OcA Λ ΟΜ | Method F; pgSO | 2.47 minutes9; 363 |
194 | Γ°Ί /ΝΛ I / νΛ5 Ν Ν | Method F; P2 | 1.94 minutes13; 312 |
195 | °À°0 ΓΑ- ’ιί ly ΕΝΤ-1 Ν Η | Ex 520,31,17 | characteristic peaks: 12.37 (br s, 1H), 8.43 (s, 1 H), 7.99-8.02 (m, 1 H), 7.85 (ddd, J=7.8, 1, 1 Hz, 1H), 1H), 7.75 (ddd, J=7.8, 1, 1 Hz, 1H), 7.71 (s, 1H), 7.65 (dd, J=7.8, 7.8 Hz, 1 H), 4.67 (dd, J=9.5, 2.5 Hz, 1 H), 3.85 (br d, J=13 Hz, 1 H), 3.68-3.74 (m, 1H), 3.18 (dd, J=13, 9 Hz, 1H), 2.86-2.94 (m, 1H), 2.57 (s, 3H); 388.1 |
196 | \=Ν °'Ν Υ°> T J #t-cn ΕΝΤ-2 A | Ex 520,31,12 | characteristic peaks: 12.37 (br s, 1H), 8.43 (s, 1H), 8.00 (dd, J=1.5, 1.5 Hz, 1H), 7.85 (ddd, J=7.8, 1.5, 1.5 Hz, 1H), 7.75 (ddd, J=7.8, 1.5, 1.2 Hz, 1H), 7.71 (s, 1H), 7.65 (dd, J=7.8, 7.8 Hz, 1H), 4.67 (dd, J=9.7, 2.6 Hz, 1H), 3.85 (brd, J=13 Hz, 1H), 3.68-3.74 (m, 1H), 3.18 (dd, J=13.0, 9.5 Hz, 1H), 2.862.94 (m, 1H), 2.57 (s, 3H); 388.1 |
197 | ηΑ r>cN W yJ Ν ιτΑ I II Χ> ΕΝΤ-2 Η | Ex 616,12 | 1H NMR (400 MHz, CDCI3) δ 8.48 (s, 1H), 7.75 (br s, 1H), 7.65-7.70 (m, 2H), 7.59 (dd, J=7.8, 7.5 Hz, 1H), 7.33 (s, 1H), 4.02 (br d, J=13.3 Hz, 1 H), 3.89 (br d, J=13.3 Hz, 1 H), 3.80 (brdd, J=12.0, 2.3 Hz, 1H), 3.41-3.54 (m, 2H), 3.29 (s, 3H), 3.25-3.3 (m, 1H), 3.22 (dd, half of ABX pattern, J=10.2, 4.6 Hz, 1H), 2.98-3.08 (m, 1H), 2.87 (dd, J=13.2, 10.7 Hz, 1H); 350.2 |
112
203 | Γ Ί rycN n \=\ n'Va 1 H | Example 3; P2 | 1H NMR (400 MHz, CDCI3) δ 10.10 (brs, 1H), 8.50 (s, 1H), 7.67 (brd, J=7.5 Hz, 1H), 7.55 (br d, J=7.5 Hz, 1H), 7.38 (dd, J=7.9, 7.8 Hz, 1H), 7.11-7.13 (m, 1H), 3.35-3.42 (m, 4H), 3.21-3.26 (m, 4H), 2.49 (s, 3H); 319.9 |
204 | Γ°Ί /N Of?0 n'S'A H | Example 4; P2 | 8.34 (s, 1H), 7.75 (s, 1H), 7.37 (d, J=6.5 Hz, 1 H), 6.49 (br s, 1 H), 6.44 (dd, J=7.0, 1.5 Hz, 1H), 3.60-3.66 (m, 4H), 3.21-3.27 (m, 4H, assumed; partially obscured by water peak); 297.9 |
205 | .0. ( Ί ZVS W yiV N'S'A IN H | Example g32; p233 | 1H NMR (400 MHz, CDCI3) δ 10.08 (br s, 1H), 8.51 (s, 1H), 7.36 (d, J=0.9 Hz, 1H), 7.29-7.31 (m, 1H), 7.25-7.27 (m, 1H, assumed; partially obscured by solvent peak), 6.87 (dd, J=4.5, 1.0 Hz, 1H), 3.31- 3.35 (m, 4H), 3.26-3.31 (m, 4H); 327.1 |
206 | Cf H rycN n XL· (+/-) W H | Example 4; C14 | 1H NMR (400 MHz, CDCI3), characteristic peaks: δ 11.32 (br s, 1 H), 8.42 (s, 1 H), 7.78 (br s, 1 H), 7.72 (br d, J=7.8 Hz, 1 H), 7.62 (br d, J=7.8 Hz, 1 H), 7.52 (dd, J=7.8, 7.8 Hz, 1H), 7.18 (s, 1H), 4.34 (br dd, J=5, 5 Hz, 1H), 3.83-3.91 (m, 1H), 3.74 (ddd, J=8.3, 7.8, 5.3 Hz, 1H), 3.46-3.56 (m, 3H), 3.19 (dd, J=12.4, 4.9 Hz, 1H), 2.74-2.84 (m, 1H), 1.99- 2.10 (m, 1H); 331.9 |
207 | Λ H rycN N ii^SA (+/_) ^ΓΓΝ N H | Example 4; C14 | 1H NMR (400 MHz, CDCI3), δ 10.25 (br s, 1 H), 8.43 (s, 1 H), 7.81 (br s, 1 H), 7.73 (br d, J=7.8 Hz, 1 H), 7.63 (br d, J=7.8 Hz, 1 H), 7.54 (dd, J=7.8, 7.7 Hz, 1H), 7.18 (s, 1H), 3.71 (br dd, J=Q.O, 6.2 Hz, 2H), 3.56 (br dd, J=11.3, 7.2 Hz, 2H), 3.47 (dd, J=9.0, 2.6 Hz, 2H), 3.21 (dd, J=11.4, 4.1 Hz, 2H), 2.75-2.81 (m,2H); 331.9 |
113
208 | <Ô ryCN ν T w (+/-) νΆτΗ il JL > N H | Example 4; C14 | 8.49 (s, 1H), 8.14 (br s, 1H), 8.03 (brd, J=7.8 Hz, 1H), 7.79 (s, 1H), 7.76 (br d, J=7.5 Hz, 1H), 7.68 (dd, J=7.8, 7.8 Hz, 1H), 3.43.50 (m, 2H, assumed; partially obscured by water peak), 2.92-3.08 (m, 2H), 2.78 (br d, J=12.3 Hz, 1H), 2.65-2.75 (m, 1H), 2.42-2.5 (m, 1 H, assumed; partially obscured by solvent peak), 1.83-1.94 (m, 1H), 1.61-1.83 (m, 2H), 1.47-1.61 (m, 1H), 1.31-1.45 (m, 1 H); 345.9 |
209 | NC O Y Ί py-CN n yc nYa w <♦'-> | Example 4; C14 | 8.45 (s, 1 H), 8.04 (br s, 1 H), 7.91 (br d, J=8 Hz, 1 H), 7.80 (br d, J=8 Hz, 1 H), 7.76 (s, 1H), 7.66 (dd, J=8, 8 Hz, 1H), 5.06-5.09 (m, 1H), 3.79-3.86 (m, 1H), 3.43-3.52 (m, 2H), 3.3-3.41 (m, 1 H, assumed; partially obscured by water peak), 3.10-3.18 (m, 1H), 2.82-2.91 (m, 1H); 353.1 [M+Na+] |
210 | y} 0rCN n y=/ n ta IN H | Example 4; C14 | 8.37 (s, 1 H), 7.95 (br s, 1 H), 7.87 (br d, J=7.9 Hz, 1 H), 7.78 (br d, J=7.6 Hz, 1 H), 7.64-7.69 (m, 2H), 3.21-3.27 (m, 2H), 3.17 (br s, 2H), 2.87-2.93 (m, 2H), 1.19 (s, 6H); 334.0 |
211 | Γ°Ί a/cn V Çs N TA IN H | Example 3; P2 | 12.54 (br s, 1 H), 8.41 (s, 1 H), 8.00 (d, J=3.8 Hz, 1H), 7.78 (d, J=2.5 Hz, 1H), 7.28 (d, J=3.8 Hz, 1 H), 3.52-3.58 (m, 4H), 3.20-3.26 (m, 4H);311.9 |
212 | ,0. C zn A. / N<J Ln^n IN H | Example 3; P2 | 8.54 (br d, J=4.3 Hz, 1 H), 8.36 (s, 1 H), 8.20 (br d, J=9.3 Hz, 1 H), 7.94 (s, 1 H), 7.72 (s, 1H), 7.28 (dd, J=9.2, 4.4 Hz, 1H), 3.01-3.13 (m, 8H); 321.9 |
114
213 | νΛτ°ί rvcN I J F nAA ENT-2 II J ? <N H | Example 41; C134 | 1H NMR (400 MHz, DMSO-de+ D2O) δ 8.41 (s, 1H), 7.80-7.86 (m, 1H), 7.70-7.77 (m, 1 H), 7.65 (d, J=1 Hz, 1H), 7.42 (dd, J=7.8, 7.8 Hz, 1H), 4.74-4.80 (m, 1H), 3.78-3.85 (m, 1H), 3.60-3.66 (m, 1H), 3.29-3.45 (m, 3H), 2.88-2.97 (m, 1H), 2.34 (s, 3H); LCMS m/z 428.0 [M+Na+] |
214 | _Λ° Av rVCN 1 J F nAA ENT-1 || I X> N H | Example 41; C134 | 1H NMR (400 MHz, DMSO-d6+ D2O) δ 8.38 (s, 1H), 7.75-7.82 (m, 1H), 7.68-7.74 (m, 1H), 7.60 (s, 1H), 7.40 (dd, J=7.8, 7.8 Hz, 1H), 4.68-4.74 (m, 1H), 3.71-3.78 (m, 1H), 3.56-3.64 (m, 1H), 3.29-3.44 (m, 3H), 2.89-2.98 (m, 1H), 2.31 (s, 3H); LCMS m/z 428.0 [M+Na+] |
215 | Γ°Ί U Çp n yp ^iA-N · HCOOH N H | Example 4; P2 | 12.46 (br s, 1 H), 8.40 (s, 1 H), 8.23 (br s, 1 H), 8.11 (d, J=2.5 Hz, 1H), 8.06 (dd, J=8.0, 7.5 Hz, 1H), 7.85-7.90 (m, 2H), 7.77 (brs, 1H), 3.49-3.55 (m, 4H), 3.21-3.27 (m, 4H); 347.1 [M+Na+] |
216 | Ô AV 7 y^N nSa N H | Example 335; P2 | characteristic peaks: 9.16 (br d, J=7 Hz, 1H), 8.57-8.60 (m, 1H), 8.41 (s, 1H), 8.35 (s, 1H), 7.58 (s, 1H), 7.06-7.11 (m, 1H), 3.14-3.19 (m, 4H); 322.1 |
217 | r°> ACN V<U N n IN H | Example 3; P2 | 12.31 (brs, 1H), 8.38 (s, 1H), 7.42 (d, J=2.3 Hz, 1H), 7.35 (d, J=1.8 Hz, 1H), 7.08 (d, J=1.8 Hz, 1H), 3.82 (s, 3H), 3.54-3.60 (m, 4H), 3.27-3.33 (m, 4H); 308.9 |
218 | v N AA · HCOOH | Example 3; P2 | 12.42 (brs, 1H), 8.40 (s, 1H), 8.13 (s, ~0.6 H), 7.58 (d, J=2.3 Hz, 1H), 7.53 (d, J=4.5 Hz, 1H), 7.25 (d, J=4.3 Hz, 1H), 3.22-3.31 (m, 2H), 3.06-3.14 (m, 2H), 2.97-3.06 (m, 4H), 2.30 (s, 3H); 340.9 |
115
219 | 0 Ύ Ί fV « (+/-) N H | Example @109; C14 | characteristic peaks: 12.40 (brs, 1H), 8.53 (d, J=1.5 Hz, 1H), 8.44 (s, 1H), 8.00-8.02 (m, 1 H), 7.86 (br d, J=8 Hz, 1 H), 7.75 (br d, J=8 Hz, 1H), 7.71 (d, J=2.5 Hz, 1H), 7.66 (dd, J=8, 8 Hz, 1H), 6.39 (d, J=1.5 Hz, 1H), 4.66- 4.71 (m, 1H), 3.80-3.86 (m, 1H), 3.72-3.78 (m, 1H), 3.04-3.11 (m, 1H), 2.88-2.97 (m, 1 H); 394.9 [M+Na+] |
220 | ô SCN N VN n^Sa Sr N n H • cf3cooh | Example 4; Ρ2θθ | 1.43 minutes37; 310.3 |
221 | 0 N9 Ûh n A nAA A N H | Method F; P2 | 1.95 minutes38; 312.2 |
222 | C 0 ΛΓΊ n yxy nSS w IN H | Method F; P2 | 1.57 minutes38; 321.3 |
223 | 0 N9 ô& n VA n SA A N H | Method F; P2 | 1.86 minutes38; 323.3 |
224 | r°> n-v™ Vy n 'Sa w H • CF3COOH | Example 4; Ρ2^9 | 1.63 minutes37; 310.2 |
225
Example 4;
C1440 characteristic peaks: 12.38 (br s, 1H), 8.42 (s, 1H), 8.00 (dd, J=1.6, 1.4 Hz, 1H), 7.86 (ddd, J=7.7,1.7,1.4 Hz, 1H), 7.77 (ddd,
J=7.6, 1.5, 1.4 Hz, 1H), 7.71-7.73 (m, 1H),
7.69 (dd, J=8.0, 7.5 Hz, 1H), 3.72-3.79 (m, 1H), 3.60-3.68 (m, 2H), 2.63-2.77 (m, 4H); 344.9
1. In this case, tetrakis(trîphenylphosphine)palladium(0) was used in the Suzuki reaction.
2. Boronate ester 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1/-/-pyrazole was used in the Suzuki reaction.
3. Conditions for analytical HPLC. Column: Waters XBridge C18, 2.1 x 50 mm, 5 pm; Mobile phase A: 0.1% trifluoroacetic acid in water; Mobile phase B: 0.1% trifluoroacetic acid in acetonitrile; Gradient: 5% B for 1.0 minute, then 5% to 100% B over 5.75 minutes; Flow rate: 0.5 mL/minute.
4. Dichlorobis(triphenylphosphine)palladium(ll) was used in the Suzuki reaction.
5. 1 N Sodium hydroxide solution was employed in the Suzuki reaction; this served to remove the (4-methylphenyl)sulfonyl protecting group.
6. In this case, préparative HPLC purification was carried out using a 10 pm Sunfire ΟΙ 8 column; Eluent: 1:1 acetonitrile / (0.1% formic acid in water).
7. A boronic acid was used rather than a boronic ester.
8. The final deprotection was carried out using tetrabutylammonium fluoride in tetrahydrofuran.
9. Conditions for analytical HPLC. Column: Waters XBridge C18, 2.1 x 50 mm, 5 pm; Mobile phase A: 0.0375% trifluoroacetic acid in water; Mobile phase B: 0.01875% trifluoroacetic acid in acetonitrile; Gradient: 1% to 5% B over 0.60 minutes; then 5% to 100% B over 3.40 minutes; Flow rate: 0.8 mL/minute.
10. Conditions for analytical HPLC as in footnote 9, except that the gradient employed was 10% to 100% B over 4.00 minutes.
11. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AD, 5 pm; Eluent: 68:32 carbon dioxide / methanol.
12. This Example was the second-eluting enantiomer from the supercritical fluid chromatographie séparation.
13. Conditions for analytical HPLC. Column: Waters XBridge C18, 2.1 x 50 mm, 5 pm; Mobile phase A: 0.05% ammonium hydroxide in water; Mobile phase B: acetonitrile; Gradient: 5% to 100% B over 3.40 minutes; Flow rate: 0.8 mL/minute.
14. [1,r-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) was used in the Suzuki reaction.
15. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AD, 5 pm; Eluent: 60:40 carbon dioxide / (methanol containîng 0.05% diethylamine).
16. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AD, 20 pm; Eluent: 60:40 carbon dioxide / (éthanol containîng 0.05% diethylamine).
17. This Example was the first-eluting enantiomer from the supercritical fluid chromatographie séparation.
18. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AS, 5 pm; Eluent: 60:40 carbon dioxide / (2-propanol containîng 0.05% diethylamine).
19. 3-lodo-1-methyl-1/-/-pyrazole was used in the Suzuki reaction.
20. The requisite 2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholine may be prepared from 4benzylmorpholine-2-carbonitrile using chemistry described by D. Sakai and K. Watanabe, PCT Int. Appl. 2009, WO 2009035159 A1 20090319.
21. In this case, the displacement reaction was carried out at 110 °C.
22. The requisite 2-{[(6-methylpyridin-3-yl)oxy]methyl}morpholine may be prepared via a Mitsunobu reaction between tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate and 6methylpyridin-3-ol, followed by acidic removal of the protecting group.
23. 2-{[5-(Difluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}morpholine may be prepared in the following manner: reaction of (4-benzylmorpholin-2-yl)acetonitrile with hydroxylamine hydrochloride and base provides 2-(4-benzylmorpholin-2-yl)-/V'-hydroxyethanimidamide. Coupling of this compound with difluoroacetic acid may be carried out using any of a number of coupling reagents, such as 1,3-dicyclohexylcarbodiimide. Subséquent cyclization using thermal conditions or tetrabutylammonium fluoride (see A. R. Gangloff et al., Tetrahedron Lett. 2001, 42,1441-1443), followed by débenzylation, provides the requisite amine.
24. Reaction of 4-benzylmorpholine-2-carbonitrile with hydroxylamine hydrochloride and sodium hydroxide provided 4-benzyl-/V'-hydroxymorpholine-2-carboximidamide, which was condensed with cyclopropanecarboxylic acid using 1,3-dicyclohexylcarbodiimide. Cyclization using tetrabutylammonium fluoride (see A. R. Gangloff et al., Tetrahedron Lett. 2001, 42,14411443), followed by débenzylation, afforded 2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)morpholine.
25. The requisite 3-(morphohn-2-ylmethoxy)benzonitrile may be prepared in a manner analogous to that described in footnote 22.
26. 2-(Pyrimidin-4-yl)morpholine may be prepared from 1 -(4-benzylmorpholin-2yl)ethanone via conversion to the enamine and reaction with 1,3,5-triazine (see D. L. Boger et al., J. Org. Chem. 1982, 47, 2673-2675), followed by débenzylation.
27. 2-[(5-Methyl-1,2,4-oxadiazol-3-yl)methyl]morpholine may be prepared via the chemistry described in footnote 23, by employing acetic acid in place of difluoroacetic acid.
28. Compound C20 was /V-alkylated with ethyl iodide and potassium tert-butoxide at 30 °C in tetrahydrofuran. Deprotection was carried out using the procedure described in step 2 of Method C.
29. 2-Chloro-6-methoxypyrazine was used in the Suzuki reaction.
30. 2-Chloro-1-fluoro-3-iodo-4-methoxybenzene may be prepared by iodination of 2chloro-1-fluoro-4-methoxybenzene according to the method of R. Sanz et al., J. Org. Chem. 2007, 72, 5113-5118 .
31. The racemic product was separated into its enantiomers using supercritical fluid chromatography. Column: Chiral Technologies Chiralpak® AS, 5 pm; Eluent: 63:37 carbon dioxide / (methanol containing 0.05% ammonium hydroxide).
32. In this case, potassium phosphate and 1,2-dimethoxyethane were used in place of sodium carbonate and 1,4-dioxane.
33. 5-Bromoimidazo[2,1-b][1,3]thiazole may be prepared via bromination of imidazo[2,1b][1,3]thiazole using /V-bromosuccinimide.
34. The two enantiomers were separated by supercritical fluid chromatography. Example 213 was the second-eluting enantiomer, and Example 214 was the first-eluting isomer, using a Chiral Technologies Chiralcel OJ-3 column, and gradient of 5% to 40% methanol in carbon dioxide containing 0.05% diethylamine.
35. In this case, the Suzuki reaction was carried out using bis[di-tert-butyl(4dimethylaminophenyl)phosphine]dichloropalladium(ll) and césium fluoride in a mixture of 1,4dioxane and water at 100 °C for 18 hours.
36. Treatment of 4-bromo-1-methyl-1 H-imidazole with lithium diisopropylamide and N,Ndimethylformamide provided 4-bromo-1-methyl-1/-/-imidazole-2-carbaldehyde, which was converted to the requisite 4-bromo-1-methyl-1H-imidazole-2-carbonitrile via reaction with ammonium hydroxide and iodine, according to the method of J.-J. Shie and J.-M. Fang, J. Org. Chem. 2007, 72, 3141-3144.
37. Conditions for analytical HPLC. Column: Waters Atlantis dC18, 4.6 x 50 mm, 5 pm; Mobile phase A: 0.05% trifluoroacetic acid in water (v/v); Mobile phase B: 0.05% trifluoroacetic
acid in acetonitrile (v/v); Gradient: 5.0% to 95% B, linear over 4.0 minutes; Flow rate: 2 mL/minute.
38. Conditions for analytical HPLC. Column: Waters XBridge C18, 4.6 x 50 mm, 5 pm; Mobile phase A: 0.03% ammonium hydroxide in water (v/v); Mobile phase B: 0.03% ammonium hydroxide in acetonitrile (v/v); Gradient: 5.0% to 95% B, linear over 4.0 minutes; Flow rate: 2 mL/minute).
39. 3-Bromo-1-methyl-1 /-/-pyrazole-5-carbaldehyde was converted to 3-bromo-1-methyl1 H-pyrazole-5-carbonitrile using the method of J.-J. Shie and J.-M. Fang; see footnote 36.
40. Treatment of (4-benzylmorpholin-2-yl)acetonitrile with ammonium cerium(IV) nitrate provided the requisite morpholin-2-ylacetonitrile.
Bioloqical Assays
LRRK2 assay
LRRK2 kinase activity was measured using Lantha Screen technology from Invitrogen. GST-tagged truncated LRRK2 from Invitrogen (Cat # PV4874) was incubated with a fluorescein-labeled peptide substrate based upon ezrin/radixin/moesin (ERM), also known as LRRKtide (Invitrogen cat # PR8976A), in the presence of a dose response of compound. Upon completion, the assay was stopped and detected with a terbium labeled anti-phospho-ERM antibody (Invitrogen, cat # PR8975A). The assay was carried out under the following protocol: 3 pL of a working solution of substrate (233 nM LRRKtide, 117 pM ATP) prepared in assay buffer (50 mM HEEPES, pH 7.5, 3 mM MgCh, with 2 mM DTT and 0.01% Brij35 added fresh) was added to a low volume Greiner 384-well plate. The compound dose response was prepared by diluting compound to a top concentration of 3.16 mM in 100% DMSO and serial diluted by halflog in DMSO 11 times. Aliquots (3.5 pL) of the 100% DMSO dose response were mixed with 46.5 pL water then 1 pL of this mixture was added to the 3 pL substrate mix in the 384-well plate. The kinase reaction was started with 3 pL of a working solution of LRRK2 enzyme at a concentration of 4 pg/mL. The final reaction concentrations were 100 nM LRRKtide, 50 pM ATP, 1.7 pg/mL LRRK2 enzyme and a compound dose response with a top dose of 32 pM. The reaction was allowed to progress at room température for two hours and then stopped with the addition of 7 pL of détection buffer (20 mM Tris pH 7.6, 0.01% NP-40, 0.02% NaN3, 6 mM EDTA with 2 nM terbium labeled anti-phospho-ERM). After an incubation of 1 hour at room température, the plate was read on an Envision with an excitation wavelength of 340 nm and a reading émission at
120
both 520 nm and 495 nm. The ratio of the 520 nm and 495 nm émission was used to analyze the data.
Inhibition of mutant G2019S LRRK2 (Invitrogen cat # PV4881) was measured in the exact same method. Ali final concentrations of substrate ATP and enzyme were the 5 same. However, since the mutant enzyme is more active the reaction time was reduced to 90 minutes to ensure that inhibition was measured at steady state before any substrate déplétion could occur.
Table 2, below, provides the LRRK2 IC50 data for the compounds of the invention.
Table 2
Example Number | IUPAC Name | LRRK2 WT IC50 (nM)* | LRRK2 G2019S IC50 (nM)* |
1 | 5-(1-methyl-1H-pyrazol-4-yl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-c(|pyrimidine | 13a | 36a |
2 | 3-[6-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3- c(|pyrimidin-5-yl]benzonitrile | 12 | 43 |
3 | 6-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidin-5- yl]pyridine-2-carbonitrile | 9 | 26 |
4 | 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidin-5- yl]benzonitrile | 3a | 11a |
5 | 3-[4-(dimethylamino)-7/7-pyrrolo[2,3-d]pyrimidin-5- yljbenzonitrile | 5 | 15 |
6 | 3-{4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 7 | 37 |
7 | (3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3- d|pyrimidin-5-yl}phenyl)methanol | 18a | 18a |
8 | 4-(morpholin-4-yl)-5-(1/-/-pyrazol-4-yl)-7H-pyrrolo[2,3cfipyrimidine, formate sait | 25 | 33 |
9 | 3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 42 | 513 |
10 | {3-[4-(dimethylamino)-7H-pyrrolo[2,3-d]pyrimidin-5yl]phenyl}methanol | 34 | 23 |
121
11 | 3-[4-(3,3-dimethylpiperidin-1 -yl)-7/7-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 90 | 325 |
12 | 3-[4-(piperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5- yljbenzonitrile | 6 | 28 |
13 | 1-(5-phenyl-7/7-pyrrolo[2,3-c(|pyrimidin-4-yl)piperidine-3- carboxamide | 41 | 39 |
14 | 3-{4-[(3S)-3-hydroxypiperidin-1-yl]-7H-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 17b | 95b |
15 | 4-[(3S)-3-methylpiperidin-1-yl]-5-phenyl-7/7-pyrrolo[2,3- cdpyrimidine | 91 | 92 |
16 | 3-{4-[(3S)-3-methylpiperidin-1-yl]-7A7-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 16a | 45a |
17 | 4-[(3S)-3-methylpiperidin-1 -yl]-5-( 1 -methyl-1 /7-pyrazol- 4-yl)-7H-pyrrolo[2,3-d]pyrimidine | 14 | 12 |
18 | 5-phenyl-4-(pyrrolidin-1-yl)-7/-/-pyrrOlo[2,3-c7|pyrimidine | 71 | 47 |
19 | [1-(5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4yl]methanol | 38 | 29 |
20 | 1-{5-[3-(hydroxymethyl)phenyl]-7H-pyrrolo[2,3d|pyrimidin-4-yl}piperidine-3-carbonitrile | 56 | 31 |
21 | 1-[5-(3-cyanophenyl)-7/7-pyrrolo[2,3-d]pyrimidin-4- yl]piperidine-3-carbonitrile | 57 | 183 |
22 | 4-(3,5-c/s-dimethylpiperidin-1 -y I )-5-( 1 -methyl-1 /7pyrazol-4-yl)-7/7-pyrrolo[2,3-d]pyrimidine | 16 | 16 |
23 | 4-methoxy-3-[4-(3-methylpiperidin-1-yl)-7/7-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 25 | 46 |
24 | 3-[4-(dimethylamino)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]-4- methoxybenzonitrile | 24 | 30 |
25 | 5-(5-chloro-2-methoxyphenyl)-/\/,A/-dimethyl-7/7pyrrolo[2,3-d]pyrimidin-4-amine | 22 | 19 |
26 | 3-{4-[4-(1 /7-imidazol-2-yl)piperidin-1 -yl]-7H-pyrrolo[2,3c/Jpyrimidin-5-yl}benzonitrile, trifluoroacetate sait | 42 | 230 |
27 | 3-{4-[3-(methoxymethyl)piperidin-1-yl]-7/7-pyrrolo[2,3- c/|pyrimidin-5-yl}benzonitrile | 95 | 219 |
122
28 | 3-[4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7/-/pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile | 40 | 201 |
29 | 3-[4-(3-methoxypiperidin-1-yl)-7H-pyrrolo[2,3- d|pyrimidin-5-yl]benzonitrile | 79 | 154 |
30 | 3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 17 | 121 |
31 | /^-[S-ÎS-cyanophenyl^H-pyrrolo^.S-c/IpyrimidirM-yl]A/,A/-dimethyl-beta-alaninamide | 54 | 248 |
32 | 3-[4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 67 | 333 |
33 | 3-[4-(4-fluoropiperidin-1-yl)-7/-/-pyrrolo[2,3-d|pyrimidin- 5-yl]benzonitrile | 17 | 96 |
33A | 3-[4-(4-fluoropiperidin-1-yl)-7/7-pyrrolo[2,3-c/|pyrimidin- 5-yl]benzonitrile | 17 | 56b |
34 | 3-{4-[4-(1 /7-pyrazol-3-yl)piperidin-1 -yl]-7/7-pyrrolo[2,3a0pyrimidin-5-yl}benzonitrile | 69 | 136 |
35 | 3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 30 | 155 |
36 | 3-{4-[2-(1 /7-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 43 | 238 |
37 | 3-{4-[3-(1 /-/-pyrazol-3-yl)piperidin-1 -yl]-7/7-pyrrolo[2,3d|pyrimidin-5-yl}benzonitrile | 84 | 200 |
38 | 3-{4-[3-(1 /-/-imidazol-2-yl)piperidin-1 -yl]-7/7-pyrrolo[2,3c0pyrimidin-5-yl}benzonitrile, formate sait | 53 | 331 |
39 | 3-{4-[(1-methylpiperidin-3-yl)amino]-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile, formate sait | 78 | 243 |
40 | 3-[4-(3-oxo-2,7-diazaspiro[4.5]dec-7-yl)-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 35 | 119 |
41 | 3-[4-(3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-G(]pyrimidin- 5-yl]benzonitrile, ENT-2 | 70 | 172 |
42 | 3-(4-{[2-(morpholin-4-yl)ethyl]amino}-7/7-pyrrolo[2,3d|pyrimidin-5-yl)benzonitrile, formate sait | 89 | 487 |
43 | 3-[4-(2-oxa-7-azaspiro[4.5]dec-7-yl)-7/7-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 34 | 244 |
123
44 | Λ/-{1 -[5-(3-cyanophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl]piperidin-4-yl}acetamide | 50 | 190 |
45 | 5-(1 /7-indazol-5-yl)-4-[(3S)-3-methylpiperidin-1 -yl]-7Hpyrrolo[2,3-d]pyrimidine | 67 | 66b |
46 | 3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3- c(|pyrimidin-5-yl}benzenesulfonamide | 24 | 33b |
47 | 5-(2-fluorophenyl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/- pyrrolo[2,3-d]pyrimidine | 97 | 122b |
48 | 5-(1 H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1 -yl]-7H- pyrrolo[2,3-d]pyrimidine | 10a | 14 |
49 | 5-(6-fluoro-5-methylpyridin-3-yl)-4-[(3S)-3methylpiperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidine, trifluoroacetate sait | 64 | 65b |
50 | 5-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl}-2,3-dihydro-1 /7-isoindol-1 -one | 33 | 33b |
51 | 4-[(3S)-3-methylpiperidin-1-yl]-5-(pyridin-3-yl)-7Hpyrrolo[2,3-c(|pyrimidine, formate sait | 56 | 95b |
52 | 4-[(3S)-3-methylpiperidin-1-yl]-5-(5-methylpyridin-3-yl)- 7H-pyrrolo[2,3-d]pyrimidine, formate sait | 15 | 19b |
53 | 4-[(3S)-3-methylpiperidin-1-yl]-5-(7H-pyrrolo[2,3b]pyridin-5-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine, formate sait | 74 | 69b |
54 | 6-{4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3- d]pyrimidin-5-yl}-2,3-dihydro-1 H-isoindol-1 -one | 68 | 59b |
55 | 4-[(3S)-3-methylpiperidin-1 -y l]-5-( 1 H-pyrrolo[3,2b]pyridin-6-yl)-7H-pyrrolo[2,3-c(|pyrimidine, formate sait | 53 | 50b |
56 | 4-{4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3- d]pyrimidin-5-yl}phenol | 26 | 28b |
57 | 4-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3- c(|pyrimidin-5-yl}benzamide | 13 | 9b |
58 | 3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3- c/]pyrimidin-5-yl}phenol | 9 | 12b |
59 | 5-(2-chloro-5-methylpyridin-3-yl)-4-[(3S)-3methylpiperidin-1-yl]-7/7-pyrrolo[2,3-c/|pyrimidine, formate sait | 30 | 30b |
124
60 | 3-{4-[(3S)-3-methylpiperidin-1 -yl]-7H-pyrrolo[2,3d]pyrimidin-5-yl}benzamide | 86 | 58 |
61 | 3-[4-(3-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-d|pyrimidin- 5-yl]benzonitrile | 12 | 80 |
62 | 3-[4-(4-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin- 5-yl]benzonitrile, hydrochloride sait | 91 | 273 |
63 | 3-{4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3- d]pyrimidin-5-yl}benzoic acid | 55 | 39 |
64 | 3-[4-(methylamino)-7/-/-pyrrolo[2,3-d]pyrimidin-5- yl]benzonitrile | 45 | 97 |
65 | 3-[4-(3,5-c/s-dimethylpiperidin-1-yl)-7/7-pyrrolo[2,3- d]pyrimidin-5-yl]-4-methoxybenzonitrile | 85 | 176 |
66 | 4-methoxy-3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/- pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile | 21 | 51 |
67 | 2-fluoro-3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/- pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile | 11 | 35 |
68 | /V,/V-dimethyl-5-phenyl-7/-/-pyrrolo[2,3-d]pyrimidin-4- amine | 63 | 39 |
69 | 3-[4-(dimethylamino)-7/7-pyrrolo[2,3-c(]pyrimidin-5-yl]-2fluorobenzonitrile | 6 | 17 |
70 | 3-[4-(pyrrolidin-1-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5- yljbenzonitrile | 8 | 64 |
71 | 3-[4-(3-methylpyrrolidin-1-yl)-7/7-pyrrolo[2,3-d]pyrimidin- 5-yl]benzonitrile, ENT-2 | 21 | 102 |
72 | 3-[4-(dimethylamino)-7/7-pyrrolo[2,3-c(]pyrimidin-5-yl]-4fluorobenzonitrile | 37 | 190 |
73 | 3-[4-(diethylamino)-7/-/-pyrrolo[2,3-dlpyrimidin-5- yljbenzonitrile | 13 | 119 |
74 | 3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/7-pyrrolo[2,3c(]pyrimidin-5-yl}benzonitrile, ENT-1 | 12 | 100 |
75 | 3-[4-(dimethylamino)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]-5fluorobenzonitrile | 53 | 396 |
76 | 3-{4-[2-(1H-pyrazol-3-yl)morpholin-4-yl]-7/7-pyrrolo[2,3d]pyrimidin-5-yl}benzonitrile, ENT-2, formate sait, | 23 | 208 |
125
77 | 3-[4-(3-methylpyrrolidin-1 -yl)-7H-pyrrolo[2,3-d|pyrimidin- 5-yl]benzonitrile, ENT-1 | 39 | 158 |
78 | 2-fluoro-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 2 | 7 |
79 | 3-{4-[(2/:î)-2-methylmorpholin-4-yl]-7/7-pyrrolo[2,3- cQpyrimidin-5-yl}benzonitrile | 18 | 69 |
80 | 4-fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 49 | 393 |
81 | 4-(4-fluoropiperidin-1 -yl)-5-( 1 -methyl-1 H-pyrazol-4-yl)- 7H-pyrrolo[2,3-c/|pyrimidine | 36 | 50 |
82 | 2-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidin-5- yljbenzonitrile | 95 | 148 |
83 | 5-(3-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- djpyrimidine | 8 | 13 |
84 | 5-(2-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine | 22 | 30 |
85 | 5-(3-fluoro-5-methoxyphenyl)-4-(morpholin-4-yl)-7/-/- pyrrolo[2,3-d|pyrimidine | 9 | 20 |
86 | 5-(2,5-difluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3- d|pyrimidine | 76 | 145 |
87 | 5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine | 12 | 24 |
88 | 5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d]pyrimidine | 9 | 12 |
89 | {2-fluoro-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl]phenyl}methanol | 32 | 75 |
90 | 5-(2,4-difluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3- c/jpyrimidine | 41 | 62 |
91 | 5-(3-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine | 9 | 21 |
92 | 5-(3,5-difluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3- djpyrimidine | 92 | 238 |
93 | 4-(morpholin-4-yl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidine | 9 | 14 |
126
94 | 5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-d]pyrimidine | 7 | 10 |
95 | 5-(2-chlorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3- djpyrimidine | 21 | 33 |
96 | 5-(5-fluoro-2-methylphenyl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d]pyrimidine | 91 | 223 |
97 | 5-(3-methoxyphenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3djpyrimidine | 28 | 46 |
98 | {2-fluoro-5-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3cflpyrimidin-5-yl]phenyl}methanol | 70 | 135 |
99 | 5-(4-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- djpyrimidine | 95 | 154 |
100 | {3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5- yl]phenyl}methanol | 12 | 19 |
101 | 5-(2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- djpyrimidine | 14 | 23 |
102 | 5-[3-(methylsulfanyl)phenyl]-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d]pyrimidine | 52 | 78 |
103 | 4-(morpholin-4-yl)-5-(pyridin-3-yl)-7/7-pyrrolo[2,3d|pyrimidine, formate sait | 35 | 159 |
104 | 4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/|pyrimidin-5yljisoquinoline, formate sait | 27 | 51 |
105 | 5-(5-bromopyridin-3-yl)-4-(morpholin-4-yl)-7/-/pyrrolo[2,3-c(|pyrimidine, formate sait | 6 | 14 |
106 | 5-(2-chloro-5-methylphenyl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d|pyrimidine | 22 | 44 |
107 | 5-(3-methylphenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3- cflpyrimidine | 13 | 20 |
108 | 5-(1 -methyl-1 H-pyrazol-3-yl)-4-(morpholin-4-yl)-7/-/pyrrolo[2,3-c(|pyrimidine | 53 | 90 |
109 | 3-[4-(4-hydroxypiperidin-1-yl)-7/-/-pyrrolo[2,3aflpyrimidin-5-yl]benzonitrile | 52 | 109 |
110 | 3-{4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]- 7/-/-pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | 20 | 176 |
127
111 | 3-methyl-5-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3- d|pyrimidin-5-yl]benzonitrile | 14b | 64b |
112 | 3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]- 7H-pyrrolo[2,3-cflpyrimidin-5-yl}benzonitrile | 10 | 41 |
113 | 3-[4-(6-oxa-3-azabicyclo[3.1.1]hept-3-yl)-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 58b | 523b |
114 | 3-chloro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3c/|pyrimidin-5-yl]benzonitrile | 77b | 406b |
115 | 4-methoxy-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3- d|pyrimidin-5-yl]benzonitrile | 48 | 121 |
116 | 5-(5-chloro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/- pyrrolo[2,3-d]pyrimidine | 85 | 67 |
117 | 6-methyl-5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(morpholin-4- yl)-7H-pyrrolo[2,3-d|pyrimidine | 47 | 89 |
118 | 3-methoxy-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 77 | 177 |
119 | 5-(1 -methyl-1 H-pyrazol-4-yl)-4-(thiomorpholin-4-yl)-7Hpyrrolo[2,3-d]pyrimidine | 71 | 51 |
120 | 1 -[5-(1 -methyl-1 /7-pyrazol-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-4-yl]piperidin-3-ol | 44 | 34 |
121 | 4-[(2S)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 /7-pyrazol- 4-yl)-7H-pyrrolo[2,3-cflpyrirnidine | 57 | 59 |
122 | 4-[(2fî)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 /7-pyrazol- 4-yl)-7/7-pyrrolo[2,3-d|pyrimidine | 67 | 31 |
123 | 4-(3-fluoropiperidin-1 -y 1)-5-( 1 -methyl-1 H-pyrazol-4-yl)7H-pyrrolo[2,3-d]pyrimidine | 31 | 27 |
124 | (4-[5-( 1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3d]pyrimidin-4-yl]morpholin-2-yl}methanol | 77 | 80 |
125 | 5-(1 -methyl-1 H-pyrazoI-4-yl)-4-(2-{[(6-methylpyridin-3yl)oxy]methyl}morpholin-4-yl)-7H-pyrrolo[2,3djpyrimidine | 54 | 87 |
126 | A/,A/-dimethyl-5-(1 -methyl-1 /7-pyrazol-4-yl)-7 Hpyrrolo[2,3-d]pyrimidin-4-amine | 55 | 35 |
127 | /V-cyclopropyl-/\/-methyl-5-(1 -methyl-1 H-pyrazol-4-yl)- 7H-pyrrolo[2,3-d|pyrimidin-4-amine | 37 | 37 |
128
128 | 3-(4-(3,3-difluoropiperidin-1-yl)-7H-pyrrolo[2,3c/jpyrimidin-5-yl]benzonitrile | 79 | 169 |
129 | 3-[4-(3-aminopiperidin-1-yl)-7/7-pyrrolo[2,3-d]pyrimidin- 5-yl]benzonitrile | 14 | 21 |
130 | 3-[4-(2-{[5-(difluoromethyl)-1,2,4-oxadiazol-3yl]methyl}morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidin-5yl]benzonitrile | 44 | 134 |
131 | 3-(4-(2-(1,3-thiazol-2-yl)morpholin-4-yl]-7/7-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 45 | 181 |
132 | 3-[4-(4-oxopiperidin-1-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5- yljbenzonitrile | 66 | 223 |
133 | 3-{4-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]-7A/pyrrolo[2,3-dlpyrimidin-5-yl}benzonitrile | 42 | 106 |
134 | 3-{4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7Hpyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile | 91 | 281 |
135 | 3-{4-[2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)morpholin-4- yl]-7H-pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | 19 | 47 |
136 | 3-(4-(3,3-difluoropyrrolidin-1-yl)-7/7-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 74 | 194 |
137 | 3-(4-{2-[(3-cyanophenoxy)methyl]morpholin-4-yl}-7/7pyrrolo[2,3-c(|pyrimidin-5-yl)benzonitrile | 30 | 51 |
138 | 3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3c(|pyrimidin-5-yl]benzonitrile | 10 | 27 |
139 | 1-[5-(3-cyanophenyl)-7H-pyrrolo[2,3-c(|pyrimidin-4- yl]piperidine-3-carboxamide | 49 | 136 |
140 | 3-[4-(2-ethylmorpholin-4-yl)-7/7-pyrrolo[2,3-d|pyrimidin- 5-yl]benzonitrile | 61 | 95 |
141 | 3-{4-[2-(pyrimidin-4-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 79 | 193 |
142 | 3-{4-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)morpholin-4- yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile | 30 | 84 |
143 | 3-(4-{2-[(dimethylamino)methyl]morpholin-4-yl}-7/-/pyrrolo[2,3-d|pyrimidin-5-yl)benzonitrile | 45 | 110 |
144 | 3-(4-(1 H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-c/]pyrimidin- 5-yl]benzonitrile | 69 | 36 |
129
145 | 3-(4-{2-[(5-methyl-1,2,4-oxadiazol-3- yl)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-d|pyrimidin-5yl)benzonitrile | 55 | 155 |
146 | 3-{4-[3-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-1 -yl]-7/7pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile | 96 | 217 |
147 | 3-[4-(dimethylamino)-7/7-pyrrolo[2,3-c(]pyrimidin-5-yl]-5- methoxybenzonitrile | 37 | 93 |
148 | 5-(1 -ethyl-1 /7-pyrazol-4-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-d|pyrimidine | 77b | 92b |
149 | 5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-c/|pyrimidine | 18 | 30 |
150 | 5-(5-chloropyridin-3-yl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d|pyrimidine | 28 | 36 |
151 | 5-(6-methoxypyrazin-2-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-d|pyrimidine | 32 | 37 |
152 | 5-(1,3-dimethyl-1 /7-pyrazol-4-yl)-4-(morpholin-4-yl)-7/7pyrrolo[2,3-d|pyrimidine, formate sait | 60 | 91 |
153 | 3-{4-[(3S)-3-methylmorpholin-4-yl]-7/7-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 44 | 165 |
154 | 2-fluoro-3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3- d|pyrimidin-5-yl]benzonitrile | 30 | 365 |
155 | 3-{4-[(3fî)-3-hydroxypiperidin-1-yl]-7/7-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 8b | 37b |
156 | 1-[5-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrirnidin-4- yl]piperidin-3-ol | 57 | 86 |
157 | 5-(5-fluoro-2-methoxyphenyl)-4-[2-(5-methyl-1,2,4oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3cflpyrimidine | 44 | 46 |
158 | 2-fluoro-3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3- d|pyrimidin-5-yl]benzonitrile | 18 | 86 |
159 | 4-(4-fluoropiperidin-1-yl)-5-(2-methoxyphenyl)-7H- pyrrolo[2,3-d|pyrimidine | 67 | 74 |
160 | 5-(3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)- 7/-/-pyrrolo[2,3-d]pyrimidine | 84 | 96 |
130
161 | 3-(4-(4,4-difluoropiperidin-1 -yl)-7H-pyrrolo[2,3cflpyrimidin-5-yl]-2-fluorobenzonitrile | N.D.C | N.D. |
162 | 1-[5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl]piperidin-3-ol, formate sait | 36 | 67 |
163 | 5-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)- 7H-pyrrolo[2,3-d]pyrimidine | 25 | 29 |
164 | 1-[5-(3-fluoro-5-methoxyphenyl)-7/7-pyrrolo[2,3- d]pyrimidin-4-yl]piperidin-3-ol | 29 | 38 |
165 | 1-[5-(2-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4- yl]piperidin-3-ol | 58 | 62 |
166 | 2-fluoro-3-{4-[2-(3-methyl-1,2,4-oxadiazol-5yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile | 38 | 272 |
167 | 2-fluoro-3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/7- pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | 61 | 372 |
168 | 4-(azetidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-7/-/- pyrrolo[2,3-d]pynmidine | 85 | 75 |
169 | 4-[(2S)-2-methylmorpholin-4-yl]-5-(5-methylpyridin-3-yl)- 7/7-pyrrolo[2,3-d]pyrimidine, formate sait | 99 | 280 |
170 | 5-(3-fluorophenyl)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3- d]pyrimidine | N.D. | N.D. |
171 | 5-(3-fluorophenyl)-4-[2-(5-methyl-1,2,4-oxadiazol-3yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-tyjpyrimidine | N.D. | N.D. |
172 | 5-(2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]- 7H-pyrrolo[2,3-cf]pyrimidine | N.D. | N.D. |
173 | 5-(2-methoxyphenyl)-/V,/\/-dimethyl-7H-pyrrolo[2,3- d]pyrimidin-4-amine | 43 | 29 |
174 | 2-fluoro-3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7/7- pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | N.D. | N.D. |
175 | 4-[(3S)-3-fluoropyrrolidin-1-yl]-5-(2-methoxyphenyl)-7H- pyrrolo[2,3-d|pyrimidine | 41 | 54 |
176 | 5-(2-methoxyphenyl)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3- d|pyrimidine | 54 | 68 |
177 | 5-(3-fluoro-5-methoxyphenyl)-A/,/V-dimethyl-7/7pyrrolo[2,3-d|pyrimidin-4-amine | 41 | 49 |
131
178 | 2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 9 | 42 |
179 | 5-(5-fluoro-2-methoxyphenyl)-4-[(2S)-2- methylmorpholin-4-yl]-7/7-pyrrolo[2,3-d|pyrimidine | 19 | 30 |
180 | 2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7/7pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | 10 | 62 |
181 | 5-(5-fluoro-2-methoxyphenyl)-4-(3-fluoropiperidin-1-yl)- 7/-/-pyrrolo[2,3-d]pyrimidine | 22 | 24 |
182 | 5-(3-fluorophenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7H- pyrrolo[2,3-d]pyrimidine | 38 | 82 |
183 | 5-(5-fluoro-2-methoxyphenyl)-A/,/V-dimethyl-7/-/pyrrolo[2,3-d]pyrimidin-4-amine | 13 | 11 |
184 | 2-fluoro-3-[4-(pyrrolidin-1-yl)-7/7-pyrrolo[2,3-d]pyrimidin- 5-yl]benzonitrile | 15 | 82 |
185 | 5-(5-fluoro-2-methoxyphenyl)-4-[(3S)-3-fluoropyrrolidin- 1-yl]-7H-pyrrolo[2,3-d|pyrimidine | 15 | 23 |
186 | 2-fluoro-3-{4-[2-(5-methyl-1,2,4-oxadiazol-3yl)morpholin-4-yl]-7f/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile | 17 | 90 |
187 | 5-(4-methyl-1,3-thiazol-2-yl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d]pyrimidine | N.D. | N.D. |
188 | 5-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)-7/7pyrrolo^.S-c/Ipyrimidine, formate sait | 43 | 90 |
189 | 5-(2-fluoro-6-methoxyphenyl)-A/,A/-dimethyl-7/-/pyrrolo[2,3-d]pyrimidin-4-amine | 40 | 27 |
190 | 5-(2-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7/-/- pyrrolo[2,3-d]pyrimidine | 25 | 34 |
191 | 5-(2,6-difluorophenyl)-4-(morpholin-4-yl)-7A/-pyrrolo[2,3- djpyrimidine | N.D. | N.D. |
192 | 5-(3-methyl-1,2-thiazol-5-yl)-4-(morpholin-4-yl)-7/-/- pyrrolo[2,3-d|pyrimidine | 23 | 73 |
193 | 5-(2-chloro-3-fluoro-6-methoxyphenyl)-4-(morpholin-4- yl)-7H-pyrrolo[2,3-d]pyrimidine | 47 | 51 |
194 | 5-(4-methoxypyridin-3-yl)-4-(morpholin-4-yl)-7f/pyrrolo[2,3-d]pyrimidine, formate sait | N.D. | N.D. |
132
195 | 3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]- 7/7-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile, ENT-1 | 8 | 73 |
196 | 3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]- 7/-/-pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile, ENT-2 | N.D. | N.D. |
197 | 3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/7-pyrrolo[2,3- d]pyrinnidin-5-yl}benzonitrile, ENT-2 | 214 | 245 |
198 | 3-[6-(difluoromethyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 127 | 1080 |
199 | 5-(5,6-dihydro-2H-pyran-3-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-dlpyrimidine | 97.8b | 351b |
200 | 5-(3,4-dihydro-2/7-pyran-5-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-d]pyrimidine | 76.7b | 167b |
201 | 4-(morpholin-4-yl)-5-[3-(1,2,4-oxadiazol-3-yl)phenyl]- 7H-pyrrolo[2,3-d]pyrimidine | 129b | 475b |
202 | 3-{4-[2-(3-methyl-1,2-oxazol-5-yl)morpholin-4-yl]-7/-/- pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | 64.7 | 350 |
203 | 2-methyl-3-[4-(morpholin-4-yl)-7f/-pyrrolo[2,3- d]pyrimidin-5-yl]benzonitrile | 13.2 | 90.1 |
204 | 4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/|pyrimidin-5- yl]pyridin-2(1 /-/)-one | 11.7 | 32.7 |
205 | 5-(imidazo[2,1-b][1,3]thiazol-5-yl)-4-(morpholin-4-yl)-7/7- pyrrolo[2,3-d|pyrimidine | 15.8 | 60.5 |
206 | re/-3-{4-[(3aS,6aS)-hexahydro-5H-furo[2,3-c]pyrrol-5- yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile | 139 | 591 |
207 | re/-3-{4-[(3afî,6aS)-tetrahydro-1/7-furo[3,4-c]pyrrol- 5(3/-/)-yl]-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile | 223b | 687b |
208 | re/-3-{4-[(4a/?,7aS)-hexahydiOcyclopenta[b][1,4]oxazin- 4(4a/J)-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile | 27.2 | 186 |
209 | 4-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-d]pyrimidin-4- yl]morpholine-2-carbonitrile | 42.2 | 336 |
210 | 3-[4-(2,2-dimethylmorpholin-4-yl)-7H-pyrrolo[2,3- <yjpyrimidin-5-yl]benzonitrile | 35.2 | 304 |
211 | 5-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidin-5- yl]thiophene-2-carbonitrile | 21.9 | 118 |
133
212 | 5-(imidazo[1,2-£>]pyridazin-3-yl)-4-(morpholin-4-yl)-7H- pyrrolo[2,3-d|pyrimidine | 6.26 | 12.3 |
213 | 2-fluoro-3-(4-[2-(3-methyl-1,2,4-oxadiazol-5yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile, ENT-2 | 7.71 | 95.7 |
214 | 2-fluoro-3-{4-[2-(3-methyl-1,2,4-oxadiazol-5yl)morpholin-4-yl]-7/7-pyrrolo[2,3-c/|pyrimidin-5yljbenzonitrile, ENT-1 | N.D. | N.D. |
215 | 6-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5- yl]pyridine-2-carboxamide, formate sait | 30.6 | 79.3 |
216 | 4-(morpholin-4-yl)-5-(pyrazolo[1,5-a]pyrimidin-3-yl)-7/-/- pyrrolo[2,3-d|pyrimidine | 35.6 | 119 |
217 | 1-methyl-4-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3- d|pyrimidin-5-yl]-1H-pyrrole-2-carbonitrile | 6.37 | 13 |
218 | 5-(6-methylimidazo[2,1 -b][1,3]thiazol-5-yl)-4-(morpholin- 4-yl)-7/7-pyrrolo[2,3-d]pyrimidine, formate sait | 37.4b | 135b |
219 | 3-{4-[2-(1,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3- d]pyrimidin-5-yl}benzonitrile | 37 | 234 |
220 | 1-methyl-4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3c(]pyrimidin-5-yl]-1H-imidazole-2-carbonitrile, trifluoroacetate sait | 7.47 | 14.7 |
221 | 4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/|pyrimidin-5- yl]thiophene-2-carbonitrile | N.D. | N.D. |
222 | 4-(morpholin-4-yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-7H- pyrrolo[2,3-c(|pyrimidine | N.D. | N.D. |
223 | 1,5-dimethyl-4-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3c(|pyrimidin-5-yl]-1/7-pyrrole-2-carbonitrile | N.D. | N.D. |
224 | 1-methyl-3-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3cf|pyrimidin-5-yl]-1H-pyrazole-5-carbonitrile, trifluoroacetate sait | N.D. | N.D. |
225 | 3-{4-[2-(cyanomethyl)morpholin-4-yl]-7H-pyrrolo[2,3- c0pyrimidin-5-yl}benzonitrile | N.D. | N.D. |
* Géométrie mean of 2 - 5 déterminations unless otherwise indicated
a. ΙΟ50 value représente the géométrie mean of S6 déterminations.
b. IC50 value derived from a single détermination.
c. N.D. - not determined
K
134
Certain of the compounds of the présent invention were assessed for
kinase selectivity using a commercially available ActiveX targeted kinase probe in which the tissue employed was human peripheral blood mononuclear cells (PBMC). The test compounds were provided to ActivX Biosciences, Inc., 11025 North Torrey Pines Road, 5 Suite 120; LaJolla, CA, USA 92037. The compounds were run in the ActivX proprietary kinase assay and results were obtained at compound test concentrations of 1μΜ (columns 2, 4 and 6) and 0.1 μΜ (columns 3, 5 and 7). The results as percent inhibition obtained for the compounds of Examples 1,4 and 217 are provided below in Table 3.
TABLE 3
Example 1 Example 4 Example 217
Kinase | 1 μΜ | 0.1 μΜ | 1 μΜ | 0.1 μΜ | ΙμΜ | 0.1 μΜ |
ABL,ARG | 22.5 | 25.8 | -0.9 | -29.4 | -1.6 | 4.6 |
ACK | -8 | 5.2 | 7.7 | 0.8 | -19.5 | -9.8 |
AKT1 | 18.8 | 11.3 | -6.3 | -8.8 | -3.6 | 5.5 |
AKT2,AKT3 | 10.7 | 1.6 | 6.8 | -2.6 | -3.8 | -9.7 |
AMPKal | 27 | 1.5 | 16.4 | -2.1 | 48.8 | 27.2 |
AMPKal,AMPKa2 | 49.7 | 10.8 | 32.5 | -4.5 | 16.5 | 5.7 |
BRAF | -51.5 | -6.5 | -1.2 | 1.2 | -10.4 | -8.4 |
BTK | 3.7 | 8.7 | 9.5 | -2.2 | 8.5 | 24.3 |
CaMKla | 6.3 | 2 | 1.9 | -9.2 | -7.1 | -5.4 |
CaMKld | 3.2 | 8.4 | 0.9 | -12.1 | 3.1 | 11.7 |
CaMK2d | -38.1 | -45.3 | 10.8 | -0.4 | 16.1 | 9.8 |
CaMK2g | -15.5 | -16.9 | 2.9 | -13.6 | 18.7 | 4.3 |
CDC2 | 14.7 | -4 | 12.9 | -6.7 | 24.4 | 28.7 |
CDK11,CDK8 | 2.4 | 4.4 | 36 | 5 | -5.2 | -5.6 |
CDK2 | 9.5 | -12.1 | 9.2 | 11 | 16.5 | 3.6 |
CDK5 | -35.1 | -6.5 | 0.1 | -12.2 | 7.9 | 0.5 |
CHK2 | 17.7 | 0.9 | 2.2 | -6.8 | 6.4 | 8.6 |
DGKA | -16.6 | -21 | -8.7 | -15.9 | 4.7 | -2.8 |
DNAPK | -30 | -4.4 | 14.7 | -19.3 | 31.5 | 31.0 |
eEF2K | -6.5 | -9.6 | 2.8 | -27.1 | 2.2 | -12.1 |
EphAl | 19.6 | -9.5 | -2.5 | -17 | -16.1 | 11.1 |
Erk5 | -41.9 | -32.8 | -6.3 | -5 | -5.4 | -2.6 |
FAK | 20 | 18 | 11.1 | -8.9 | 17.4 | 8.1 |
FER | -17.9 | -7.3 | 1.6 | -26.4 | 16.3 | 5.2 |
FES | -0.9 | 4.3 | 6.9 | -9.2 | 6.2 | 8.4 |
FGR | 4.6 | 12.9 | 1.7 | -10.8 | -0.5 | -1.2 |
FRAP | -1.2 | -3.2 | 9.8 | -20.7 | 0.9 | 0.7 |
FYN | -10.1 | 6.7 | -9.1 | -1.9 | -6.8 | -2.1 |
FYN,SRC,YES | -56.3 | -24.1 | -8.8 | -22.8 | -1.4 | 18.4 |
135
GCK | -6.7 | 4.4 | 31.2 | 3.6 | 27.2 | -5.2 |
GCN2 | -25.1 | 0.1 | 0.6 | -13.6 | -3.1 | -7.7 |
GPRK6 | 23.7 | 8.9 | 10.9 | -3.9 | 3.6 | -0.8 |
GSK3A | -11.4 | -0.2 | 7.2 | -0.9 | 8.9 | 0.6 |
GSK3B | -5.2 | 2.4 | 6.7 | -3.7 | 12.4 | -4.3 |
HPK1 | -14.9 | -9.7 | 5.7 | -1.5 | 1.7 | -13.7 |
IKKa | -40.5 | -20 | -6.6 | -12.1 | -3.7 | -2.5 |
IKKb | 10.8 | 16.1 | -15.8 | -15.5 | 6.5 | 7.1 |
IKKe | 17.7 | 2.6 | 7.4 | -7 | 20.4 | -3.0 |
IKKe,TBKl | 23.7 | 1.5 | 18.8 | -6.7 | 13.3 | 2.3 |
ILK | -56.6 | -34 | -31.6 | -8.9 | -3.8 | -6.3 |
IRAK1 | -9.1 | -13.8 | 2.1 | -2.9 | 7.5 | -1.7 |
IRAK3 | 68.7 | 30.1 | 33.7 | 29.8 | 72.4 | 16.0 |
IRAK4 | 34.7 | 17.7 | 10.7 | -12.8 | 34.5 | 14.7 |
IRE1 | -8 | -1.3 | 1.8 | -16 | -19.5 | 3.2 |
JAK1 | 54.2 | 15 | 5 | -9.3 | 11.4 | -3.0 |
JAK1 domain2 | -13.7 | -8.1 | 18.9 | -6.2 | 10.1 | 7.4 |
JAK2 domain2 | 16.7 | 13.8 | 16.4 | 0.7 | -6.4 | 4.8 |
JAK3 domain2 | -5.2 | 2.7 | 6.8 | 6.9 | 4.9 | -7.8 |
JNK1,JNK2,JNK3 | 7.7 | 7.1 | 5.4 | -5.3 | -6.4 | -18.2 |
KHS1 | 24.6 | 17.8 | 12.9 | -25.9 | 7.6 | 10.7 |
KSR1,KSR2 | -14 | 1.5 | 11.7 | -8.7 | -6.8 | -6.2 |
LATS1 | -16.2 | 4.2 | 5.4 | -4.8 | 1.9 | -3.9 |
LATS2 | 11 | 21.2 | 16.2 | -7.2 | -23.7 | 5.8 |
LKB1 | -14 | -1.1 | 16.5 | 3.5 | 2.4 | -5.3 |
LOK | 22.6 | 5.7 | 53.6 | 11.9 | 56.1 | -6.4 |
LRRK2 | 88.1 | 69 | 94.1 | 79.9 | 88.4 | |
LYN | 7.8 | 3.8 | 0.8 | -5.4 | -19.2 | 8.3 |
MAP2K1 | 17 | 3.5 | 14 | -17.2 | -1.5 | 17.2 |
MAP2K1,MAP2K2 | -2.2 | 1 | 6.4 | -7.1 | -2.6 | 10.9 |
MAP2K3 | -9 | 14.4 | 6.2 | -12.5 | 3.3 | 2.5 |
MAP2K4 | 9.6 | 10.1 | 19.2 | -20.5 | 1.6 | 2.3 |
MAP2K6 | 19 | 17.5 | 13.5 | -15.1 | -0.1 | 11.3 |
MAP3K1 | 11.9 | -9.4 | 44.5 | 6.4 | 14.8 | -17.3 |
MAP3K3 | 7.2 | -9.2 | 7.4 | -0.5 | -6.7 | -3.4 |
MAP3K4 | 6.9 | -14 | 29.8 | 9.7 | -27.4 | -35.5 |
MAP3K5 | 2.1 | 6.2 | 21.3 | 3.3 | 44.5 | 7.0 |
MARK2 | 41.6 | 10.1 | 27.3 | -4.7 | 13.1 | -5.0 |
MARK3 | 29.1 | 1 | 23.7 | -2.6 | 18.4 | 16.2 |
MAST3 | -6.7 | 9 | 0.8 | 2.6 | 0.4 | -11.7 |
MLK3 | 4.5 | 1.4 | 19.9 | -14.1 | -9.6 | -13.5 |
MLKL | 8.4 | 1.6 | 14.5 | -10.1 | -3.3 | 2.5 |
MSK1 domainl | -30.4 | -7 | -3.8 | 1 | -2.2 | -12.1 |
136
MST1 | 50.8 | 13.2 | 82.2 | 41.9 | 73.5 | 25.6 |
MST1,MST2 | 24.8 | -14.5 | 70.8 | 34.4 | 72.6 | 21.9 |
MST2 | 49.4 | 10.1 | 82.6 | 47.3 | 83.2 | 34.9 |
MST3 | 28.4 | 10.9 | 46.2 | 0.1 | 10.9 | 6.7 |
MST4,YSK1 | 15.1 | -11.4 | 60.7 | 11.9 | 9.9 | 5.3 |
NDR1 | -7.8 | -19.6 | 1.7 | -4.4 | -17.7 | 16.3 |
NDR2 | 31.2 | 22.8 | 22.1 | -18.7 | -6.0 | 28.9 |
NEK1 | -10.1 | 7 | -1.9 | -8.9 | -5.1 | 4.8 |
NEK6,NEK7 | -17 | -1.7 | -4.9 | -5.3 | 6.4 | -2.9 |
NEK7 | -18.8 | -0.6 | 7.3 | 2.2 | -2.3 | -9.0 |
NEK9 | 12.6 | -0.9 | 1 | -7.1 | 1.5 | -11.0 |
NuaK2 | 8.9 | 3.6 | 18.1 | -11.9 | 24.9 | 1.3 |
0SR1 | -4 | -7.8 | -55.4 | -23.1 | -12.3 | 5.2 |
p38a | -19.8 | -23.5 | -1.7 | -14.6 | -4.6 | -1.1 |
p38d,p38g | -24 | -37.3 | -5.7 | -17.5 | 1.5 | -0.4 |
p70S6K | 18.9 | 23 | 11.1 | -9 | -9.6 | 3.5 |
p70S6K,p70S6Kb | -3.5 | 9.4 | -9.6 | -10.5 | 5.4 | 5.5 |
p70S6Kb | 10.1 | 15 | 18.5 | 11.4 | -16.7 | -2.2 |
PAN3 | 0.8 | 0.6 | 15.1 | -0.2 | -7.5 | 5.6 |
PCTAIRE2,PCTAIRE3 | -2.5 | 7.5 | 24.7 | -5.4 | 15.1 | -2.6 |
PI4KB | 16.1 | 34 | 4.9 | -7.4 | -0.5 | 9.9 |
PIK3C3 | 4.8 | 23.3 | 13.6 | -2.4 | 10.2 | 19.9 |
PIK3CB | -29.8 | -2.6 | -2.5 | 0.5 | -29.7 | -5.3 |
PIK3CD | -65.4 | -101.6 | -12.4 | -14 | 10.0 | -0.4 |
PIK3CG | -62.9 | -18.6 | -5.6 | -20.4 | -22.0 | -3.4 |
PIP4K2A | 6.8 | 12.1 | 1.9 | -12.1 | 8.2 | 7.8 |
PIP4K2C | -1.4 | 1.4 | 58.4 | 3.1 | -11.9 | 6.2 |
PIP4K2C | 0.9 | -48 | 54.3 | 9.3 | 4.0 | -4.7 |
PIP5K3 | 15 | 1.9 | 21.6 | -11.2 | 2.5 | 16.0 |
PITSLRE | -3.2 | -13 | 10.7 | -12.4 | 6.6 | -6.7 |
PKD2 | 20.1 | 2.7 | 9.4 | 0.7 | 4.5 | 5.8 |
PKR | -17.3 | -4.3 | 7.2 | -3.3 | 1.8 | -7.7 |
PRPK | -13.8 | -3.4 | -3.7 | 3 | 12.5 | 2.6 |
PYK2 | 19.5 | 5.9 | 2.5 | -3.9 | 8.4 | -1.0 |
RIPK3 | -4.2 | 5.6 | 8 | -3.2 | -9.1 | -7.3 |
RSK1 domainl | 59.8 | 16.3 | 32.9 | -26.8 | 45.6 | 27.6 |
RSK1 domain2 | 18.1 | -12.7 | 55.8 | 2.7 | 5.0 | -3.4 |
RSK1,RSK2,RSK3 domainl | 18.7 | 3 | 13.4 | -0.4 | 48.5 | 5.0 |
RSK2 domainl | 5.6 | -6.8 | -11.2 | -6 | 61.6 | 13.2 |
RSK2 domain2 | 9.1 | 0.6 | 21.4 | -10 | 2.8 | -4.1 |
RSKL1 domainl | -0.2 | 5.5 | -1.8 | 1.1 | -30.6 | -15.9 |
SGK3 | 9.9 | 2.5 | -0.8 | -5.5 | 16.9 | 8.5 |
SLK | 50.6 | 22.9 | 60.7 | 10.5 | 39.1 | 22.5 |
137
SMG1 | -19.2 | -1.3 | 13 | -2.5 | -6.1 | 1.5 |
smMLCK | -1.9 | -11.5 | 16.2 | -21.6 | 3.5 | 1.7 |
SRC | 9.7 | 1.5 | -2.2 | -18.3 | 1.1 | -1.0 |
STLK5 | -46.5 | -1.5 | 1.2 | -15.4 | -11.5 | -6.9 |
SYK | -6.1 | -8.9 | 7.2 | -8.3 | -5.1 | -2.0 |
ΤΑ01/ΓΑ03 | -14.9 | -24 | 5.9 | -6.5 | -16.5 | -9.7 |
TA02 | -24.2 | -6.3 | -2.5 | -12.7 | -18.4 | -20.2 |
TBK1 | 13.4 | 0.1 | 16.4 | 7.3 | 0.1 | 1.9 |
TLK1 | 2.7 | 7.8 | -3.7 | -4.6 | 16.7 | 7.6 |
TLK2 | -21.1 | -5.8 | -9.4 | -8.4 | 16.0 | 11.1 |
ULK3 | 8 | -1.9 | 5.2 | 3.1 | 17.4 | -8.6 |
Wnkl,Wnk2,Wnk3 | -24 | -18.8 | -6 | 1.7 | -21.1 | -6.3 |
Wnkl,Wnk2,Wnk4 | -13.5 | -15 | -1.3 | -1.9 | -5.4 | 2.2 |
ZAK | 23.1 | 15 | -42.2 | -20.5 | -1.2 | -2.9 |
ZAP70 | 3.1 | -23.2 | 6.8 | -4.9 | -6.0 | -25.0 |
ZC1/HG K,ZC2/TN I K,ZC3/M IN K | 4.9 | -18 | 14.8 | -3.2 | 7.7 | -1.2 |
ZC2/TNIK | 31.2 | -10.6 | 29.2 | -7.9 | 3.9 | -10.7 |
Claims (5)
1-methyl-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidin-5-yl]-1/-/-pyrazole-5carbonitrile; and
1,5-dimethyl-4-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]-1/-/-pyrrole-2carbonitrile;
1-methyl-4-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]-1/-/-imidazole-2carbonitrile;
1-methyl-4-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]-1/-/-pyrrole-2-carbonitrile;
5- (6-methylimidazo[2,1 - b][1,3]thiazol-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3djpyrimidine;
1 -[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrirnidin-4-yl]piperidin-3-ol;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidine;
1- [5-(2-methoxyphenyl)-7/-/-pyrrolo[2,3-c(]pyrimidin-4-yl]piperidin-3-ol;
1-[5-(3-fluoro-5-methoxyphenyl)-7/-/-pyrrolo[2,3-c/]pyrimidin-4-yl]piperidin-3-ol;
1-[5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-c(]pyrimidine;
1- [5-(3-fluorophenyl)-7/7-pyrrolo[2,3-c/|pyrimidin-4-yl]piperidin-3-ol;
5-(5-fluoro-2-methoxyphenyl)-4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/pyrrolo[2,3-d]pyrimidine;
1-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-c/|pyrimidin-4-yl]piperidine-3-carboxamide;
1 -[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]piperidin-3-ol;
/\/-{1-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-c/]pyrimidin-4-yl]piperidin-4-yl}acetamide;
5-(1/-/-indazol-5-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidine;
1-[5-(3-cyanophenyl)-7/7-pyrrolo[2,3-c7]pyrimidin-4-yl]piperidine-3-carbonitrile;
1-{5-[3-(hydroxymethyl)phenyl]-7/-/-pyrrolo[2,3-d]pyrimidin-4-yl}piperidine-3-carbonitrile;
[1-(5-phenyl-7/-/-pyrrolo[2,3-c/|pyrimidin-4-yl)piperidin-4-yl]methanol;
1-(5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-3-carboxamide;
1. A compound of Formula I
5 or a pharmaceutically acceptable sait thereof wherein
R1 and R2 are each independently hydrogen, Ci-Cealkyl, C3-C7cycloalkyl, a four to seven membered heterocycloalkyl which contains one to three heteroatoms selected from N, O and S; or a five to six membered heteroaryl which contains one to four heteroatoms selected from N, O and S, wherein the CrCealkyl, C3-C7cycloalkyl, four to 10 seven membered heterocycloalkyl, or five to six membered heteroaryl are optionally substituted with one to three R6;
or R1 and R2 taken together with the nitrogen to which they are attached are a four to seven membered heterocycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S, and optionally contains one double 15 bond; a six to eleven membered heterobicycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; or a six to twelve membered heterospirocycloalkyl which optionally contains one to two additional heteroatoms selected from N, O and S; and wherein the four to seven membered heterocycloalkyl, six to eleven membered heterobicycloalkyl or six to twelve membered 20 heterospirocycloalkyl is optionally substituted with one to three R7;
R3 is phenyl or a five to ten membered heteroaryl which contains one to four heteroatoms selected from N, O and S; wherein the phenyl and five to ten membered heteroaryl are optionally substituted with one to three R9 and wherein the phenyl is optionally fused with a Cs-Cecycloalkyl or a five to six membered heterocycloalkyl which 25 contains one to three heteroatoms selected from N, O and S and which is optionally substituted with oxo;
R4 and R5 are each independently hydrogen or CrC3alkyl;
139
R6 at each occurrence is independently selected from Ci-C3alkyl, CrCsalkoxy, hydroxy, halo, -NRaRb, -C(O)NRaRb, or a four to seven membered heterocycloalkyl which contains one to three heteroatoms selected from N, O and S;
R7 at each occurrence is independently selected from halo, hydroxy, cyano, NRaRb, -C(O)NRaRb, Ci-Cealkyl, CrCealkoxy, phenyl, a five to six membered heteroaryl containing one to four heteroatoms selected from N, O and S, or two R7 when attached to the same carbon and taken together can be oxo; wherein the CrC6alkyl, phenyl and five to six membered heteroaryl are optionally substituted with one to three R8;
R8 at each occurrence is independently hydroxy, halo, cyano, CpCaalkoxy, NRaRb, CrCsalkyl optionally substituted with one to three halo, C3-C7cycloalkyl, phenoxy optionally substituted with cyano, or a five to six membered heteroaryloxy containing one to four heteroatoms selected from N, O and S and which is optionally substituted with one or two halo or CrCsalkyl;
R9 at each occurrence is independently cyano, halo, hydroxy, CrC3alkyl-S-, CO2H, -C(O)NH2, -S(O)2NH2, CrCsalkyl optionally substituted with one to three halo or hydroxy, or CrC3alkoxy optionally substituted with one to three halo or hydroxy; and
Ra and Rb at each occurrence are each independently hydrogen, CrC6alkyl, C3C7cycloalkyl or-C(O)CrC6alkyl.
2- fluoro-3-{4-[2(S)-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3d|pyrimidin-5-yl}benzonitrile;
6- [4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]pyridine-2-carboxamide;
2-fluoro-3-{4-[2(R)-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7/7-pyrrolo[2,3c(|pyrimidin-5-yl}benzonitrile;
2-methyl-3-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
2- fluoro-3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/7-pyrrolo[2,3-
d]pyrimidin-5-yl}benzonitrile;
5-(3-methyl-1,2-thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine; and
2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-i/|pyrimidin-5-yl}benzonitrile;
2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
2-fluoro-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl]benzonitrile;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
2- fluoro-3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3c/]pyrimidin-5-yl}benzonitrile;
5-(4-methyl-1,3-thiazol-2-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(4-methylpyridin-2-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine;
5-(2-fluoro-6-methoxyphenyl)-/V,/V-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
5-(2-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(]pyrimidine;
5-(2,6-difluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidine;
5-(3-methyl-1,2-thiazol-5-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(|pyrimidine;
5-(2-chloro-3-fluoro-6-methoxyphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidine;
5-(4-methoxypyridin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidine;
2-fluoro-3-[4-(pyrrolidin-1-yl)-7/7-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(3S)-3-fluoropyrrolidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidine;
2-fluoro-3-{4-[(2S)-2-methylmorpholin-4-yl]-7/7-pyrrolo[2,3-c(|pyrimidin-5-yl}benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-(3-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
5-(3-fluorophenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidine;
5-(5-fluoro-2-methoxyphenyl)-/V,/V-dimethyl-7/-/-pyrrolo[2,3-c/]pyrimidin-4-amine;
2-fluoro-3-[4-(3-hydroxypiperidin-1-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
5-(5-fluoro-2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/7-pyrrolo[2,3c/]pyrimidine;
2-fluoro-3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile;
2-fluoro-3-{4-[2-(methoxymethyl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/|pyrinnidin-5yljbenzonitrile;
2- fluoro-3-{4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3ûf]pyrimidin-5-yl}benzonitrile;
2- fluoro-3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile;
2- fluoro-3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
{2-fluoro-3-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]phenyl}methanol;
5-(2,4-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidine;
5-(3-fluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(3,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(]pyrimidine;
2-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c0pyrimidin-5-yl]benzonitrile;
5- (3-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidine;
5-(2-fluorophenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidine;
5-(3-fluoro-5-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-cflpyrimidine;
5-(2,5-difluorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(2,3-difluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(5-chloro-2-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-cdpyrimidine;
2- fluoro-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
2- fluoro-3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
A/,/V-dimethyl-5-phenyl-7/-/-pyrrolo[2,3-d]pyrimidin-4-amine;
2. The compound of claim 1 wherein R4 and R5 are each hydrogen; or a pharmaceutically acceptable sait thereof.
3-{4-[2-(cyanomethyl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile;
or a pharmaceutically acceptable sait thereof.
17. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 16, or a pharmaceutically acceptable sait thereof together with a pharmaceutically acceptable carrier.
152
18. Use of a compound or pharmaceutically acceptable sait thereof according to any one of claims 1 to 16 in the manufacturer of a pharmaceutical composition for treating Parkinson’s disease in a patient.
3- {4-[2-(1,2-oxazol-5-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3- [4-(2,2-dimethylmorpholin-4-yl)-7H-pyrrolo[2,3-<^pyrimidin-5-yl]benzonitrile;
5- [4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]thiophene-2-carbonitrile;
5- (imidazo[1,2-b]pyridazin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
3- {4-[2-(3-methyl-1,2-oxazol-5-yl)morpholin-4-yl]-7/7-pyrrolo[2,3-c/|pyrimidin-5yljbenzonitrile;
3- [6-(difluoromethyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
5-(5,6-dihydro-2/-/-pyran-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidine;
5-(3,4-dihydro-2/-/-pyran-5-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine;
3- {4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yl}benzonitrile;
or a pharmaceutically acceptable sait thereof.
16. A compound according to claim 1 selected from the group consisting of:
3-[4-(piperidin-1 -yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3- {4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile;
3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]pyridine-2-carbonitrile;
3-{4-[(2S)-2-(methoxymethyl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5yljbenzonitrile;
or a pharmaceutically acceptable sait thereof.
15. A compound according to claim 1 selected from the group consisting of:
5- (1-methyl-1/-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(|pyrimidine;
3-{4-[2-((5S)-5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5yljbenzonitrile;
3- {4-[2-((5fî)-5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c(|pyrimidin-5yljbenzonitrile;
3- [4-(4l4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-ûf]pyrimidin-5-yl]-2-fluorobenzonitrile;
3- {4-[(3R)-3-hydroxypiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-{4-[(3S)-3-methylmorpholin-4-yl]-7H-pyrrolo[2,3-c(]pynmidin-5-yl}benzonitrile;
3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]-5-methoxybenzonitrile;
148
5-(1 -ethyl-1 H-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
5-(5-methylpyridin-3-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidine;
5-(5-chloropyridin-3-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
5-(6-methoxypyrazin-2-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(1,3-dimethyl-1H-pyrazol-4-yl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
3-{4-[3-(5-methyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5yljbenzonitrile;
3-(4-{2-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-
d]pyrimidin-5-yl)benzonitrile;
3-[4-(1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d|pyrirnidin-5-yl]benzonitrile;
3-(4-{2-[(dimethylamino)methyl]morpholin-4-yl}-7H-pyrrolo[2,3-i/]pyrimidin-5yl)benzonitrile;
3-{4-[2-(pyrimidin-4-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile; 3-{4-[2-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5yljbenzonitrile;
3-[4-(2-ethylmorpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(3-hydroxypiperidin-1-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3-(4-{2-[(3-cyanophenoxy)methyl]morpholin-4-yl}-7/-/-pyrrolo[2,3-c/]pyrimidin-5yl)benzonitrile;
3-[4-(3,3-difluoropyrrolidin-1-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-{4-[2-(3-hydroxyphenyl)morpholin-4-yl]-7H-pyrrolo[2,3-d|pyrimidin-5-yl}benzonitrile; 3-{4-[2-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c(]pyrimidin-5yljbenzonitrile;
3-{4-[4-fluoro-4-(hydroxymethyl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5yljbenzonitrile;
3-[4-(4-oxopiperidin-1-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-{4-[2-(1,3-thiazol-2-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-[4-(2-{[5-(difluoromethyl)-1,2,4-oxadiazol-3-yl]methyl}morpholin-4-yl)-7/-/-pyrrolo[2,3c(]pyrimidin-5-yl]benzonitrile;
3-[4-(3-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(3,3-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-c/|pyrimidin-5-yl]benzonitrile;
3- methoxy-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
5-(1 -methyl-1 /-/-pyrazol-4-yl)-4-(thiomorpholin-4-yl)-7/7-pyrrolo[2,3-d]pyrimidine;
3- chloro-5-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(6-oxa-3-azabicyclo[3.1.1]hept-3-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-{4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
3-methyl-5-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-{4-[2-(3-methyl-1,2,4-oxadiazol-5-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5yljbenzonitrile;
3-[4-(4-hydroxypiperidin-1-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl]benzonitrile;
3- {4-[(2/:?)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile;
3-[4-((3S)-3-methylpyrrolidin-1-yl)-7H-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-{4-[2-(1/-/-pyrazol-3-yl)morpholin-4-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]-5-fluorobenzonitrile;
3-{4-[(2/?)-2-(methoxymethyl)morpholin-4-yl]-7/7-pyrrolo[2,3-c/]pyrimidin-5yl}benzonitrile;
3-[4-(diethylamino)-7/7-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(dimethylamino)-7H-pyrrolo[2,3-ûf]pyrimidin-5-yl]-4-fluorobenzonitrile;
3-[4-((3fî)-3-methylpyrrolidin-1-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-[4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3- [4-(dimethylamino)-7H-pyrrolo[2,3-ûflpyrimidin-5-yl]-2-fluorobenzonitrile;
3- [4-(3,5-c/s-dimethylpiperidin-1 -yl)-7/7-pyrrolo[2,3-c(]pyrimidin-5-yl]-4methoxybenzonitrile;
3-[4-(methylamino)-7H-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzoic acid;
3-[4-(4-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
145
3-[4-(3-fluoropiperidin-1-yl)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzamide;
3-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}phenol;
5- (2-chloro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3cflpyrimidine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzenesulfonamide;
5-(2-fluorophenyl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrinnidine;
5-(1H-indazol-4-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3-c/|pyrimidine;
5-(6-fluoro-5-methylpyridin-3-yl)-4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3c/]pyrimidine;
5- {4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}-2,3-dihydro-1/-/isoindol-1-one;
3-[4-(2-oxa-7-azaspiro[4.5]dec-7-yl)-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-(4-{[2-(morpholin-4-yl)ethyl]amino}-7/7-pyrrolo[2,3-G(lpyrimidin-5-yl)benzonitrile;
3-[4-((3fî)-3-methylpiperidin-1-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-[4-(3-oxo-2,7-diazaspiro[4.5]dec-7-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-{4-[(1-methylpiperidin-3-yl)amino]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}benzonitrile;
3-{4-[3-(1/-/-imidazol-2-yl)piperidin-1-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3-{4-[3-(1H-pyrazol-3-yl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3-{4-[2-(1/7-pyrazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3-{4-[(3S)-3-fluoropyrrolidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
3-{4-[4-(1/-/-pyrazol-3-yl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c(]pyrimidin-5-yl}benzonitrile;
144
3-[4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-a(]pyrimidin-5-yl]benzonitrile;
3-[4-(4,4-difluoropiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
3-{4-[2-(methoxymethyl)morpholin-4-yl]-7H-pyrrolo[2,3-c7]pyrimidin-5-yl}benzonitrile; /V3-[5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-d]pyrimidin-4-yl]-A/,A/-dimethyl-beta-alaninamide;
3-[4-(3-methoxypiperidin-1-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3-[4-(9-methyl-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)-7/-/-pyrrolo[2,3-c(]pyrimidin-5yljbenzonitrile;
3-{4-[3-(methoxymethyl)piperidin-1-yl]-7H-pyrrolo[2,3-c(|pyrimidin-5-yl}benzonitrile;
3-{4-[4-(1/-/-imidazol-2-yl)piperidin-1-yl]-7/-/-pyrrolo[2,3-c(]pynmidin-5-yl}benzonitrile;
3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]-4-methoxybenzonitnle;
5- (5-chloro-2-methoxyphenyl)-/V,/V-dimethyl-7/-/-pyrrolo[2,3-c/]pyrimidin-4-amine;
3- {4-[(3S)-3-methylpiperidin-1-yl]-7H-pyrrolo[2,3-cflpyrimidin-5-yl}benzonitrile;
3- {4-[(3S)-3-hydroxypiperidin-1-yl]-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl}benzonitrile;
3-[4-(piperidin-1-yl)-7H-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
3-[4-(3,3-dimethylpiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
{3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-c/]pyrimidin-5-yl]phenyl}methanol;
3-[2-methyl-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
(3-{4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3-c/]pynmidin-5-yl}phenyl)methanol;
3- {4-[(2S)-2-methylmorpholin-4-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5-yl}benzonitrile;
3-[4-(dimethylamino)-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]benzonitrile;
3-[4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
3. The compound of claim 2 wherein R1 and R2 taken together with the nitrogen to which they are attached are azetidin-1-yl, pyrrolidin-1-yl, piperidin-1 -yl, morpholin-4-yl, thiomorpholin-4-yl, 6-oxa-3-aza-bicyclo[3.1.1]heptan-3-yl,
HN each of which is optionally substituted with one to three R7; or a pharmaceutically acceptable sait thereof.
140
4-(morpholin-4-yl)-5-(pyrazolo[1,5-a]pyridin-3-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
4- [4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]thiophene-2-carbonitrile;
4- (morpholin-4-yl)-5-(pyrazolo[1,5-a]pyrimidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine;
4- [5-(3-cyanophenyl)-7/-/-pyrrolo[2,3-d]pyrimidin-4-yl]morpholine-2-carbonitrile;
4- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]pyridin-2(1/7)-one;
5- (imidazo[2,1 - d] [ 1,3]thiazol-5-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine; re/-3-{4-[(3aS,6aS)-hexahydro-5/-/-furo[2,3-c]pyrrol-5-yl]-7H-pyrrolo[2,3-c/]pyrimidin-5yl}benzonitrile;
re/-3-{4-[(3afî,6aS)-tetrahydro-1H-furo[3,4-c]pyrrol-5(3/-/)-yl]-7/-/-pyrrolo[2,3-G(]pyrimidin-
5-yl}benzonitrile;
151 re/-3-{4-[(4a/?,7aS)-hexahydrocyclopenta[b][1,4]oxazin-4(4aH)-yl]-7/-/-pyrrolo[2,3-
d]pyrimidin-5-yl}benzonitrile;
4- (morpholin-4-yl)-5-[3-(1,2,4-oxadiazol-3-yl)phenyl]-7H-pyrrolo[2,3-c/|pyrimidine;
4- (morpholin-4-yl)-5-(1/-/-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
150
4- [(3S)-3-fluoropyrrolidin-1-yl]-5-(2-methoxyphenyl)-7/7-pyrrolo[2,3-c(|pyrimidine;
5- (2-methoxyphenyl)-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine;
149
5-(3-fluoro-5-methoxyphenyl)-A/,/V-dimethyl-7H-pyrrolo[2,3-d|pyrimidin-4-amine;
4- [(2S)-2-methylmorpholin-4-yl]-5-(5-methylpyridin-3-yl)-7/-/-pyrrolo[2,3-c(]pyrinnidine;
5- (3-fluorophenyl)-4-(pyrrolidin-1-yl)-7/-/-pyrrolo[2,3-c(]pyrimidine;
5-(3-fluorophenyl)-4-[2-(5-methyl-1,2,4-oxadiazol-3-yl)morpholin-4-yl]-7/-/-pyrrolo[2,3c/]pyrimidine;
5-(2-methoxyphenyl)-4-[(2S)-2-methylmorpholin-4-yl]-7/-/-pyrrolo[2,3-c/]pyrimidine;
5-(2-methoxyphenyl)-A/,A/-dimethyl-7H-pyrrolo[2,3-c(|pyriiTiidin-4-amine;
4- (azetidin-1-yl)-5-(5-fluoro-2-methoxyphenyl)-7/-/-pyrrolo[2,3-d]pyrimidine;
4- (4-fluoropiperidin-1-yl)-5-(2-methoxyphenyl)-7/+pyrrolo[2,3-cf]pyrimidine;
5- (3-fluoro-5-methoxyphenyl)-4-(4-fluoropiperidin-1-yl)-7H-pyrrolo[2,3-c(]pyrimidine;
4-(3-fluoropiperidin-1 -y 1)-5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
147 {4-[5-(1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]morpholin-2- yljmethanol;
5-(1-methyl-1/7-pyrazol-4-yl)-4-(2-{[(6-methylpyridin-3-yl)oxy]methyl}morpholin-4-yl)-7/-/pyrrolo[2,3-c/]pyrimidine;
/V,A/-dimethyl-5-(1 -methyl-1 /-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-4-amine;
/V-cyclopropyl-/V-methyl-5-(1 -methyl-1 H-pyrazol-4-yl)-7/7-pyrrolo[2,3-d]pyrimidin-4amine;
4-[(2/7)-2-methylmorpholin-4-yl]-5-(1-methyl-1/-/-pyrazol-4-yl)-7/-/-pyrrolo[2,3djpyrimidine;
4- [(2S)-2-methylmorpholin-4-yl]-5-(1 -methyl-1 /7-pyrazol-4-yl)-7H-pyrrolo[2,3djpyrimidine;
4- methoxy-3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/]pyrimidin-5-yl]benzonitrile;
5- (5-chloro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
6- methyl-5-(1-methyl-1/7-pyrazol-4-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c/]pyrimidine;
4- [4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]isoquinoline;
5- (5-bromopyridin-3-yl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(|pyrimidine;
5-(2-chloro-5-methylphenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c(|pyrimidine; 5-(3-methylphenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(|pyrimidine;
5-(1-methyl-1 H-pyrazol-3-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
4-(morpholin-4-yl)-5-(pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine;
4-(morpholin-4-yl)-5-phenyl-7H-pyrrolo[2,3-c/]pyrimidine;
146
5-(5-fluoro-2-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine;
5-(2-chlorophenyl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5-(5-fluoro-2-methylphenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-c(|pyrimidine;
5-(3-methoxyphenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidine; {2-fluoro-5-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-cf|pyrimidin-5-yl]phenyl}methanol;
5-(4-fluorophenyl)-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidine; {3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d|pyrimidin-5-yl]phenyl}methanol;
5-(2-methoxyphenyl)-4-(morpholin-4-yl)-7/7-pyrrolo[2,3-G(]pyrimidine;
5-[3-(methylsulfanyl)phenyl]-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c/]pyrimidine;
4- (4-fluoropiperidin-1 -y 1)-5-( 1 -methyl-1 /7-pyrazol-4-yl)-7/7-pyrrolo[2,3-d]pyrimidine;
4- fluoro-3-[4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-c(|pyrimidin-5-yl]benzonitrile;
4- methoxy-3-{4-[(3S)-3-methylpiperidin-1-yl]-7/7-pyrrolo[2,3-d]pyrimidin-5-yl}benzonitrile;
4- {4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/lpyrimidin-5-yl}benzamide;
4-{4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl}phenol;
4-[(3S)-3-methylpiperidin-1-yl]-5-(1/-/-pyrrolo[3,2-b]pyridin-6-yl)-7/7-pyrrolo[2,3djpyrimidine;
4-[(3S)-3-methylpiperidin-1-yl]-5-(7/-/-pyrrolo[2,3-b]pyridin-5-yl)-7H-pyrrolo[2,3cflpyrimidine;
6- {4-[(3S)-3-methylpiperidin-1-yl]-7/-/-pyrrolo[2,3-c/|pyrimidin-5-yl}-2,3-dihydro-1/-/isoindol-1-one;
4-[(3S)-3-methylpiperidin-1-yl]-5-(5-methylpyridin-3-yl)-7H-pyrrolo[2,3-c/]pyrimidine;
4- [(3S)-3-methylpiperidin-1-yl]-5-(pyridin-3-yl)-7/-/-pyrrolo[2,3-c/|pyrimidine;
4- methoxy-3-[4-(3-methylpiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
4-(3,5-c/s-dimethylpiperidin-1 -y 1)-5-( 1 -methyl-1 H-pyrazol-4-yl)-7/-/-pyrrolo[2,3c/Jpyrimidine;
4- [(3S)-3-methylpiperidin-1 -yl]-5-( 1 -methyl-1 H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine;
5- phenyl-4-(pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pynmidine;
4- [(3S)-3-methylpiperidin-1-yl]-5-phenyl-7/7-pyrrolo[2,3-d]pyrimidine;
4- (morpholin-4-yl)-5-(1H-pyrazol-4-yl)-7/-/-pyrrolo[2,3-i/|pyrimidine;
4. The compound of claim 3 wherein R1 and R2 taken together with the nitrogen to which they are attached are piperidin-1 -yl or morpholin-4-yl; each optionally substituted with a hydroxy, methyl or 5-methyl-1,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable sait thereof.
5. The compound of claim 4 wherein R1 and R2 taken together with the nitrogen to which they are attached are morpholin-4-yl optionally substituted with a methyl or 5methyl-1,2,4-oxadiazol-3-yl; or a pharmaceutically acceptable sait thereof.
6. The compound of claim 2 wherein R1 and R2 taken together with the nitrogen to which they are attached are methylamino, dimethylamino, diethylamino, Nmethylcyclopropylamino or pyrazolylamino; each of which is optionally substituted with one to three R6; or a pharmaceutically acceptable sait thereof.
7. The compound of claim 3 wherein R3 is phenyl substituted with one or two R9; and each R9 is independently selected from cyano, fluoro, chloro or methoxy; or a pharmaceutically acceptable sait thereof.
8. The compound of claim 3 wherein R3 is pyrazolyl, isothiazolyl, or pyridinyl, each optionally substituted with one R9; and R9 is cyano or methyl; or a pharmaceutically acceptable sait thereof.
9. The compound of claim 1 wherein
R1 and R2 taken together with the nitrogen to which they are attached is selected from the group consisting of:
141
OH
R3 is 1-methylpyrazol-4-yl, 1 H-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1,2thiazol-5-yl, 5-cyano-1-methylpyrrol-3-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2fluorophenyl, 3-fluorophenyl, 2,3-difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-35 cyanophenyl or 2-methoxy-5-fluorophenyl; and
R4 and R5 are each independently hydrogen or methyl;
or a pharmaceutically acceptable sait thereof.
10. The compound of claim 9 wherein R1 and R2 taken together with the nitrogen to
10 which they are attached are a group selected from
142 and R4 and R5 are each hydrogen; or a pharmaceutically acceptable sait thereof.
11. The compound of claim 10 wherein R1 and R2 taken together with the nitrogen to which they are attached is or a pharmaceutically acceptable sait thereof.
12. The compound of claim 11 wherein
R3 is 3-cyanophenyl, 1 -methylpyrazol-4-yl or 5-cyano-1 -methylpyrrol-3-yl; or a pharmaceutically acceptable sait thereof.
13. The compound of claim 1 wherein
R1 and R2 taken together with the nitrogen to which they are attached are piperidinyl or 3-hydroxypiperidinyl;
R3 is 1-methylpyrazol-4-yl, 1/-/-pyrazol-4-yl, 2-cyanopyridin-6-yl, 3-methyl-1,2thiazol-5-yl, 3-methylpyridin-5-yl, 3-cyanophenyl, 2-fluorophenyl, 3-fluorophenyl, 2,3difluorophenyl, 2-fluoro-5-chlorophenyl, 2-fluoro-3-cyanophenyl or 2-methoxy-5fluorophenyl; and
R4 and R5 are each independently hydrogen or methyl;
or a pharmaceutically acceptable sait thereof.
14. A compound according to claim 1 selected from the group consisting of:
5- (1-methyl-1/-/-pyrazol-4-yl)-4-(morpholin-4-yl)-7H-pyrrolo[2,3-c/|pyrimidine; 3-[6-methyl-4-(morpholin-4-yl)-7/-/-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile;
6- [4-(morpholin-4-yl)-7/7-pyrrolo[2,3-dJpyrimidin-5-yl]pyridine-2-carbonitrile;
143
5 19. The compound or pharmaceutically acceptable sait thereof according to any one of claims 1 to 16 for use in the treatment of Parkinson’s disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/666,299 | 2012-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA17357A true OA17357A (en) | 2016-09-21 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9642855B2 (en) | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | |
EP3083618B1 (en) | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors | |
EP3350178B1 (en) | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors | |
WO2016042775A1 (en) | Tricyclic derivative | |
EP3592740B1 (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
EP3137469A1 (en) | Heterocyclic compounds and their use as dopamine d1 ligands | |
OA17357A (en) | Novel 4-(substituted-amino)-7H-pyrrolo[2,3d]pyrimidines as LRRK2 inhibitors. |